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Abstract 
Prostate cancer (PC) is the most common cancer type in men in the western world and to date no 
definitive stratergy to image PC is avaliable.  This thesis explores the possibility of using Prostate 
Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide Receptor (GRP-R) as biomarkers 
for the targeting and imaging of PC.  The development of an imaging radiopharmaceutical to 
image all stages of PC growth would improve diagnosis, staging and personalised treatment, as 
present imaging modalities for PC rely largely on anatomical changes to allow visualisation and 
have limited sensitivity for imaging metastatic spread of the disease.  PSMA was selected due to its 
up-regulation in advanced carcinoma and metastatic disease and GRP-R due to its high levels of 
expression in the early stages of PC.  The hypothesis is that PC can be imaged by a suitably 
designed radioligand directed against an appropriate molecular target, such as PSMA and GRP-R.  
Both of these targets were believed to be appropriate as both are present preferntially in prostate 
tissue and they both internalise when bound by their ligand. To target PSMA, phage libraries were 
screened for scFv against both cell-expressed PSMA and recombinant PSMA and diabodies were 
also generated from high binding clones.  Several promising candidates were produced which 
selectively bound to LNCaP cells and PSMA protein in both FACS and ELISA.  Diabodies showed 
improved binding over corresponding scFv’s.  In vivo analysis of tumour-bearing mice failed to 
reveal tumour uptake of either the scFv or the diabody.  In vitro analysis suggested that the affinity 
of the antibody fragments were not sufficiently high.  [99mTc]-Demobesin 4 (DB 4), a radiolabelled 
GRP-R binding peptide was synthesised.  Radioligand binding assays performed on a range of 
androgen-independent and androgen-dependent PC cell lines showed high GRP-R expression in 
the androgen dependent LNCaP line but also in the androgen-independent cell lines PC3 and 
DU145.  GRP-R expression, measured by RT-PCR to determine the amount of GRP-R RNA, was 
similar to that seen using radioligand binding assays and similar patterns were observed in 
autoradiographic studies.  In vivo studies on mice bearing the PC xenografts showed tumour 
uptake and localisation of [99mTc]-DB 4 within one hour.  A limited correlation was observed 
between results obtained in vivo and in vitro.  In conclusion, the results were partly consistant 
with the hypothesis, whereby  initial aims for the PSMA project were successfully achieved with 
generation of scFv and diabodies that specifically bound, however they proved unsuitable as 
potential imaging agents, perhaps owing to low binding affinity. GRP-R was shown to be an 
effective candidate for radioimmaging PC which has the potential to descrininate [99mTc]-DB4 
uptake between androgen-independent/dependent cells.  Thus this radiopharmaceutical may 
prove a useful imaging agent for early prostate cancer but that further studies are required to 
assess its usefulness in the androgen-independent stages of the disease. 
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1 INTRODUCTION 
 
1.1 THE PROSTATE 
  
The prostate gland is a small, walnut-shaped gland that lies in front of the rectum.  It 
surrounds the urethra, just below the urinary bladder and can be felt during a rectal 
examination.  Its primary function is the storage and secretion of a clear, slightly alkaline 
fluid that constitutes approximately one-third of the volume of semen.  Although not a 
vital organ, it is surrounded by a complex network of nerves and blood vessels that can be 
damaged as a result of PC and during its treatment.   
 
1.1.1 Prostate Cells 
The normal prostate is a tubular-aveolar gland composed of a well-developed stromal 
compartment containing nerves, fibroblasts, infiltrating lymphocytes and macrophages, 
endothelial cell capillaries and smooth muscle (Figure 1.1) [1].  
 
 
 
Figure 1.1:  Cellular architecture of the prostate comprises of blood vessels, which provide nutrients 
including androgens to the fibrous stromal layer, which primarily consist of fibroblasts, smooth muscle cells, 
and basal and secretory cells.  
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Two morphologically defined components make up the prostatic epithelium, the basal and 
luminal layers, which contain three types of cell; basal, secretory and neuroendocrine, 
distinguished on the basis of their location, morphology and phenotypic characteristics.  
Luminal secretory or glandular cells constitute the exocrine compartment, secreting 
prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) into the glandular 
lumina [2].  They are terminally differentiated and represent the major cell type in normal 
and hyperplastic epithelium.  They express high levels of androgen receptor (AR) and are 
dependent on androgen for survival [3].  In contrast, basal cells are non-secretory and 
relatively undifferentiated.  They rest on the basement membrane, express low or 
undetectable levels of AR, and are thus not dependent on androgen for survival.  
Neuroendocrine cells are distributed throughout the basal and luminal layers and are 
characterised by their expression of chromogranin A and serotonin, but not AR [4].  They 
are thought to play a role in growth and differentiation, but their function is largely 
unknown [3].  
 
  
1.2 ANDROGENS AND THE PROSTATE 
 
1.2.1 Androgen Production 
It is important to understand how androgen affects the growth of the prostate gland and 
in turn PC.  Testosterone, which circulates throughout the body, is primarily produced by 
the Leydig cells in the testes, and is mainly required for the maintenance of muscle mass, 
bone and cardiovascular health, spermatogenesis and sex drive [5].  Androgenic effects 
are also caused by adrenal androgens, such as androsterone, dehydropiandrosterone 
(DHEA) and its sulfate, although these are not as potent as testosterone, and make up 
only 10% of circulating androgens. The production of testosterone is carefully regulated 
through the hypothylamic-pituitary testicular axis (Figure 1.2).  In a series of chain 
reactions, gonadotrophin-releasing hormone (GnRH)1 is secreted by the hypothalamus; 
this in turn causes GnRH to bind to gonadotropes in the anterior pituitary, which 
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 Also known as luteinising hormone releasing hormone (LHRH) 
Chapter 1  Introduction 
    4 
 
stimulates the release of gonadotropic hormone (Gn)2 and follicle-stimulating hormone 
(FSH).  Gn reacts with the Leydig cells where it stimulates the production of androgen [6].  
Circulating testosterone acts in a negative feedback loop to down-regulate the expression 
of GnRH. Adrenocorticotropic hormone (ACTH), also made by the pituitary, stimulates 
androgen synthesis in the adrenal gland (Figure 1.2) [7]. 
 
 
 
Figure 1.2:  Hypothalamic-pituitary testicular axis, showing the production of testosterone regulated by the 
negative feedback loop.  Testosterone (T) and dihydrotestosterone (DHT) bind to the androgen receptor 
(AR) in the prostate, causing increased expression of androgen-responsive genes [7]. 
 
Once testosterone has entered the cell in the prostate, it is usually converted to 
dihydrotestosterone (DHT) by 5α-reductase, which regulates intraprostatic androgen-
mediated processes.   Both testosterone and DHT can bind to the androgen receptor (AR), 
although DHT has 2- to 10-fold greater affinity for the AR,  and is consequently the 
primary androgen bound by the AR [6].   
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1.2.2 Androgen Receptor 
The actions of both testosterone and DHT are mediated by the AR, acting as a 
transcription factor [8].  Although present in both sexes, AR is abundantly expressed in 
male sex tissues, and its functions are to promote the growth and differentiation of the 
male urogenital structures.  It is also necessary for the initiation and maintenance of 
spermatogenesis [6].  
 
During the development of the normal prostate and also prostate cancer, cell survival is 
dependent on the AR.  In the prostate gland, AR, a member of the steroid receptor 
superfamily, is preferentially situated in the nuclei of stromal and secretory epithelial cells.  
Unbound to DHT, AR protein resides in the cytoplasm and is bound to chaperone 
molecules viz. heat-shock proteins (HSP).  Whilst situated here, it is held inactive and 
precluded from DNA binding [5].    
 
Once DHT binds to the AR, the protein dissociates from HSP, undergoes a conformational 
change, and is quickly translocated to the nucleus [9].  Once in the nucleus, the androgen 
receptor dimerises and binds to the androgen-response elements in DNA, activating the 
transcription of genes involved in the growth and survival of the cell [10] (Figure 1.3).  The 
presence of androgens causes prostate epithelial and stromal cells to proliferate and 
differentiate, whereas depletion of androgens causes apoptosis of both the secretory 
epithelial and stromal compartments [1].  
 
Androgen action in the normal prostate is a paracrine process which has different effects 
on different cell types [8, 11].   
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Figure 1.3:  In normal prostate, growth maintenance of prostate epithelium depends on andromedins 
(growth (GF) and survival (SF) factors) produced by stromal cells.  Production of andromedins is a result of 
androgen signalling through the AR.  Production of secretory proteins (PSA & human kallikrein-2 (HK2)) is 
dependent on androgen signalling in the prostate epithelium.  AR is not expressed by basal epithelial cells 
[12]. 
 
AR found in stromal cells activates the secretion of soluble peptide growth factors known 
as andromedins.  Diffusion of these andromedins across the basement membrane into the 
epithelial compartment, which contains both basal and secretory luminal cells, allows the 
andromedins to bind to specific membrane receptors.  Upon binding, the signalling for 
proliferation and epithelial cell survival is initiated [5, 11].   
 
In the nuclei of the secretory cells, AR stimulates the transcription of a series of genes 
encoding prostate-specific differentiation markers, such as PSA and human glandular 
kallikrein-2.  Although transcriptional regulation of these markers is regulated by the AR in 
the nuclei of the secretory luminal cells, the receptor does not stimulate proliferation or 
survival; it suppresses the growth of the secretory cells by inhibiting andromedin-induced 
proliferation [1]. 
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1.2.3 Growth Factors 
In conjunction with androgens, growth factors are important in the development of the 
prostate and abnormal hyperplastic growth.  There is a fine balance between proliferation 
and apoptosis; these processes are mediated by the expression of growth factors.  
Interactions between the stimulatory and inhibitory growth factors regulate the stromal-
epithelial interactions that are involved in the development of the prostate, and maintain 
homeostasis in the normal functioning gland (Figure 1.4). 
 
 
Figure 1.4:  Homeostatic balance between proliferation and apoptosis is maintained by androgens and 
growth factors.  Adapted from [13] 
 
The DHT-AR complex in the prostatic stroma affects the expression of a number of growth 
factors that stimulate proliferation, including epidermal growth factor (EGR), basic 
fibroblast growth factor (bFGF), keratinocyte growth factor (KGF) and insulin-like growth 
factor (IGF).  Andromedins are also up-regulated and cause signalling which represses the 
apoptotic pathway [1]. 
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1.3 PROSTATE CANCER 
 
After skin cancer, PC is one of four most common cancers in the UK, along with breast, 
lung and colorectal cancers [14].  A quarter of all new cases of cancer diagnosed in men 
are prostate cancers.  Every year, over 35,000 men are diagnosed with the disease and it is 
the second most common cause of male cancer death, with 10,200 deaths each year in 
the UK alone [15].  PC primarily affects men over the age of 60, and increases by 60% in 
the 7th decade of life [15].  The exact trigger for development of prostatic adenocarcinoma 
has not yet been elucidated, although epidemiological and genetic factors are seen as 
possible contributors.     
 
1.3.1 Biology of Prostate Cancer  
McNeal (1981) [16] developed the concept of the zonal anatomy of the prostate.  
Approximately 60-70% of prostatic cancers occur in the peripheral zone (the largest zone, 
located near the rectum), and 10-20% in the transition zone (surrounding the proximal 
urethra), with only 5-10% originating from the central zone (involved in the connection of 
the seminal vesicles to the prostate) [17]. 
 
In excess of 99% of PCs develop from glandular epithelial cells in the prostate and are 
therefore described as prostatic adenocarcinomas.  However the identification of the 
specific epithelial sub-type in which the carcinogenic process initiates remains unclear.  It 
is thought that the precursor for most peripheral-zone prostatic carcinomas is high-grade 
prostatic intraepithelial neoplasia (HGPIN) [17], and that HGPIN arises from low-grade PIN, 
which in turn arises from normal prostate epithelium [18]. 
 
The aetiology of PC is insufficiently understood, although a number of molecular events 
occur during the progression of initial tumour formation in most cancers, such as 
abnormal methylation, proto-oncogene activation, inactivation of DNA repair mechanisms 
and tumour repressors, and an increase in the synthesis of growth factors and growth 
factor receptors [6].  Eventually, with progression, the cancer spreads out of the capsule 
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and metastasises to neighbouring tissues such as the lymph nodes and bone; therefore 
the cancer succeeds in evading apoptosis, invades tissue, and forms new blood vessels.   
 
 
1.4 SCREENING AND TREATMENT 
 
Diagnosis of the disease is made difficult by the extreme variability in the clinical course.  
PC can be an indolent, latent disease in elderly patients who do not present clinical 
symptoms.  Other forms of PC take an aggressive course, spreading out from the capsule 
into the seminal vesicles, bladder and rectum and metastasising to lymph nodes, bone, 
lungs and other organs.  In order to select the best first-line of treatment, it is important 
to know the stage and advancement of the tumour growth.  Pathophysiological studies of 
the tumour, such as the measurement of PSA expression and histological assessment 
(Gleason score), are necessary. 
 
1.4.1 Gleason Score 
In the absence of more accurate and reliable tissue or blood biomarkers, the Gleason 
score and the stage at the time of diagnosis remain the mainstays of prognosis. Despite 
extensive research efforts, to date very few biomarkers of PC have been introduced into 
clinical practice. 
 
The grading system is entirely based on the histological pattern of arrangement of 
carcinoma cells in hematoxylin and eosin-stained prostatic tissue sections.  A grade is 
assigned to the most common tumour pattern detected in the observed area by simple 
visual inspection (the primary pattern) and a second grade to the next most common 
pattern (the secondary pattern).  The sum of the two grades gives the Gleason Score.  A 
histological score is generated for both primary and secondary patterns grading on a scale 
of 1 to 5; the grade of 1 is given to sections most resembling healthy prostatic tissue, and 
increasing grades are apportioned with decreasing normal cell morphology (grades 2-4), 
with grade 5 showing no healthy prostatic or organised cell growth.  Diagnoses are 
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difficult to make from tissue samples obtained by needle biopsies, due to the small 
amount of tissue available for histological examination.  Morphologically, PC is tricky to 
diagnose because the clues to malignant disease can be subtle, increasing the risk of 
underdiagnosis [19].  The Gleason score, was developed by Donald Gleason in 1974 [20] 
when very little was known about the disease, and immunohistochemistry was developed 
afterwards in the 1980s; therefore new screening techniques are seriously required. 
 
1.4.2 Prostate Specific Antigen  
PSA is a serine protease which is synthesised by healthy prostate tissue, in benign 
prostatic hyperplasia (BPH) and at all stages of PC growth.  For both initial diagnosis and 
monitoring, PSA is widely regarded as a cancer marker, and testing for it has come into 
widespread use; but its reliability has been questioned, as there is no threshold with 
which PSA levels can be compared, because PSA expression varies between individuals 
[21].  Numerous non-malignant processes, including BPH and prostatitis, which occur in 
older men, frequently lead to PSA elevations; thus PSA screening alone is not 
recommended [22].  
 
Prior to the measurement of PSA serum levels, other screening procedures were 
employed such as digital rectal examination (DRE); an invasive and uncomfortable 
procedure.  A major disadvantage of this method of screening was that the tumours 
detected were typically already advanced and had extended beyond the organ capsule or 
had metastasised. 
 
 
1.5 TREATMENT 
 
For localised PC, surgery and radiation therapy can be curative.  However, this is not 
appropriate for most of the cases that present locally advanced or widespread disease, 
and therefore require hormone therapy to suppress tumour growth.  Despite medical and 
drug treatment, the majority of patients with PC will gradually transform to a metastatic 
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hormone-refractory state, which currently remains incurable and which will, in time (1-2 
years), kill them [23]. 
 
A number of procedures are currently available for managment, all of which are 
dependent on the stage and aggressiveness of the cancer.  Watchful waiting, although not 
a treatment, is a course of action taken in patients with slowly developing PC.  
Radiotherapy by either external beam radiation therapy (EBRT) or brachytherapy can be 
used to treat the cancer.  EBRT uses a linear accelerator to focus powerful beams of X-rays 
to target the cells within the cancer.  Radiation damages the DNA of these cells, 
preventing them from dividing [24].  Brachytherapy is a minimally invasive procedure, 
where small interstitial radioactive seed implants are placed within the PC [25] and can 
provide a 10-year disease-free survival [26].  Both treatments have given at best tumour 
regression without severe side-effects, but are not curative.  Another option is 
cryotherapy, whereby a probe in which liquid nitrogen is circulated is inserted in the 
urethra in an attempt to destroy the cancerous tissue.  Advances in recent technology 
including an urethral warming device and high-quality transrectal ultrasound guidance 
have improved the efficacy considerably, providing an encouraging 5-year disease-free 
survival [27]. 
 
1.5.1 Androgen Deprivation Therapy   
While tumour growth is androgen dependent, PC can be effectively treated with androgen 
ablation.  Although androgen ablation is the most effective treatment to date, it has not 
yet been shown to prolong survival [28]; in most cases decreased levels of androgens 
favour the selection and growth of tumour cells that are androgen-independent.  The 
withdrawal of androgens by either physical or chemical castration often leads to 
regression of the disease, but patients tend to relapse after 12-18 months and develop 
Androgen Independent PC (AIPC), a lethal form of PC for which to date there is no cure. 
 
Orchidectomy, the surgical removal of one or both testes used to be considered the 
standard ablation therapy for PC.  Although the advantages of this procedure include cost 
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efficiency, low mortality and the avoidance of complications associated with drug therapy, 
they are heavily outweighed by the physical trauma and side-effects associated with 
castration.  
 
Therapy by chemical castration involves the administration of luteinising hormone-
releasing hormone (LHRH), or LHRH analogues, which bind to the receptors on the 
gonadotropes (pituitary gland), and can remain there for a period of up to 7-10 days.  The 
binding causes a sudden increase in testosterone (a hormone flare) which initiates the 
negative feedback control in the hypothalamic–pituitary testicular axis, blocking further 
natural testosterone production which in time results in the decrease of circulating 
testosterone (Figure 1.5). 
 
 
Figure 1.5:  The hypothalamus secretes pulses of luteinising hormone-releasing hormone (LHRH) every 90-
120 minutes, causing a chain of events that results in the production of testosterone.  LHRH analogue 
administration binds to the gonadotropes, initially causing a hormone flare, but thereafter blocking the 
natural testosterone pathway, greatly reducing the level of circulating testosterone. 
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1.5.1.1 Hormone-Refractory PC 
Fundamental changes in the AR signalling pathways occur during prostatic carcinogenesis 
after andogen ablation therapy, altering the suppression of growth:  AR binding in the 
nuclei of malignant cells no longer suppresses continuous growth.  Prostate cancer cells 
can divert stromal control and change from the paracrine pathway (Figure 1.3) to an 
autocrine one, whereby the cancer now neither relies on external androgens nor on 
androgen-induced stromal-mediated factors for its growth and survival, and the AR 
directly stimulates the growth of malignant cells (Figure 1.6). 
 
 
Figure 1.6:  Autocrine Pathway:  During the transformation to cancer, the paracrine pathway is lost and is 
replaced by an emergent autocrine mechanism, whereby cancer cells are less dependent on stromal cell 
factors.  Production of growth and survival factors is directly stimulated by cancer cells when androgens 
interact with AR [12]. 
 
 
It is still not fully understood what triggers the development of AIPC, but the cancer’s 
unique ability to rely on androgens for growth and avoid apoptosis, allowing the early 
formation of tumours, has been the target of many therapies.  While androgen ablation 
therapy initially causes tumours to regress, they eventually become androgen-
independent and unresponsive to the therapy.  Genetic modification may be responsible 
for tumour progression and the emergence of AIPC.  Five possible mechanisms have been 
proposed by which AIPC can develop:  the hypersensitive, promiscuous, outlaw, bypass 
and lurker cell pathways (Figure 1.7). 
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Figure 1.7:  Five possible pathways to androgen independence [9], which directly or indirectly affect the 
activation of AR. 
 
The hypersensitive pathway:  A possible mechanism by which PC circumvents the effects 
of androgen ablation could be by increasing the sensitivity to low levels of androgens.  
Neither chemical nor surgical androgen ablation can fully prevent low levels of androgen 
production by the adrenal gland.  The cancer exploits these low levels by amplifying its 
expression of AR, thereby increasing the ligand-occupied receptor content [29].  Up to 
30% of tumours that have become AIPC after androgen ablation have AR genes that have 
been amplified over the levels observed in the primary tumours of the same patient, 
indicating amplification of the receptor, possibly by clonal selection.  As well as 
amplification, increased AR sensitivity is possible, with increased stability and enhanced 
nuclear localisation, but also increasing the local production of androgens to compensate 
for the decline in circulating testosterone, by increasing the rate of conversion of 
testosterone to the more potent DHT via an enhanced 5α-reductase activity [9].  
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Reductions of 95% in serum testosterone levels have in fact been observed, though with 
increases in DHT concentration of only 60% [30, 31]. 
 
The promiscuous pathway:  This is where genetic changes in the AR show a decrease in 
specificity of ligand binding and an increase in inappropriate activation by various non-
androgen steroids and androgen antagonists [29].  The androgen signal is maintained by 
this broadening of the range of ligands that can bind and activate the receptor.   
 
The outlaw pathway:  The AR becomes activated by ligand-independent mechanisms, 
creating an outlaw receptor.  Certain growth factors such as insulin growth factor 1, 
keratinocyte growth factor and epidermal growth factor have been found to bind and 
activate the AR.  It is not clear whether these factors have a direct effect on the AR 
pathway, or whether the effect is a result of a downstream molecule that is induced by 
the signalling pathway.  Receptor tyrosine kinases (RTKs) are activated, and the AR is 
phosphorylated, either by the AKT (member of the protein kinase B family) or the 
mitogen-activated protein kinase (MAPK) pathway, producing a ligand-independent AR 
[9]. 
 
The bypass pathway:  Another possibility is, that complementary or alternative pathways 
can be evoked that are capable of by-passing the AR completely.  The anti-apoptotic 
protein B-cell lymphoma 2 (BCL2) can obviate the need for AR or its ligand [29].  
 
The lurker cell pathway:  Androgen ablation fails as a result of cells that are not androgen-
dependent for growth, which take over and drive the formation of the tumour in an 
androgen-independent manner.  AIPC development has been postulated to be due to a 
sub-population of androgen-independent tumour cells present before any treatment was 
initiated; thus their rates of proliferation and death are not affected by androgen ablation, 
and when androgen-dependent cells began to apoptose as a result of treatment, these 
lurking epithelial stem cells remain viable and continue to proliferate, driving the 
formation of an androgen-independent tumour [32].  An example of such pathway has 
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been shown with neuroendocrine cells, which are widely distributed throughout the 
prostate gland and produce a number of bioactive substances which constitute a complex 
mechanism that regulates growth and differentiation of the developing prostate and 
secretory processes of the mature gland.  Only 1% of all cases of prostate cancers 
exclusively contain neuroendocrine cells, they are dispersed individually or in small 
clusters throughout prevailing population of malignant cells.  Neuropeptides such as 
bombesin and growth factors produced by neuroendocrine cells are thought to interact 
with neighbouring non-neuroendocine cells and cross activate androgen-dependent 
mitogenic pathways in the absence of testosterone [33].  Neuroendocrine cells do not 
express the AR and continue to proliferate despite androgen ablation and can be 
responsible for androgen-independent re-growth in PC [34]. 
 
A new pathway has recently been proposed which would help to explain proliferation and 
growth in androgen-independent PC.  The backdoor pathway is the formation of DHT from 
progesterone, instead of from testosterone by the action of 5α-reductase. [35].  This 
pathway suggests that cancer cells can synthesise androgens de novo when androgens are 
not available from the bloodstream [5, 31]. 
 
1.5.1.2 Other Treatments  
In the last decade, three agents have been approved by the Food and Drug Administration 
(FDA) in the USA for the treatment of patients with metastatic prostate cancer viz. 
zoledronic acid, mitoxantrone and docetaxel.  Zoledronic acid and mitoxantrone provide 
palliative treatment without any advantage to overall survival, while docetaxel is a 
chemotherapeutic agent which has shown in combination with prednisone, to improve 
the quality of life dramatically and to improve survival rates, more so than mitoxantrone 
with prednisone [36].   
 
1.5.1.3 Antibody Therapy 
Antibodies were first approved for treatment of cancer in 1995.  Since then five have been 
approved for the treatment of cancer: Campath (alemtuzumab) for chronic lymphocytic 
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leukaemia; Herceptin (trastuzumab) for breast cancer; Mylotarg (gemtuzumab 
ozogamicin) for acute myelogenous leukaemia; Panorex (edrecolomab) for colorectal 
cancer, and Rituxan (rituximab) for non-Hodgkin’s lymphoma [37].  Many others are 
currently in clinical trials.   
 
This emergence of antibodies as therapeutics was made possible with the advent of 
technologies designed to overcome limitations of mouse monoclonal antibodies (mAbs) 
such as immunogenicity, inefficient effector functions, and short half-lives.  Core 
technologies such as chimerisation and humanisation of mouse antibodies, and direct 
routes to high-affinity human antibodies using phage display libraries or transgenic mice, 
have opened up the possibilities of using antibodies to target cancer.   
 
Most clinically-approved antibodies and experimental antibody drugs target tumour cells 
directly, therefore to increase the efficacy of these antibodies, the possibility has been 
explored of enhancing effector functions by direct and indirect arming or pre-targeting 
them with pro-drugs and radionuclides.  Currently the most-explored strategy is direct 
arming, by linking antibodies that target antigens highly expressed only on tumour cells, to 
toxins [Mylotarg (gemtuzumab ozogamicin)] [38] or radionuclides [Bexxar (tositumomab) 
and Zevalin (ibritumomab tituxetan)] [37], which target antigens more highly expressed on 
tumour cells than on normal cells. 
 
Most recently, Zhang and co-workers (2010) have developed a mAb F77 which targets a 
unique prostate-specific glycolipid, termed prostate cancer lipid antigen (PCLA) [39].  The 
authors found that PCLA is expressed predominately in the prostate, in both androgen-
dependent and independent PC, considerably higher levels than in normal tissue by 
immunohistological studies, showing intense staining correlating with tumour grade.  mAb 
F77 has been shown to modestly initiate direct cell death in PC cells, mediating 
complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity as well 
as significantly inhibiting androgen-independent PC3 and DU145 tumour growth in cells.  
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Radiolabelled F77 was also shown to specifically bind PC3 tumour-bearing nude mice and 
represents a possible radiopharmaceutical for both imaging and therapy [39]. 
 
 
1.6 PROSTATE-SPECIFIC MEMBRANE ANTIGEN  
 
PSMA is a membrane-bound type II glycoprotein3 of approximately 100 kDa in size, with 
an intracellular domain (amino acids 1-18), a transmembrane domain (amino acids 19-43) 
and an extensive highly glycosylated extracellular domain (amino acids 44-750; Figure 1.8) 
[40, 41]. 
 
 
 
Figure 1.8:  Schematic diagram of the globular nature of Prostate-Specific Membrane Antigen (PSMA).   It 
has a small cytoplasmic domain (CD) which anchors it to the cell, a hydrophobic transmembrane domain 
(TM), and a large extracellular domain (ED) [40].    Y-shapes signify glycosyl groups. 
 
PSMA, also known as folate hydrolase 1 (FOLH1), glutamate carboxypentidase II or N-
acetyl-α-linked acidic dipeptidase I [42], is expressed in secretory cells within the prostatic 
epithelium and is absent or moderately expressed in most hyperplastic and benign tissue 
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[43-45].   Although the significance of PSMA expression within the vasculature is unknown, 
PSMA has two unique enzymatic functions, folate hydrolase and NAALADase (cleaving the 
glutamate from the neurodipeptide, N-acetyl-aspasrtyl-glutamate, NAAG) [41].  NAAG is 
present in neuronal synapses while folypoly-γ-glutamates are present in dietary 
components.  PSMA protein (folate hydrolase), which is located in the brush border 
surface of small intestine, enables the generation of folates and subsequent folate uptake 
[42, 46, 47].  However the specific biochemical function of PSMA in the prostate tissue and 
the reason for its increase in expression in PC remains unclear, in contrast to other 
prostate-related antigens, such as PSA and PAP, PSMA is not a secretory protein and 
undergoes internalisation constitutively [48].  However, at present no naturally-occurring 
PSMA ligand is known. 
 
PSMA is expressed in healthy prostate [42, 49], immunohistochemistry studies have found 
weak to moderate staining in normal and hyperplastic tissue, restricted to the epithelial 
cells of the prostate [50], although the levels of expression increases considerably with PC 
and tumour aggressiveness, androgen-independence, metastatic disease and disease 
recurrence [51],   Despite its name, PSMA is expressed in other tissues besides the 
prostate.  Studies have demonstrated PSMA expression in the small intestine, proximal 
renal tubules and salivary glands [52].  Although present in other tissues, PSMA levels are 
100-1000-fold greater in the prostate than anywhere else [43, 53].  Some minimal 
expression is also observed in the brain but most agents, particularly antibodies, do not 
penetrate the blood-brain barrier.  Furthermore, PSMA is expressed in the neovasculature 
of numerous other solid tumours, including bladder, pancreas, lung and kidney cancers, 
but not in normal vasculature [45]. 
 
Mannweiler and co-workers (2009) found differences in internalisation of PSMA 
immunostaining that appeared to be related to the differentiation pattern of the tumour 
with 96% PSMA expression in primary tumours and 84% in metastasised PC [54].  
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PSMA has been identified as an excellent target and a good clinical biomarker for the 
diagnosis, detection and management of PC, because it is (i) primarily expressed in the 
prostate; (ii) is progressively increasingly expressed in high-grade cancers, metastatic 
disease and AIPC; (iii) up-regulated in metastatic disease; (iv) presented at the cell surface 
but not released into the circulation, and (v) internalised after antibody binding by 
receptor-mediated endocytosis [55, 56].  Moreover, PSMA protein is expressed as a 
homodimer on prostate epithelial cells and is not secreted into the circulation; therefore it 
exhibits an extensive extracellular domain to be readily targeted. 
 
1.6.1 PSMA Antibodies 
A number of anti-PSMA antibodies have been evaluated, a few having entered clinical 
trials as well as currently being under development.  mAbs have the advantage of 
possessing specificity and high affinity for their molecular target, as well as their ability to 
initiate immunological effects, block receptors, or be used as vehicles to deliver highly 
cytotoxic radionuclides, drugs or toxins to the desired cell population [56].   
 
Although PSMA represents an attractive antigen for therapy due to its abundance and 
restricted surface expression on prostate epithelial cells, in contrast to other tumour-
associated antigens, there are few approaches that use PSMA.  Only a few reports have 
appeared that propose using monoclonal antibodies and scFv that bind to cell-adherent 
PSMA [57-62]. 
 
The first mAb against PSMA, reported by Horoszewicz et al (1987), was 7E11, which 
recognised the internal domain of the N-terminus of PSMA [63, 64].  The first IgG1 mAb 
which they described, termed 7E11-C5.3, was generated using cell membranes from the 
cell line LNCaP to immunise mice and form hybridomas [63].  This mAb showed specific 
binding to PSMA presented on PC tumour tissue, benign prostatic hyperplasia (BPH)4, and 
healthy prostatic tissue in immunohistochemistry analysis [43].  ProstaScint® (Capromab 
Pendetide, Cytogen, Philadelphia), the [111In]-labelled form of 7E11, is a commercially 
                                                 
4
 Enlargement of the prostate, not cancerous 
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available monoclonal antibody conjugate.  Capromab Pendetide received FDA approval in 
1996 for use as an imaging agent for the detection of soft tissue metastases in PC.  It is 
utilised either at the time of initial diagnosis or in the setting of suspected recurrent 
disease [65].  The radiopharmaceutical is administered by intravenous injection, and 
SPECT imaging is performed between 3-7 days post injection, allowing visualisation of the 
PC and any metastasis [66].  Questions have arisen concerning the value of in-vivo imaging 
with ProstaScint®, as the antibody only recognises the internal, cytoplasmic domain of 
PSMA, which is exposed only in dead or apoptosising cells, as opposed to the viable cells 
within the tumour; a drawback that certainly limits the value and applicability of this 
radiopharmaceutical, as it is important to know where new and existing tumour growth 
exists.  Murphy and co-workers (1997) addressed this question by FACS analysis of viable 
LNCaP cells, and concluded that these cells specifically bound and internalised FITC-
labelled 7E11-C5.3 antibody over cells of the non-PSMA expressing lines DU145 and PC3 
[67]; however this antibody retains its reputation as binding to internal, cytoplasmic 
domain of PSMA. 
 
Liu et al (1997) developed four IgG mAbs to the external domain of PSMA which were 
found to be reactive to vascular endothelium within a number of carcinomas, but not to 
normal endothelial cells [68].  One of the four, J591, showed improved reactivity over that 
of 7E11, and has been taken forward for a number of clinical trials with a range of 
radionuclides.  Clinical trials have proven successful; specificity has been demonstrated to 
PC tumours including those in bone, soft tissue metastases, and importantly non-
immunogenic [69].   
 
In one such clinical trial, designed primarily to define dose and toxicity rather than anti-
tumour response, [90Y]-labelled J591 also demonstrated anti-tumour activity, reducing PSA 
levels by as much as 85% and measurable tumour lesions by 90% for periods of up to and 
beyond eight months [70].  Another group, Elsässer-Beile and co-workers [62, 66], have 
generated three mAbs (3/A12, 3/E7 and 3/F11) against PSMA with strong and specific 
affinity for the large extracellular portion.  After binding, these mAbs were internalised by 
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PSMA-expressing PC cells, and showed immunohistochemical activity to frozen sections of 
prostatic tissue, but no reactivity to normal non-PSMA expressing human tissues.  In 
preclinical studies, these mAbs have also revealed high and specific tumour uptake in PET 
imaging studies [66]. 
 
Although mAbs to PSMA are available, much interest has been focused on smaller 
antibody fragments viz. scFv, diabodies, triabodies and Fabs, which have the advantage of 
displaying improved tumour penetration and rapid clearance from the circulation.  
However, to date, only Elsässer-Beile and co-workers have published and successfully 
generated a PSMA-specific scFv in the form of a bispecific diabody for detection [7], and a 
scFv-immunotoxin for treatment [71], using respectively Quadroma Technology5 and 
Phage Display.  Both approaches use PSMA as the targeting antigen.  For treatment, one 
approach employs CD3, which increases antigen-specific cytotoxicity in T-cells (potent 
effector cells), which on coming into contact with their target, release the cytotoxins 
perforin and granulysin.  Perforin forms pores in the target cell’s plasma membrane, 
allowing the entry of granulysin (a serine protease) activating the caspase cascade.  The 
second approach utilises the immunotoxin Pseudomonas exotoxin A which, once 
internalised by the cell, catalyzes the transfer of the adenine ribosyl moiety of adenosine 
diphosphate from nicotinamide adenine dinucleotide to elongation factor 2, which results 
in the inactivation of the latter and the inhibition of protein biosynthesis [72].  Further 
investigation of PSMA binding is needed to exemplify its true potential as a target for 
therapy in PC.  
 
As well as generating antibodies against PSMA, the possibilities of developing a vaccine for 
PC are currently under investigation.  Dendritic cell (DC)-based vaccines hold promise as a 
safe therapy for PC.  PSMA has been employed as a tumour-associated antigen (TAA) 
presented by DC-triggering naïve CD8+ cytotoxic T lymphocytes, which are capable of 
recognising and destroying tumour cells that expose peptides derived from TAAs in 
                                                 
5
 Quadroma Technology is based on the somatic fusion of two different hybridoma cell lines expressing 
murine monoclonal antibodies with the desired specificities of the bispecific antibody. 
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complex with human leukocyte antigen (HLA) class I molecules [73-75].  Tumour proteins 
such as PSMA can be administered to the patient to stimulate DC activation, whereby 
PSMA is presented to T cells in the lymph nodes.  Alternatively, DCs can be loaded ex vivo 
with the respective tumour antigen preparation, and injected into the patient as a DC 
vaccine.  Garetto and co-workers have successfully selected PSMA peptides that show 
detectable binding to mature DC and are able to show co-localisation of PSMA and HLA 
class I molecules [73]. 
 
 
1.7 ANTIBODIES 
 
Intact antibodies (IgG, IgM, IgA and IgE) are highly specific targeting agents.  The Y-shaped 
multidomain protein possesses two antigen-binding sites located on the two Fab tips, and 
the framework Fc domain mediates the recruitment of effector functions [75].  IgGs are 
bivalent in their ability to bind two antigens, which increases their functional avidity and 
confers higher retention times on many-cell surface receptors.  IgGs can be dissected into 
constituent domains by proteolysis using enzymes such as papain and pepsin, and recently 
advances in molecular biology have enabled small monovalent (Fab, single chain Fv, single 
variable VH and VL-domain) and bivalent (Fab’2, diabody and minibody) fragments to be 
made.  Many of these smaller antibody fragments have successfully entered clinical and 
preclinical trials.  Although they are not curative alone, many have been utilised as 
vehicles, conjugated to radionuclides [65, 76], toxins [56] or immunological effector cells 
[61] (Figure 1.9). 
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Figure 1.9:  Current uses of antibodies and their analogues in cancer.  Attachment to a range of derivatives 
can be beneficial for both imaging and therapy.  This present project focuses on imaging with a radioactive 
isotope and the remainder of the introduction will focus on imaging using radiolabelled antibodies [77]. 
 
The present project focuses on imaging (see Figure 1.9), and the remainder of this 
introduction will focus on imaging using radiolabelled antibodies and peptides.  mAbs 
however, are not ideal for imaging, due to their large size (150 kDa) and consequent poor 
tissue penetration.  Although tumour specificity In vivo is observed; less than 1% of the 
injected dose normally reaches the tumour [77], therefore mAbs are not ideal vehicles to 
use for imaging with radioactive isotopes (Figure 1.10). 
  
                                   
 
Figure 1.10:  Schematic representation of scFv and diabody antibody formats, respectively ~25 and ~50 kDa.  
The formation of the diabody is driven by the removal of the polypeptide (glycine-serine) linker.    
 
   Toxin 
Enzyme 
Bi-
specific 
scFv 
~ 25 kDa 
diabody 
~ 50 kDa 
Linker 
(G3S) 
Chapter 1  Introduction 
    25 
 
Single-chain Fv (scFv), ~25 kDa in size, are popular formats in which VH and VL domains are 
held together with a flexible 15-amino acid glycine-serine linker (G4S)3.  ScFvs are 
advantageous over whole intact antibodies as they show specific binding, exhibiting 
improved pharmacokinetics of tissue penetration and high-affinity binding [78].  Although 
considerably smaller than mAbs, they retain full antibody activity and are easily cloned 
and expressed as functional antibody fragments on the surface of bacteriophages [77].  
Manipulations of the linker by shortening, or its complete removal between the VL and VH 
domains, prevent the alignment of the V-domains into a single scFv, but allow the 
association and non-covalent interaction of two scFv molecules so as to form a dimer or 
diabody.  This interaction, however, does not result in covalent linkage, and the two scFv 
fragments can therefore easily dissociate.  Larger divalent molecules termed minibodies 
can be produced by fusing the gene for an scFv to that for a CH3 domain [79].  Minibody 
formats confer an advantage over scFv and diabodies due to the greater stability of the 
protein complex. 
 
A diabody ~50 kDa in size is a scFv dimer with two functional paratopes, which therefore 
has higher avidity than a single scFv alone.  The association of three or four scFv fragments 
can respectively form a triabody or a tetravalent tetrabody.  Diabodies are advantageous 
over scFv due to their increased binding avidity; possession of two paratopes increases the 
binding affinity and the increase in size slows the rate of systemic clearance from the 
target tissue.   
 
 
 
1.8 PHAGE TECHNOLOGY PRINCIPLE 
 
Smith (1985) first described Phage Display, using a non-lytic filamentous bacteriophage for 
the display of specific binding peptides on a phage coat [80].  Further development of the 
methodology was enhanced by groups such as those of Winter [81] and Wells [82].  Phage 
display involves the expression of proteins, including antibodies, or peptides on the 
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surface of filamentous phage.  DNA sequences of interest can be inserted into the genome 
of a filamentous bacteriophage, such that the encoded protein is expressed or “displayed” 
on the phage surface as a fusion product to one of the phage coat-proteins [83].  This 
eliminates the need to genetically engineer proteins or peptide variants one-by-one and 
then express, purify and analyse each variant, phage display libraries containing several 
billion variants can be constructed simultaneously [84].  Screening of these libraries can 
easily select and purify phage particle bearing sequences with desired binding specificities 
from the non-binding variants.   Antibody phage display technology allows foreign DNA 
inserted into the filamentous phage gene III to be expressed as a fusion protein and 
displayed on the surface of a phage as well as successful expression of functional antibody 
fragments in the periplasmic space of E. coli (Figure 1.11) [83].    
 
 
 
Figure 1.11:  Display of scFv antibodies on filamentous phage.  A phagemid encoding the VH and VL 
immunoglobulin genes fused to gene III (encoding the phage coat protein III) of a filamentous phage is 
superinfected (rescued) with helper phage to drive the production of phage particles expressing scFv in E. 
coli strain TG1 [a non-suppressor strain (sup+)], as a fusion product with the phage coat protein pIII on the 
phage surface and its encoding DNA inside (in colour).  Alternatively it can be secreted as soluble fragments 
by the use of a non-suppressor strain [E. coli HB2151 (sup-); see the section Phagemid vectors below].  Key:  
P lacZ - the promoter that drives expression of antibody-pIII fusions; Tag - either the myc or his tag that is 
used in purification; AMPr – ampicillin resistance gene [85, 86]. 
 
Helper 
phage 
Sup + 
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1.8.1 Filamentous Phage – M13 Biology  
M13 phages consists of a helical structure which has five types of constituent coat 
proteins: major coat protein pVIII, which constitutes the rod-shaped body of the phage 
particle and four minor coat proteins, pIII, pVI, pVII and pIX located at the ends.  
Incorporation of exogenous DNA into the phage genome results in display of the protein 
(such as scFv) on the surface of the phage particle without affecting its infectivity.  The 
exogenous sequence is usually inserted into the gene encoding coat protein pIII, the 
resultant protein being anchored at the N-terminal end of the pIII coat protein [83].  This 
protein anchored on the viral scaffold corresponds to the insert inside the phage, 
therefore phage particles isolated from a library can be easily characterised by DNA 
sequencing (Figure 1.11).  This linkage of genotype to phenotype is the fundamental 
aspect of phage display [87]. 
 
Infection is initiated by the attachment of pIII to the f pilus of a male E. coli strain such as 
TG1.  Only the circular phage single-stranded (ssDNA) enters the bacterium, where it is 
converted by the host DNA replication machinery into a double-stranded plasmid-like 
replication form, which undergoes rolling circle replication to make ssDNA [87].  Phage 
progeny are assembled by packaging ssDNA into protein coats, and are then extruded 
through the bacterial cell membrane into the medium [83].  The genome is therefore 
replicated by interaction of both phage and host-derived proteins and packaged into 
elongated filamentous viral particles [88].  A distinctive trait of filamentous phages is that 
once they infect their host, they do not lyse the cell; instead, in contrast to phages such as 
T4 and T7, they replicate and are released through the cell membrane while the host cell 
continues to grow and divide. 
 
Recombinant antibodies and folded proteins are typically expressed as pIII-fusion proteins 
and are displayed at the tip of the M13 phage, which enables its visualisation since after  
antibody binding to the target antigen; the bound phage can be detected with an HRP-
labelled antibody which recognises the g8p coat protein.  Amplification of the detection 
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signal is consequently achieved, since several thousand copies of g8p exist on the phage 
surface [83].  
 
1.8.2 Phagemid Vectors 
Phagemids, a popular vector for display, are hybrids of phage and plasmid vectors.  
Phagemid vectors are designed to contain the origins of replication6 for both M13 phage 
and E. coli in addition to gene III, appropriate multiple cloning sites, and an antibiotic 
resistance gene7.  However, they lack all the other structural and non-structural gene 
products required for generating a complete phage.  The addition and aid of a helper 
phage such as M13K07 or VCSM13, provides the structural proteins that are required for 
generating a complete phage particle; this process is termed “phage rescue” [87].    
 
Phagemid vectors can also be engineered for display or for secretion of free antibody by 
the incorporation of an amber stop codon between fragment and gene III.  The antibody 
fragments are fused by pIII and displayed when the amber stop codon is suppressed in a 
suppressor strain of E. coli such as TG1 [89].  To produce soluble scFv, the infection of a 
non-suppressor strain of E. coli such as HB2151 with antibody-positive phage will directly 
produce soluble scFv (Figure 1.11) [90].  The phagemid is also designed to introduce a 
poly-histidine tag fused to the expressed scFv, thereby allowing the rapid and simple 
purification of the protein by Ni-NTA affinity chromatography [83]. 
 
Phage display selection allows in vitro isolation of proteins and antibodies such as Fabs 
and scFvs with the desired properties or selection of natural proteins from vast numbers 
of phage particles.  Greater than 1012 different displayed sequences can easily be selected 
from at the same time, considerably more than conventional hybridomas that screen only 
102 -103 clones.  Since the selected phage pool can be amplified by propagation in E. coli, 
multiple rounds of selection can be carried out to select antibodies with the strongest 
binding affinity to a target antigen, in which the antigen of interest is either immobilised in 
                                                 
6
 A particular sequence in the genome at which replication is initiated 
7
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the form of a purified protein, or as membrane-bound protein on cells.  As a consequence 
of this, even very rare binding specificities present in large repertoires can be selected and 
amplified from a background of phage bearing irrelevant binding specificities [88].   
 
1.8.3 Antibody Phage Display Libraries 
In many diagnostic and therapeutic applications, phage display technology of antibody 
fragments is rapidly replacing the classical hybridoma technology, due to the advantages 
over earlier techniques.  Advances in molecular biology have allowed for the use of E. coli 
to produce recombinant antibodies.  By restricting the size of the antibody to either a Fab, 
an Fv or a linker-stabilised scFv, such fragments can not only be expressed in bacterial 
cells but also displayed by fusion to phage coat proteins [91]. 
 
There are a number of phage libraries available for successful antibody fragment selection 
to a large range of target antigens [92, 93], such as immune, single pot [94], naïve and 
synthetic libraries [90, 95].  Immune libraries contain variable immunoglobulin genes of B-
cells from an animal or an immune patient. They are enriched in antigen-specific 
immunoglobulin domains, some of which have already been matured by the immune 
system [96].  In synthetic libraries such as the one used in this project (Tomlinson I, based 
on a single human framework for VH (DP-47) and Vκ (DPK9))  
[see www.geneservice.co.uk/products/proteomic/datasheets/tomlinsonIJ.pdf] 
combinatorial diversity is introduced into a limited number of antibody scaffolds by 
substituting degenerate complementarity-determining regions (CDRs) within a fixed 
antibody sequence.  The specificity of any antibody resides in the six CDRs that shape the 
antigen binding sites [97].  There are three CDRs on each of the variable-heavy and -light 
chains. Structural studies have shown that five of the six CDRs have limited structural 
variation.  The CDR3 of the heavy chain (VH-CDR3), the most diverse loop in composition 
and length is estimated to have a potential diversity of 1023 sequences, and it is the most 
central to the antigen-binding site of all CDRs [98].   
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To improve antibody affinity, various in vitro strategies have been optimised to mimic the 
mammalian in vivo process of somatic hypermutation and selection [99].  These include 
site-specific mutagenesis, combinatorial mutagenesis of CDRs, random mutagenesis of the 
entire gene, mutator strain, error-prone PCR or chain shuffling [78].  In the immune 
system, antibodies are produced either by plasma cells that have differentiated from 
naive B cells which have encountered and bound to an antigen, or by long-lived memory 
cells, which produce antibodies with improved binding affinity due to hypermutation [85].  
Technologies for making antibodies in vitro by imitating the selection strategies of the 
immune system have emerged.  The use of filamentous bacteriophages with their ability 
to display single antibody species on the surface have allowed the production of soluble 
antibody fragments, which are secreted from infected bacteria.  As in the immune system, 
the V genes can be subjected to random mutation which may generate species with 
higher binding affinities for selection. 
 
1.8.4 Generation of Small Antibody Fragments 
Antibody libraries displayed on phage have successfully been used in both scFv and Fab 
formats.  Fab fragments are usually more stable than Fv fragments, as the latter tend to 
dissociate because of the lack of covalent or disulphide bonds between the two chains.  
The expression of the scFv fragment has less toxic effects on the producing cells than 
larger Fab molecules, resulting in better yields and diversity in scFv libraries (Figure 1.10) 
[89].  Expression in E. coli ensures that sufficient quantities of scFv can be easily produced. 
Many secreted eukaryotic proteins such as antibodies require disulphide bonds for 
stability, and the oxidising environment of the E. coli periplasm, where filamentous phage 
assembles, provides the appropriate conditions for antibody folding [90].  For tumour 
imaging using immunoscintigraphic techniques, the use of whole antibodies is not ideal, 
due to their slow blood clearance and their uptake by the liver.  Smaller antibody 
fragments, such as Fab and scFv, may be utilised instead, as these are cleared rapidly 
through the kidneys [88].   
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Phage display has identified a number of antibody fragments against a range of diseases.  
A highly characterised scFv, MFE-23, was selected using phage display by Chester and co-
workers against carcinoembryonic antigen (CEA), a tumour-selective marker which is 
highly expressed in a range of cancers including most gastrointestinal, breast, lung and 
ovarian carcinomas [84].  MFE-23 scFv is the most characterised scFv and was the first to 
enter clinical trials.  The safety and efficacy of radiolabelled MFE-23 for imaging CEA-
expressing tumours in a cohort of 10 patients, was examined using [123I]-MFE-23.  It 
showed stability and rapid clearance from the blood, with specific uptake seen in the 
tumour, although high uptake by the kidneys was also observed [76].  Thirteen scFv have 
been selected against carbonic anhydrase IX (CAIX) a biomarker for the early stages of 
renal clear cell carcinoma (RCC) but not in corresponding normal tissue, allowing for the 
potential development of new immunotherapies for the treatment of RCC [100].  Phage 
display on LNCaP C42B cells selected scFv against intercellular adhesion molecule 1 
(ICAM), which upon binding to ICAM effectively blocks prostate cancer invasions in vitro 
through extracellular matrix components [101].  A number of antigens expressed in 
hormone-refractory PC were screened and one identified as the activated leukocyte cell 
adhesion molecule (ALCA) by immunohistochemistry, its potential advantages in screening 
PC is still under evaluation [102].  scFv against PSMA has been successfully selected by 
Elsässer-Beile and co-workers and its potential for therapy has been evaluated by the 
conjugation of immunotoxins [56].   
 
Despite the advent of smaller antibody fragments which provide faster delivery vehicles, 
mAbs are not yet redundant and are still used to target and deliver potent drugs such as 
ibritumomab tiuxetan (Zevalin) and [131I]-tositumomab (Bexxar), and one drug conjugate, 
gemtuzumab ozogamicin (Mylotarg).  Although mAb larger size means slower clearance 
from the blood supply and poor tumour delivery, they still show improved affinity over 
smaller antibody fragments (scFv and Fabs) [103].  A balance between high affinity binding 
and improved tumour penetration and rapid clearance has been addressed by the 
engineering of antibody fragments such as scFv, diabodies Fabs and minibodies which 
have shown improved tissue penetration as well as affinity.  
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1.9 PEPTIDES AND CANCER IMAGING 
 
Over the last 30 years, monoclonal antibodies have been hailed as magic bullets for 
imaging and treating cancer.  The difficulties previously experienced with the use of whole 
antibodies were overcome when smaller antibody fragments showing improved binding 
and penetration became available, and peptides have since attracted interest due to their 
relatively small size (1.5 kDa) and high affinity binding. 
 
Peptides are molecules ranging from 2 to 50 amino acids in length linked together by 
peptide bonds.  Unlike proteins, small peptides generally lack a well-defined three-
dimensional tertiary structure.  They can exist naturally, but more importantly can also be 
designed synthetically as novel molecules [104].  Due to their molecular structure and 
small size, peptides have a number of potential advantages over antibodies.  Their 
hydrophilic nature and small size allow for rapid tissue permeation after systemic 
injection, and rapid elimination from the body by either the renal or the hepatobiliary 
route.  They are relatively stable molecules that can withstand harsh modification and 
radiolabelling conditions in aqueous solution; however peptides are particularly sensitive 
to peptidases, which can rapidly degrade them in plasma unless modifications are 
introduced.  They are also non immunogenic, readily radiolabelled, being suitably large 
enough to attach a radioactive isotope without affecting their binding ability. 
 
1.9.1 Somatostatin Analogues 
Somatostatin analogues were the first peptides to be exploited and are now commonly 
used for localising neuroendocrine tumours.  Their high binding affinity and the 
subsequent internalisation of ligand-receptor complexes have proven valuable in 
detecting neuroendocrine tumours by nuclear medicine [105, 106]. 
 
Somatostatin is a regulatory tetradecapeptide which is endogenously produced by the 
hypothalamus and pancreas and has a wide spectrum of actions on multiple organs[107].  
The most well defined biological activity of somatostatin is its inhibitory effect on the 
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secretion of numerous hormones, viz. growth hormone, thyrotropin, insulin, glucagon, 
vasoactive intestinal peptide and secretin and to date, radiolabelled analogues of 
somatostatin have been the gold standard for peptide-receptor imaging and therapeutic 
agents, with clinical success with [111In]-DTPA-octreotide (Octreoscan® Mallinckrodt 
Medical Inc. USA).  
 
1.9.2 Substance P 
Substance P (SP), functions as a neurotransmitter, neuromodulator and a potent 
vasodilator.  It is distributed through the central and peripheral nervous system and has 
been found in glial8 tumours, medullary thyroid carcinoma and breast tumours.  [111In]-
DTPA-Arg-SP has been synthesised for diagnostic imaging of SP receptor positive 
autoimmune diseases such as inflammatory bowel disease and arthritis as well as SP 
receptor positive neoplasms [108]. 
 
1.9.3 Vasoactive Intestinal Peptide 
Vasoactive intestinal peptide (VIP), a neuropeptide which binds to two G-coupled 
receptors (VPAC1-R and VPAC2-R) has been identified in normal prostate cells and is over 
expressed in malignant prostate tissues [109].  VIP stimulates PSA and increases 
proliferation of prostatic epithelial cells in culture as well as increasing angiogenesis acting 
as a survival factor in androgen-independent PC cells.  VIP induces neuroendocrine 
differentiation in LNCaP cells and protects from apoptosis in PC3, suggesting it is involved 
in prostate carcinogenesis and its evolution to a more aggressive form [110-112].  Rekasi 
and co-workers developed a series of analogues which have antagonistic properties (JV-1–
50, JV-1–51, JV-1–52, and JV-1–53) to block the action of VIP and subsequently the 
proliferation of the cancer cells [113]. 
 
1.9.4 Neurotensin 
Neurotensin (NT) is a 13 amino acid neuropeptide found in the brain and gut and is 
implicated in the regulation of LH and prolactin release.  [125I-Tyr3]-NT selectively binds to 
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endocrine pancreatic cancers over normal and chronic pancreatitis.  Improved clearance 
was observed with [111In]-DTPA [114].  
 
1.9.5 Gastrin and Cholecystokinin 
Gastrin and cholecystokinin (CCK), are gut-brain peptides with a number of roles in the 
gastrointestinal tract and the brain and bind with a strong affinity to CCK-B receptors.  This 
receptor is over-expressed in a number of human tumour tissues, such as small cell lung 
cancers (SCLC), medullary thyroid carcinomas, gastrointestinal tumours and stromal 
ovarian cancers [115]. 
 
1.9.6 Bombesin Receptors 
Bombesin (BN) receptors belong to the superfamily of G-protein-coupled receptors9, 
characterised by the typical seven transmembrane domain [116, 117].  The bombesin 
receptors comprise the gastrin-releasing peptide receptor (GRP-R or BB2-receptor), the 
neuromedin B receptor (NMB-R or BB1-receptor) and the orphan bombesin receptor 
subtype-3 (BRS-3 or BB3-receptor).  These receptors mediate the biological effects of 
bombesin related peptides.  GRP-R is characterised by high binding affinity for gastrin-
releasing peptide (GRP) and bombesin, whereas NMB selectively binds with only 
moderate affinity for NMB-R [118].   
 
GRP-R mediates a variety of cellular responses which include modulation of smooth 
muscle contraction, secretion of gastric acid and pancreatic enzymes, regulation of body 
temperature and stimulation of cell growth [119].  GRP-R has been localised in the central 
nervous system and in peripheral tissue [120], and it is also expressed in a number of 
neuroendocrine and cancer tumours, ectopically in several human cancer cell lines such as 
prostate, breast, small-cell lung and colon carcinoma [116, 121, 122].   
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Of particular clinical significance is the finding that there is a considerable receptor over-
expression in neoplastic transformed prostate and breast tissue [118, 123].  After peptide 
binding to the GRP-R, a number of cellular signal transduction pathways are activated, 
such as MAPK, which result in cell proliferation and growth [124].  Extensive studies on 
GRP and its interaction with GRP-R have observed promotion of tumour growth in a 
number of normal and human cancer cell lines, both in culture and in nude mice 
xenografts [125, 126].  Antagonists have been developed as anticancer compounds that 
exhibit antitumour activity both in vitro and in vivo, by interfering with growth factor-
signalling pathways such as epidermal growth factor (EFG) and vascular endothelial 
growth factor (VEGF) [127].   
 
1.9.7 Bombesin Peptides 
Bombesin, a tetradecapeptide, was first isolated from the skin of the European frog 
Bombina bombina in 1971 by Anastasi and colleagues [128].  The first bombesin-like 
peptide was isolated from porcine gastric tissue and named gastrin-releasing peptide 
(GRP) because of its potent gastrin-releasing action [128].  GRP belongs to the family of 
bombesin-like peptides neuromedin B (NMB) and amphibian bombesin (BB) [116].  GRP 
and bombesin share a highly-conserved 7-amino acid C-terminal sequence that is required 
for high-affinity binding to the GRP-preferring receptor [124].  BN-like peptides, including 
BN, GRP and NMB are involved in the regulation of a large number of biologic processes in 
the gut and central nervous system and mediate their action by binding BN receptors 
located on the cell membrane of target cells. 
 
GRP is believed to function as a paracrine/autocrine growth stimulator in many cancers 
[129].  GRP-R is rarely detected in benign prostate hyperplasia and healthy prostate tissue 
[118], but high levels of these receptors have been seen in PC3 and DU145, androgen-
independent cell lines from advanced stages of prostate cancer [33].  Due to the 
expression pattern and internalisation of GRP-R, it is potentially an early indicator of 
cancer and an attractive target for both radiotherapy and imaging; possibly GRP-R is an 
ideal target to image PC before and after treatment, to measure the course of the cancer.  
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GRP has also been shown to stimulate cell proliferation in PC3 cells and an antagonist of 
GRP-R can inhibit the growth of a number of prostatic carcinoma models [118].   
 
Van de Wiele and co-workers first reported the radiolabelled targeting of breast and 
prostate cancers with a [99mTc]-bombesin conjugate, RP527 [130].  Several other bombesin 
radioligands have been developed and characterised both in vitro and in vivo by Volkert’s 
group [131, 132] and the bombesin analogues Demobesins 1-6 have been developed by 
Nock and co-workers [116, 133]. 
 
Schroeder and co-workers [134] have determined peptide stability in vivo, biodistribution 
and GRP-R targeting potential by SPECT-CT of 5 radiolabelled bombesin analogues, 
antagonists PEPSIN, AMBA, MP2346 and MP2653 radiolabelled with 111InCl3 and 
antagonist DB 1 radiolabelled with 99mTc.  Biodistribution studies on PC3 tumour-bearing 
mice showed greater uptake of DB 1 than the 4 agonists, PEPSIN and AMBA were the most 
promising GRP antagonists with sufficient in vivo stabilities as well as high tumour uptake 
and retention.  177Lu-AMBA (177Lu-DO3A-CH2CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-
NH2) was taken forward for phase I clinical trials.  The agonist shows high affinity to GRP-R 
with 2-fold greater affinity to PC3 (Kd 1.02 nM) over LNCaP (Kd 0.656 nM) and DU145 (Kd 
0.536 nM), promising for imaging and therapy over advanced PC [135]. 
 
1.9.8 Demobesin 4 (DB 4) 
Demobesin 4, an agonist bombesin analogue, was selected for its ability to target GRP-R-
positive tumours in vivo with rapid internalisation in PC3 cells [116], for use as a potential 
imaging and therapeutic agent.  The hydrophilic nature of DB 4 has been demonstrated in 
vivo by its excretion via the kidney, and this combined with its specific binding to GRP-R 
thereby highlights its potential effectiveness in the diagnosis, staging and imaging of PC.  
DB 4 was modified at the N-terminal by coupling an open-chain tetra-amine framework 
for effective binding of 99mTc (Figure 1.15). 
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Tetra-amine-derivatised DB 4 was synthesised by piCHEM R&D, Graz, Austria, using solid-
phase peptide synthesis (SPPS), employing 9-fluorenylmethyloxycyclocarbonyl (Fmoc) 
protection strategy, and supplied as a lyophilised powder at >95% purity.  
 
Other bombesin analogues have been designed such as Demobesin 3, which is structurally 
similar to DB 4 as it is based on the full parent bombesin tetradecapeptide sequence after 
minor modifications.  Demobesins 5 and 6 are truncated peptides and are more lipophilic, 
being based only on the essential residues needed for receptor interaction, the bombesin 
(7-14) motif.  Both DB 4 and 6 have undergone substitution of the oxidation-sensitive 
methionine (Met14) by norleucine (Nle14) (Table 1.1) [116, 133]. 
 
Table 1.1:  Analytical data for bombesin analogues, Demobesin 1 & 3-6.  BB = bombesin [Pyr-Gln-Arg-Tyr-
Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2]. 
 
Peptide 
conjugate 
Sequence 
% 
Purity 
Excretion Interaction 
Demobesin 1 [N4-Bzdig,D-Phe
6,Leu-NHEt13,des-
Met14]BB(6-14) 
>96 Renal Antagonist 
Demobesin 3 [N4
0, Pro1,Tyr4]BB >98 Renal Agonist 
Demobesin 4 [N4
0, Pro1,Tyr4Nle14]BB ≥ 98 Renal Agonist 
Demobesin 5 [N4-Bzdig)
0]BB(7-14) 99 Hepatobiliary Agonist 
Demobesin 6 [(N4-Bzdig)
0), Nle14]BB(7-14) ≥ 98 Hepatobiliary Agonist 
 
 
Other promising BN-analogues have been tested in preclinical studies using PC3-bearing 
mice include the DOTA-chelated compounds AMBA and Pesin and the DTPA-chelated 
compound MP2653 [136]. 
 
 
 
1.10 RADIOPHARMACEUTICALS AND CANCER 
 
1.10.1 Therapy 
Therapeutic radiopharmaceuticals are radiolabelled molecules designed to deliver 
therapeutic doses of ionizing radiation to targeted sites within the body.  The treatment of 
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cancer with radiolabelled molecules has been in use for over the last 50 years [137].  
Treatment of thyroid cancer, relief of bone pain associated with skeletal metastasis and 
neuroblastoma have been respectively treated with therapies such as [131I]-sodium iodide, 
[89Sr]-strontium chloride or [32P]-sodium phosphate and [131I]-metaiodobenzylguanidine 
(MIBG) [138]. 
 
The design and selection criteria for therapeutic radionuclides include; half-life, the types 
of emission (α, β, γ, auger or conversion electrons), specific activity, chemistry, internal 
dosimetry, radiation safety, energy and cost of production and availability.  One of the 
most important parameters to take into consideration is the physical half-life which 
should be matched with the in vivo pharamacokinetics of the radiolabelled compound.  
With too short a half-life, most of the decay will have occurred before the compound 
reaches the target site, conversely, too long a half-life may cause unnecessary radiation 
dose to normal tissues during metabolism and excretion of the labeled compound [139].  
 
The nature of the particulate emission is also important to consider, ensuring maximum 
therapeutic effectiveness.  β-particles,  α-particles and auger electrons all have different 
effective ranges and linear energy transfer (LET) properties.  LET is the measurement of 
the energy deposited per unit distance over the path of the radiation (KeV/μm) [139].    β-
particles are advantageous and the most popular choice as they have high energy 
electrons emitted from the nucleus and lower ionization density [138]. 
 
Radiation damage may occur by one of two ways; the direct action or indirect action.  In 
the direct action, radiation may directly hit a particularly sensitive atom or molecule in the 
cell.  The damage from this is irreparable, and the cell either dies or is caused to 
malfunction.  In the indirect action, radiation can damage a cell indirectly by interacting 
with water molecules in the body causing free radicals.  These free radicals can cause 
damage DNA.  The cellular DNA damage leads to disruption in cellular function, mutation, 
and cancer [138].  
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1.10.2 Imaging 
Imaging modalities can be broadly divided into primary anatomical and primary molecular 
imaging techniques.  Computed tomography (CT), magnetic resonance imaging (MRI) and 
ultrasound are classed as primarily anatomical, as these techniques are limited by their 
inability to detect disease until the structural changes in tissue are large enough to be 
detected by these technologies [140].   
 
Molecular imaging provides the visualisation, characterisation and measurement of cancer 
at both molecular and cellular levels.  A number of new technologies directed at the 
diagnosis and treatment of a disease has been developed recently, which has enabled the 
production of internal images of the body.  The use of preoperative parameters such as 
PSA and the Gleason score provide limited information of cancer stage and aggression, 
but little to no information about location or advancement and metastasis. 
 
1.10.3 X-ray and Computed Tomography  
X-rays, a form of electromagnetic radiation, are used as standard practice for skeletal 
imaging.  The electron-dense bone and cartilage absorb most of the x-ray photons; the 
unabsorbed radiation generates radiographic images by photoelectric processes.  This 
method, however, is not normally sufficiently sensitive for most soft tissues such as 
tumours, which may however show up as a shadowing on an x-ray film. 
 
Computed Tomography generates 3-D images using digital geometry processing, whereby 
a series of 2-D x-ray images are taken around a single axis of rotation.  The data obtained 
can be manipulated through a process known as windowing, allowing the visualisation of 
tumours, their depth and their location in respect to other tissues and organs. 
 
1.10.4 Magnetic Resonance Imaging  
MRI provides images similar to those obtained by CT, although with increased sensitivity, 
faster acquisition times and greater soft-tissue contrast.  Unlike CT, it does not use 
ionising radiation (reduced risk to patients), but uses a powerful magnetic field to align the 
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nuclear magnetisation of (usually) hydrogen atoms in water in the body.  Radio-frequency 
fields are used to systematically alter the alignment of this magnetisation causing the 
hydrogen nuclei to produce a rotating magnetic field detectable by the scanner; different 
tissues emit a more or less intense signal based on their structure and chemical 
composition [141].  With the combination of a paramagnetic contrast agent such as 
gadolinium, MRI can provide high sensitivity for the detection of vascular tissue (tumours), 
and permit assessment of brain perfusion in stroke patients [142].  However, concerns 
over the safety and toxicity of gadolinium-based contrast agents have been raised with 
regard to impaired kidney function.  
 
1.10.5 Ultrasound 
Ultrasound imaging has advantages over MRI and CT because of its moderate cost, real-
time imaging and usefulness in making physiological measurements.  It is a form of non-
ionizing radiation with no known biological effects.  Typical diagnostic sonographic scans 
operate in the range of 2-18 megahertz.  A trade-off between spatial resolution of the 
image and imaging depth is a limitation of this procedure; although able to image soft 
tissues within the body, deeper structures such as the liver and kidneys have poorer 
resolution due to the lower frequencies employed.  Improved images have recently been 
achieved using ultrasound Doppler techniques, which demonstrate the presence of blood 
flow by detecting a frequency shift in the radio-frequency signal reflected from moving 
blood.  Ultrasound contrast agents containing encapsulated microbubbles10 (small gas-
filled microspheres with specific acoustic properties) have been used to image tumour 
microcirculation [140].  Microbubble contrast agents have been used to overcome 
problems of imaging microvasculature in the prostate [143]. 
 
Primary molecular imaging modalities such as optical imaging, positron emission 
tomography (PET) and single photon emission computed tomography (SPECT) offer the 
potential to detect molecular and cellular changes in disease, even before the tumour is 
                                                 
10
 Microbubbles are gas-filled agents that have a high degree of echogenicity (reflect ultrasound waves).  The 
echogenicity between the microbubbles and surrounding soft tissue is considerable, enhancing the 
ultrasound backscatter, producing a sonogram with increased contrast.  
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large enough to cause structural changes.  However these techniques do not possess very 
high spatial resolution, but this can be overcome by using an optimised combination of 
anatomical and molecular imaging modalities, such as PET-CT, PET-MRI and SPECT-CT, 
thereby combining the detection of pathophysiological changes in early disease by high 
structural resolution. 
 
1.10.6 Positron Emission Tomography  
PET, a technology which produces 3-D images of functional processes within the body, is 
far more sensitive than the anatomical imaging modalities previously mentioned.  A 
tumour-targeting radiotracer is intravenously injected, and upon targeting the cancer, it 
emits positrons.  The collision of a positron with an electron cause the release of two 
gamma photons at 180° to each other; this coincidence of events can be detected, 
reconstructed and analysed to determine the location and concentration of radiation 
within the body [144].     PET has been used to image a variety of different cancers, as well 
as neurological and cardiovascular conditions [145, 146].  PET can also detect increases in 
the metabolic activity of tumours with suitable radiotracers.  The most common 
radiotracer in use is fluorine-18 bound to fluorodeoxyglucose ([18F]-FDG), the principle 
being that tumours have an increased number of glucose transporters.  These reflect the 
high metabolic rate of cancerous cells, due to their increased rate of cell division which is 
often supported by an increased level of glucose consumption in comparison with other 
cells [147].  Unfortunately, the uptake of 18F-FDG is dependent on anabolic activity, and its 
incorporation into prostate cancer cells is not particularly high, because of their low 
metabolic activity [146]. 
 
1.10.7 Single Photon Emission Computed Tomography  
Using a gamma camera, SPECT monitors the emission of single photons, acquiring 2-D 
images (projections) from multiple angles.  These can, with the aid of specialised software, 
be applied to a tomographic reconstruction algorithm, yielding a 3-D dataset which can be 
further manipulated to show thin slices along any chosen axis of the body.  The acquisition 
process is very similar to planar gamma camera imaging, therefore the same isotopes can 
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be used.  The combination of SPECT and CT provide a very detailed and informative 
picture of the uptake of a radiolabelled ligand.  CT greatly assists in orientating the uptake 
by certain organs, as without this, it would be much harder to know where uptake occurs, 
and to understand the biodistribution of the radioligand. 
 
Improved attenuation correction, increased specificity as well as accurate depiction of the 
localisation of disease are many advantages of SPECT-CT.  Endocrine and neuroendocrine 
tumours, such as pulmonary nodules can be visualised by this technology, a range of 
cancers including those of the lung, brain and prostate, as well as malignant and benign 
bone lesions and infection [148].  SPECT is also used for myocardial perfusion imaging 
(MPI), used for the diagnosis of ischaemic heart disease, and functional brain imaging for 
the diagnosis of dementia. 
 
 
1.10.8 SPECT-CT and Research 
Small-animal SPECT-CT has facilitated and greatly aided in the research of new 
radiopharmaceuticals and novel drugs.  Imaging considerably reduces the number of 
animal models needed to obtain statistically significant data, as well as giving an insight 
into the biodistribution of an injected radiotracer in tumour-bearing models (Figure 1.12) 
[149].  Multiple pin-hole SPECT imaging provides <1 mm resolution in small animals, with 
good sensitivity.  Fusion with CT images provides co-localisation of structural and 
functional information.  CT images are particularly beneficial to aid in locating tumours 
that are growing subcutaneously [150]. 
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Figure 1.12:  Principle of NanoSPECT-CT, showing the combination of anatomical and molecular imaging of 
tumour-bearing mice [150]. 
 
SPECT imaging enables visualisation of the in vivo distribution of the radioligand.  Scanning 
of animal models such as mice at various times (dependent on the isotope of choice) 
following dosage permits visualisation of the uptake into organs and tumours. 
 
Dynamic acquisition (continuous repetitive rotation acquisition) allows the monitoring and 
tracking of a radiolabelled ligand from the time of administration.  It enables one to 
understand the kinetics of distribution and clearance of the radioligand.  Typically, the 
mouse is placed on the SPECT bed before intravenous injection of the radioligand, then 
scanned over a set period of time following the injection. The data acquired can be 
transferred to a video format, allowing for visualisation of the behaviour of the ligand in 
vivo over time. 
 
NanoSPECT/CT 
Scanner 
Multiple overlapping pin-
hole SPECT images 
Iterative image 
reconstruction 
Radionuclide image Fused image   CT image   
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SPECT-CT was used for in vivo imaging studies with both radiolabelled antibody fragments 
and peptides during the course of this study. 
 
 
1.11 RADIOPHARMACEUTICALS  
 
Isotopes selected for imaging should have the following characteristics:  they should be 
pure γ-emitters with little to no particulate emission.  They should have a suitable 
emission-energy (typically 100-250 keV) and should be chemically reactive to allow 
incorporation to selected ligands.  The half-life should be comparable with or less than the 
half-life of the pharmaceutical under study, and finally they should be non-toxic. 
 
1.11.1 Iodine Chemistry 
Radiohalogenation is one of the most commonly used procedures for radiolabelling 
proteins and peptides, since halogens form stable covalent bonds with carbon atoms, and 
there is a good understanding of halogen chemistry.  Minimal alterations to peptides and 
proteins are caused because of the steric properties and electronic nature of halogens, 
enabling radiolabelling to be accomplished to high specific activities.  123I, 125I and 131I are 
extensively used for scintigraphic imaging due to their relative low cost and wide 
availability [151].  
 
Direct labelling of tyrosine residues is the most favoured approach to radiohalogenation of 
peptides, and in the absence of natural tyrosine residues, the substitution of Tyr for Phe 
can be incorporated to produce analogues, or Tyr can be added to the sequence at sites 
not critical for biological activity or receptor binding [152].  Radiohalogens must be 
oxidised to form an electrophilic species to enable radiolabelling.  Oxidising agents such as 
Chloramine-T (N-monochloro-p-toluene-sulphonamide) [153], Iodogen11 [154] and N-
halosuccinimides (Figure 1.13) are commonly used.  The reactive species generated by any 
of these oxidants is then incorporated into a reactive aromatic amino acid residue of the 
                                                 
11
 Chapter 2 - section 2.2.11.1 
Chapter 1  Introduction 
    45 
 
peptide (preferentially tyrosine).  Removal of unreacted radio-iodine from the reaction 
mixture can be accomplished by separation techniques such as reverse- and normal-phase 
chromatography, and size-exclusion chromatography [151]. 
 
   
 
Figure 1.13:  N-haloamine oxidising reagents.  X = fluorine, bromine, iodine or astatine. 
 
One disadvantage of this approach can the difficulty of obtaining a mono-iodinated 
product from Tyr, because the ring tends to iodinate in both the ortho- and para-
positions.  Furthermore, Tyr residues are prone to in vivo dehalogenation. 
 
 
1.11.2 Technetium Chemistry 
Radiolabelling with 99mTechnetium is one of the commonest radiolabelling processes used 
in nuclear medicine because it has a number of important advantages over other 
radiopharmaceuticals.  It is readily available at low commercial cost, since it is obtained 
from generators on site rather than having to be obtained from an outside source.  99mTc 
has excellent imaging properties; it is a gamma-emitter providing high specific activity and 
a favourable dosimetry, producing superior images using conventional gamma cameras.  
As a result of its comparatively short half life (6 hours), it can be administered in relatively 
large doses ideal for imaging without giving a significant radiation dose to the patient 
[155].  Its versatile chemistry means it can be reduced to a number of different oxidation 
states, so it is able to react with a range of chelating agents, forming novel complexes 
which may then be used in different clinical applications. 
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99mTc, a metastable state nuclear isomer, is the immediate daughter-product of the parent 
isotope molybdenum-99 (Figure 1.14).  
 
 
 
Figure 1.14:  Decay scheme for 
99
Mo and 
99m
Tc.   
 
99mTc has oxidation states from +7 (the highest, the most stable and the form which is 
eluted from the generator to -1).  Radiolabelling reactions with 99mTc involve the reduction 
of pertechnetate (99mTcO4
-), which is relatively inactive chemically, to a lower oxidation 
state which may then be stabilised with a range of ligands, mainly N, O, S and P donors, 
prerequisite for the synthesis of 99mTc-labelled molecules.  During reduction, the ligand 
stabilises the lower oxidation state, otherwise colloidal TcO2 is formed in aqueous media.   
Pertechnetate, when reduced in the presence of ligands, usually does not release all its 
oxygen atoms, leading to complexes in which a TcO3+ and TcO2
+ core is identified [156].  
The most common and frequently-used technetium core is [Tc=O]3+, which is very stable 
in the presence of a strong chelating ligand.  [Tc=O]3+ forms a square pyramidal 
oxotechnetium complex with tetradentate ligands.  However, in labelling Demobesin 4, 
the [O=Tc=O]+ core was used, as it forms an octahedral technetium complex at the 
polydentate liganding tetra-amine site on this analogue (Figure 1.15). 
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Figure 1.15:  [
99m
Tc]-DB 4 chelation via the [O=Tc=O]
+ 
core (green) with the tetra-amine-derivatised chelator 
(red).  Substitution of Met
14
 by Nle
14
 was performed to produce a more oxidation-resistant analogue [116, 
157]  
 
Radiolabelling of peptides with 99mTc can be achieved by direct or indirect methods.  
Direct labelling with 99mTc involves the attachment of free thiol groups generated by 
reduction of a cysteine bridge to reduced 99mTc (Figure 1.16) [155].  
 
 
 
Figure 1.16:  Direct labelling with 99mTc [155]. 
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Only the peptides in which cysteine residues are cyclised are amenable to this approach; 
however since cyclisation of the peptide may be necessary to provide the configuration 
needed for receptor binding; the reduction of this peptide may inactive the peptide. 
 
To overcome this problem, it is possible to engineer the peptide sequence to provide a 
technetium labelling site by extending the peptide sequence.  Most tetra-peptides are 
able to complex technetium, and to ensure effective labelling, it is necessary to provide a 
site that is preferred over the rest of the peptide sequence.  Normally this would be 
achieved by the incorporation of cysteine residues, because Tc-S bonds are extremely 
stable.  
 
Another approach exploits the commonly incorporated His-tag, which is often used for the 
purification of such recombinant proteins by immobilised ion metal affinity 
chromatography [158]. 
  
Tc(I) can be prepared from pertechnetate eluted from the Tc generator and is stabilised as 
a tricarbonyl complex in aqueous solution which readily exchanges its water ligands for 
the sp2 electrons from imidazole nitrogen atoms, resulting in complexes which are very 
stable [159]. 
 
This labelling approach has the advantage of avoiding the introduction of unpaired 
cysteines into the scFv, which present problems for routine production and storage, due 
to interference with generation of the disulfide bonds in the scFv fragment resulting in 
misfolding and leading to poor production yields and covalent aggregates [159].  
 
 
Indirect labelling can be performed using a bifunctional chelating agent (BFCA).  For 
technetium, the BFCA must follow several requirements; firstly, the binding unit should 
selectively stabilise technetium at an intermediate or lower oxidation state so that the 
complex is not subject to redox reactions; secondly, the BFCA should form a 99mTc-
complex that is both thermodynamically stable and kinetically resistant to dissociation, 
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and thirdly, the conjugation group should be easily attached to the peptide.  The post-
labelling approach is a common method to label proteins and peptides; first a BFCA is 
attached to the peptide to form a BFCA-peptide conjugate.  The BFCA can be attached to 
C- or N-terminus of the peptide, as well as be attached to the side chain or backbone of 
the peptide, providing it does not affect the receptor binding affinity (Figure 1.17)  [139].   
 
 
Figure 1.17:  Schematic representation of indirect labelling with 
99m
Tc, commonly employed for 
radiolabelling of DB 4. 
 
Currently reagents employed for introducing bifunctional groups include 
diethylenetriamine-penta-acetic acid, N2S2 [160], N3S [161], boronic acid adducts of 
technetium dioxime [162], 6-hydrazinopyridine-3-carboxylic acid (HYNIC) and the 
tetraamine chelator employed for DB 4 (Figure 1.15) [163, 164].   
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1.12 SCOPE OF PROJECT 
 
PC remains one of the most common cancers in men.  The treatment and survival rates 
are highly dependent on the growth-type and stage of the cancer.  Currently there 
remains a fundamental gap in the ability to diagnose PC and to stage it effectively.  The 
Gleason score and measurement of PSA levels do not provide detailed and accurate 
enough information to allow the best form of treatment to be selected for the patient 
during his course of treatment.  In addition, it is also important to be able to screen 
patients for recurrent androgen-independent PC, which usually takes on a more 
aggressive nature (Figure 1.18). 
 
 
 
Figure 1.18:  A schematic diagram showing the development of PC and the effectiveness of treatment over 
time. 
 
The rationale behind this project was to design a radiopharmaceutical that would be able 
to bind specifically to the selected molecular target.  The intention was to develop a 
molecule that (a) could be easily conjugated with a radioactive isotope, and upon systemic 
intravenous injection would target receptors or ligands that were expressed primarily by 
the cancerous tissue; (b) would clear the circulation rapidly, and (c) would allow imaging 
of the development of the cancer before and after treatment. 
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PSMA and GRP-R were selected as potential targets, since both are expressed 
preferentially in PC.   
 
For the PSMA project the aims were to screen phage libraries for scFv against both cell-
expressed PSMA and recombinant PSMA to generate diabodies from high binding clones, 
to radiolabel these with suitable radionuclides and finally to compare scFv and diabody 
pharmacokinetics and targeting efficacy.   
 
For the GRP-R project, the main aims were to compare methods for measuring GRP-R 
expression in a range of PC cell lines both in vitro and in vivo and to determine changes in 
the levels of expression with PC advancement.  The potential relationship between 
androgen status and GRP-R expression would also be explored.  Radiolabelling and 
imaging in vivo would be performed to assess the distribution and behaviour of a peptide-
based radioligand.  Quantification of radiotracer uptake from imaging would be 
performed and its relationship with in vitro measures of GRP-R expression explored.   
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2 MATERIALS AND METHODS 
 
2.1 MATERIALS 
 
2.1.1 REAGENTS 
 
Reagent 
 
Supplier 
 
0.25% (w/v) Trypsin – 0.53 mM EDTA solution Cambrex 
10x Tris/Glycine/SDS  buffer - electrophoresis grade National Diagnostics 
2x TY media Cancer Research UK 
3,3’,5,5’-tetramethylbenzidine (TMB) Sigma-Aldrich 
A 
Acetone 
 
VWR 
Acetonitrile – HPLC grade Aldrich Chemicals Co. 
Agarose Sigma-Aldrich  
Albumin, bovine Sigma-Aldrich 
Ammonium persulfate Sigma-Aldrich  
Ampicillin, sodium salt Calbiochem 
Anti-M13 HRP monoclonal conjugate Invitrogen 
AR42J (Rat pancreatic) Clare Hall, Cancer Research 
B 
Beta-actin (ACTB) 
Beta-mercaptoethanol 
 
Applied Biosystems 
VWR 
Bio-agar Biogene Ltd 
Bio-assay dish Nunc 
Brilliant blue R staining Sigma-Aldrich  
Bovine serum albumin (BSA) 
C 
Sigma-Aldrich  
SuperScript® III first-strand synthesis system  Invitrogen 
Cork disc VWR 
D  
D2B 
DB 4 
Donated by Department of 
Experimental Oncology, Italy 
piCHEM R&D, Graz, Austria 
DU145 cell line  
 
E 
Donated by Dr. David Prowse, 
Molecular Oncology & 
Imaging, QMUL 
E.coli TG1 and HB2151 American Type Culture 
Collection (ATCC) 
ECL ™ Western blotting detection reagent GE Healthcare 
EDTA Sigma-Aldrich  
Ethanol BDH Laboratory 
Ethidium bromide Fisher 
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Express five serum-free medium Invitrogen 
F 
Foetal bovine serum 
 
Invitrogen 
First strand cDNA synthesis Kit Invitrogen 
G  
Gentamycin sulfate  
(Sterile -filtered, aqueous solution, cell culture tested) 
 
Invitrogen 
D-(+)-Glucose (>99.5%) Sigma-Aldrich 
Glycerol VWR 
Glycine (>99%) Sigma-Aldrich  
Goat anti-mouse alexa488 IgG (Cat no: A-11001) Invitrogen 
H 
HEPES buffer 
 
Sigma-Aldrich 
High five (Hi5) growth medium  Invitrogen 
High performance chemiluminescence film GE Healthcare 
Horseradish peroxidase anti-M13 antibody  GE Healthcare 
Horseradish peroxidase conjugated protein A  GE Healthcare 
Horseradish peroxidase conjugated protein L  GE Healthcare 
Hydrogen peroxide (30%) VWR 
I 
[125I]- [D-Tyr6[125I], βAla11, Phe13, Nle14]-bombesin (6-14)  
 
Perkin Elmer 
Internal standard for HPLC analysis (Murine antibody PRIAS)  Cancer Research 
Isopropyl-β-D-thiogalactoside (IPTG) Applied Biosystems 
ITLC-silica gel Pall 
K 
Kanamycin sulfate 
 
Calbiochem 
KM13 helper phage Generated in-house 
L 
L-glutamine 
 
Sigma-Aldrich  
LMB3 and FDSEQ primers Genome Centre, QMUL 
LNCaP C81, LNCaP C42B & LNCaP (androgen dependent) Cell 
Line  
Donated by Dr. David Prowse 
Molecular Oncology & 
Imaging, QMUL 
M 
Marvel milk powder 
 
Premier International Food Ltd 
Male SCID beige mice Charles River Research Animal 
Diagnostic Services, London 
Matrigel BD Biosciences 
Methanol (HPLC grade >99%) BDH Laboratory 
MKN45 
Molten H-top 
Clare Hall, Cancer Research  
Clare Hall, Cancer Research 
Monoclonal anti-mouse IgG (whole molecule peroxidase)  Sigma-Aldrich 
Monoclonal mouse anti- PSMA (1H8H5) Zymed, Invitrogen 
N 
NaCl  
 
VWR 
Ni-NTA purification system Invitrogen 
Nitrocellulose membrane BDH Laboratory 
Nunc maxisorb immunotubes Gibco UK 
Chapter 2  Materials 
    54 
 
P 
Para-formaldehyde 
 
Sigma-Aldrich 
Phosphate-buffered saline (PBS) Cancer Research 
Pierce iodination tubes Pierce 
Polyacrylamide  National Diagnostics Ltd 
Polyethylene glycol 6000 VWR 
Ponceau solution Sigma-Aldrich  
Precision plus protein standard  BioRad 
Protease inhibitors cocktail set I Calbiochem 
Protein A sepharose beads GE Healthcare 
Protein assay kit BioRad 
Q 
Quick plasmid miniprep kit 
 
Qiagen 
R  
Restriction endonucleases XhoI, SalI, HindIII & NotI New England Biolabs 
RNeasy mini kit Qiagen 
RPMI 1640 medium 
Rabbit polyclonal anti-GRP-R antibody (Ab39963) 
Rabbit polyclonal anti-GRP-R antibody (NB100-74434) 
Cancer Research UK 
Abcam 
Novus Biologicals 
S 
Slide-A-lyzer dialysis cassettes 
 
Pierce 
Sf9 cells  Invitrogen 
Sodium [125I]-iodide Perkin Elmer 
Sodium acetate trihydrate (>99%) Sigma-Aldrich  
Sodium azide reagentPlus®  Sigma-Aldrich  
Sodium pertechnetate Eluted from Amersham 
‘Drytec’ generator, 
Radiopharmacy Department, 
St.Bartholomew’s Hospital 
Stannous chloride (ACH grade) Sigma-Aldrich  
Streptavidin Invitrogen 
Sucrose Sigma-Aldrich 
Sulphuric acid 95-97% VWR 
T 
Tetramethylethylenediamine (TEMED) 
 
GE Healthcare 
Taq polymerase Invitrogen 
The discovery™ DAB map™ kit Ventana Medical Systems 
Tomlinson phage library Medical Solutions - Gene 
Service 
Triethylamine (>99.5%) VWR 
Trifluoroacetic acid (TFA) (>(99.5) Thermo Scientific 
Triton VWR 
Tween 20 Sigma-Aldrich  
Tryptone Biogene Ltd 
V 
Versene 
 
Cancer Research UK 
Visking tubing Sigma-Aldrich  
W  
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W3MM Blot paper Whatman International Ltd 
 
Y 
Yeast extract 
 
 
Biogene Ltd 
  
 
2.1.2 EQUIPMENT 
 
 
                    Equipment 
 
7900HT Fast real-time PCR system 
         Supplier 
 
Applied Biosystems  
1282 CS universal gamma counter LKB Wallac 
A  
Allegra 21R centrifuge Beckman Coulter 
C  
Cyclone plus storage phosphor system (OptiQuant 
programme) 
Perkin Elmer 
D  
Developer G138i curix 60 processor AGFA  
E  
ELISA plate reader Tecan, Magellan 4 Programme 
G  
Gene pulser machine 
Graphpad prims 5 software 
BioRad Ltd 
Graphpad Inc 
H  
HPLC Beckman 
I  
In-line radioactivity detector for HPLC Raytest 
L  
Large semaphor transphor unit GE Healthcare 
M  
Mini personal thermal cycler 
Microscope (Nikon ACR-1 programme) 
BioRad Ltd 
Axiophot - Zeiss 
N  
Nano SPECT (Invivo scope programme) Bioscan 
NanoDrop 2000 S spectrophotometer Thermo Scientific  
R  
Radioisotope calibrator (CRC15R) Capintec 
Reverse-phase column, C18ODS Phenomenex 
S  
Sephacryl S-200 high-resolution chromatography column GE Healthcare  
L8M shaking incubator Beckman Coulter 
Size exclusion HPLC column (Biosep-sec-s 2000) Phenomenex 
V  
Ventana discovery™ immunohistochemistry unit Ventana Medical Systems 
Vortex Scientific Industries INC 
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2.1.3 BUFFERS 
 
 
Buffer Concentration/Volume Components 
   
FACS Buffer 0.06g Bovine serum albumin (BSA) 
200 mL 0.06g Sodium azide 
 200mL PBS or RPMI  
   
Loading Buffer  7.5 mL Water 
20 mL 2.5 mL 1M Tris-HCl, pH 6.8 
 6.0 mL Glycerol 
 0.004 g 0.5% (w/v) Bromophenol blue 
 4.0 mL SDS (10% w/v) 
   
Blot Buffer  100mL Methanol 
500 mL 400mL 1x Tris-glycine-SDS Buffer 
   
TYE   15g Bacto-Agar 
1 L 8g Sodium chloride 
 10g Tryptone 
 5g Yeast Extract 
   
2x TY Medium  10 g Yeast Extract 
1 L 16 g Tryptone 
 5 g Sodium Chloride 
   
Substrate solution (To develop 
ELISA experiments) 
100 µg/mL Tetramethylbenzidine TMB  
 100 mM Sodium acetate buffer, pH 6.0 
 0.001% Hydrogen peroxide 
   
   
5X Native Purification Buffer  250 nM Disodium hydrogen 
phosphate, pH 8.0 
 5 M Sodium chloride 
   
Native Wash Buffer  1X Native Purification Buffer 
 20 nM Imidazole 
   
Native Elution Buffer 1X Native Purification Buffer 
 250 mM Imidazole 
   
 
 
Restriction Digest Mixture  
 
 
10 µL 
 
 
Miniprep 
(1 x - 30 µL)  0.3 µL BSA 
 1 µL SalI  
 1 µL XhoI 
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 3 µL Buffer 3 (optimal buffer for both 
endonucleases) 
 14.7 µL water 
   
Demobesin 4 Labelling 
 
  
Phosphate Buffer 0.25 M Na2HPO4.2H2O  (A) 
Mix 2 parts of (A) with 1 part 
(B) 
0.25 M Na3PO4.12H2O   (B) 
   
   
   
Radiolabelling Attachment  100 mM HEPES 
Buffer 130 mM NaCl 
 5 mM MgCl2 
 4.7 mM KCl 
 1 mM EGTA 
 100 µg/mL Bacitracin 
 0.1% (w/v) BSA 
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Note:  A superscripted M denotes that further information on the respective item can be 
found in the Materials section.  
 
2.2 METHODOLOGY  1 
 
This methodology relates to the results section in chapter 3 
 
2.2.1 PRODUCTION OF RECOMBINANT PSMA PROTEIN 
 
2.2.1.1 Baculovirus Expression Vector Systems 
Baculoviruses (family Baculoviridae) form part of a large diverse group of double-stranded 
DNA viruses that infect many different species of insects as their natural hosts and is a 
popular system for production of recombinant proteins [165].   
 
The propagation of in-house virus, using pAcGP67A Baculovirus transfer vector (donated 
by Pamela Bjorkman, Howard Hughes Medical Institute Laboratories, California, USA)  to 
deliver the PSMA cDNA into the Baculovirus genome was accomplished by Dr. Stella Man, 
by cotransfection with linearised wild-type AcNPV DNA into Sf912 insect cells [42].  Only 
the large extracellular portion13 (aa 44-750) of the PSMA ligand was utilised, as the smaller 
intracellular portion is only exposed when cells are necrotic or undergoing apoptosis. 
 
2.2.1.2 High 5 Cell Line 
For recombinant PSMA expression, viral infections were performed on High Five (Hi5) 
insect cells14.  Cells were grown in Express Five serum-free medium (SFM), supplemented 
with L-glutamine (200 mmol/L) and gentamycin (10 µg/mL) and encased in foil because of 
photo-sensitivity.  Cells were handled using standard tissue culture techniques.  Cells were 
grown as a monolayer culture at 27°C.  To detach them, half the medium was decanted 
off, and the side of the flask was tapped sharply to bring the cells into suspension.   
                                                 
12
 Sf9 originally established from ovarian tissues of Spodoptera frugiperda larvae  
13
 Chapter 1 - Figure 1.8  
14
 Hi5 derived from the ovarian cells of the cabbage looper Tricholusia ni   
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2.2.1.3 Protein Production Technique  
To ensure even monolayers of growth, large 175 cm2 tissue culture flasks were each 
seeded with 1.8 x 107 cells.  The fluid volume was made up to 35 mL with fresh medium, 
and flasks were left for 30 min to allow cellular adhesion to the walls.  After addition of 
PSMA house virus (500 µL; 108 PFU/mL), cultures were incubated at 27°C for 3 days.  One 
flask was left uninfected as backup and as a point of reference to compare with infected 
cells. 
 
Cells were checked daily and compared to the uninfected flask.  Cells infected with the 
virus should become fat with a large granular nucleus, indicative of infection and protein 
production; there should be a visible two-fold increase in cell size.  On day three, PSMA 
protein was harvested by centrifugation of the culture at 10,000 rpm for 5 min, and 
purification from the supernatant was carried out using the Ni-NTA purification systemM 
as per manufacturer’s instructions.  SDS-PAGE and Western blot were used to monitor the 
harvested material before and after the Ni-NTA step to ensure that the yield and 
purification of the protein were satisfactory. 
 
 
2.2.2 SDS PAGE & WESTERN BLOT ANALYSIS 
 
2.2.2.1 SDS-PAGE under Reducing Conditions    
Protein samples or antibody fragments were analysed by SDS-PAGE using 7.5 or 15% 
homogeneous gels prepared from acrylamide in 0.375 M Tris-HCl, pH 8.8, containing 0.1% 
(w/v) SDS, 0.1% (w/v) ammonium persulfate and 0.1% (v/v) tetramethylethylenediamine 
(TEMED) for resolving gels, and in 0.125 M Tris-HCl, pH 6.8, containing 0.1% (w/v) SDS, 
0.1% (w/v) ammonium persulfate and 0.1% (v/v) TEMED for stacking gels.  Samples were 
heated in loading bufferM at 95°C for 3 min to linearise proteins, and were run 
concurrently with a protein standard in 1 x Tris-glycine-SDS buffer, pH 8.3, at 150 V and 40 
mA per gel for 1.5 h.   Gels were either stained with Brilliant Blue R (0.5%, w/v) in 
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ethanol:acetic acid:water (9:2:9, by vol) for 2 h to visualise bands for determination of 
molecular weights, or were submitted to Western blot analysis. 
 
2.2.2.2 Western Blot 
PAGE gels were soaked for 20 min in blot bufferM.  A “sandwich” in the semi-dry blotter 
was constructed from 2 sheets W3MM blotting paper, a nitrocellulose membrane, the gel 
and 2 more sheets W3MM blotting paper, all pre-soaked in blot buffer, carefully excluding 
air bubbles from between layers.  Current was applied at 200 mA and 5-10 V for 1-1.5 h.  
After electro-elution, the nitrocellulose membrane was sometimes soaked with Ponceau 
solution to visualise bands and lanes, to check whether the transfer was successful.  The 
nitrocellulose membrane was blocked in 2% MPBS [2% (w/v) powdered milk (Marvel) in 
phosphate-buffered saline (PBS)] for a minimum of 1 h at room temperature, or at 4°C 
overnight, then washed twice in 0.1% (w/v) Tween 20 in PBS and incubated for 1 h at 
room temperature, or overnight at 4°C, with the primary antibody directed at the 
molecule of interest, in 2% MPBS.  After incubation the membrane was washed as before, 
adding complementary secondary antibody conjugated with horseradish peroxidase (HRP) 
for the same incubation times as for the primary antibody.  Proteins were visualised by 
ECL™ Western Blotting Detection ReagentM as per manufacturer’s instructions. 
 
 
2.2.3 PHAGE DISPLAY  
 
2.2.3.1 Selection 
Selection for an antibody fragment can be performed on a number of targets such as cells 
and immobilised antigens.  By incubating a library of phages, it is possible to select the 
specific phage for the target antigen.  Unbound and non-specific phages are washed away 
during each round of selection and the specifically bound phages are eluted and amplified 
through further cycles to enrich the population (Figure 2.1). 
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Figure 2.1:  Schematic diagram of selection against a target antigen.  Up to 5 rounds of selection can be 
performed, however 3 rounds is optimal to ensure a variety of PSMA specific binders ranging in affinity.  
 
 
2.2.3.2 Production of Large Quantities of Helper Phage 
A suspension of E. coli TG1, OD600 = 0.4, (200 µL) in a 27°C water bath, was infected for 30 
min with 10 µL of 100-fold serial dilutions of KM13 helper phage, to ensure separated 
plaques.  Molten H-top agar at 42°C (3 mL) was mixed with the infected bacteria and 
poured onto warm TYEM plates containing no antibiotics, and plates were incubated 
overnight at 37°C.   A small plaque was inoculated into 5 mL fresh TG1, OD600 = 0.4, and 
agitated (250 rpm) for 2 h at 37°C before adding to 500 mL of 2 x TYM in a 2-litre flask and 
agitating for a further 1 h.  Kanamycin15 was added to a final concentration of 50 µg/mL 
and the culture was grown overnight with shaking at 30°C, then centrifuged at 9,600 rpm 
for 15 min.  PEG/NaCl [20% (w/v) polyethylene glycol 6000/2.5 M NaCl] (100 mL) was 
added to 400 mL of the supernatant and left on ice for 1 h before centrifuging again for 30 
min.  The pellet was resuspended in 8 mL of PBS, mixed with 2 mL PEG/NaCl, and stood for 
a further 20 min on ice, then centrifuged for 30 min at 3,000 rpm.  After discarding the 
                                                 
15
 Helper phage KM13 is kanamycin-resistant 
Coat immunotube 
with target antigen 
 
Add phage library Wash Elute Enrich phage population 
Propagate this phage population in TG1 bacteria, isolate and purify.  
Repeat 3-5 times; enriching the phage sample in order to select for 
target-specific phages. 
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supernatant, the pellet was resuspended in 5 mL of PBS to remove remaining bacterial 
debris, and re-centrifuged.  Helper phage was stored with 15% (v/v) glycerol at -80°C as a 
cryoprotectant. 
 
 
2.2.4 SELECTION FOR ANTI-PSMA SCFV AGAINST RECOMBINANT PSMA PROTEIN 
 
2.2.4.1 Tomlinson Library 
The Tomlinson I Phage Library is a phage antibody library (diversity of 1.47 x 108) which is 
based on a single human framework comprising the germline heavy-chain genes V3-
23/DP-47 and JH4b and the κ-light chain genes O12/O2/DPK9 incorporated at position in 
the antigen binding site [90, 166].  The CDR3 of the heavy chain was designed to be as 
short as possible whilst maintaining an antigen binding surface.  Library diversity was 
achieved by randomisation of 11 residues in key CDR2 and CDR3 positions of the heavy 
chain and 7 residues in the light chain.  The library contains clones that were pre-selected 
for active folding domains by binding to protein-L and protein-A, which facilitate the 
capture and/or detection of the antibody fragments without interfering with antigen 
binding [90, 167]. 
 
2.2.4.2 Selection using Recombinant PSMA Protein 
An immunotube was coated overnight with 4 mL of recombinant PSMA protein (10 
µg/mL) in PBS.  Next day the tube was washed 3 times with PBS, then blocked by addition 
of 2% MPBS, with incubation at room temperature for 2 h.  Washing was repeated as 
before with PBS, then 1 mL of Tomlinson I Library (1012 to 1013 PFU) was added in 4 mL of 
2% MPBS and incubated at room temperature, with rotation for 1 h, and stood for a 
further 1 h.  The phage suspension was discarded and the tubes were washed several 
times, dependent on the number of rounds of selection; 10 (round 1) and 20 (rounds 2 
and 3) times, with 0.1% (w/v) Tween 20 in PBS.  After removing excess PBS, bound phage 
was eluted by addition of 500 µL of trypsin-PBS [trypsin (1 mg/mL) / 0.1 mM CaCl2 in 5 
mM Tris-HCl, pH 7.4 / PBS] and incubated at room temperature for 10 min with agitation. 
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Eluted phage (250 µL) was taken and incubated in 1.75 mL of exponentially growing E. coli 
TG1 (OD600 = 0.4) at 37°C for 30 min.  (A 250 µL-portion was stored as backup at 4°C).  
Phage titration after each round of selection was undertaken by serially diluting phage-
infected cells and spotting 10 µL of each dilution onto TYE plates containing 100 µg 
ampicillin/mL and 1% (w/v) glucose, and incubating overnight at 37°C.  The remaining TG1 
culture was centrifuged at 11,600 rpm in a micro-centrifuge for 5 min; the pellet was re-
suspended in 50 µL of 2 x TY and plated on a Bio-Assay dish of TYE containing 100 µg 
ampicillin /mL and 1% (w/v) glucose.  Plates were incubated overnight at 37°C.  
 
2.2.4.3 Rescue with Helper Phage  
After overnight incubation, 2 mL of 2 x TY containing 15% (v/v) glycerol was added, into 
which the growth on the plate was suspended using a glass spreader; then 50 µL of the 
suspension was added to 50 mL of 2 x TY containing 100 µg ampicillin/mL and 1% (w/v) 
glucose, and cultured with agitation (250 rpm) at 37°C until OD600 = 0.4 was achieved 
(approximately 1-2 h).  The remaining suspension was stored as back-up at -80°C. 
 
To 10 mL of the culture, KM13 helper phage (5x1010 PFU) was added, followed by 
incubation at 37°C for 30 min, then centrifugation at 3,200 rpm for 10 min. The 
supernatant was discarded and the pellet was re-suspended in 2 x TY medium containing 
100 µg ampicillin/mL, 50 µg kanamycin/mL and 0.1% (w/v) glucose, followed by 
incubation with shaking overnight at 30°C.   
 
2.2.4.4 Phage purification 
The overnight culture was centrifuged for 10 min at 3,200 rpm and 40 mL of the 
supernatant was mixed with 10 mL PEG/NaCl and held on ice at 4°C to precipitate the 
phage, which occurred over 1-2 h.  The preparation was centrifuged for 30 min at 4°C and 
the pellet was re-suspended in 2 mL cold PBS, then dispensed into tubes and further 
centrifuged at 11,600 rpm for 2 min.  A further round of selection was initiated from 1 mL 
of the phage suspension and the remainder was either stored at 4°C, or at -80°C after 
adding 15% (w/v) glycerol. 
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2.2.4.5 Mixed Population of Phage Particles in 96-Well Plates 
A 96-well plate was inoculated with individual plaques picked from the titration plates 
after each round of selection and grown in 100 µL 2 x TY medium per well containing 100 
µg ampicillin/mL and 1% (w/v) glucose.  The plate was incubated with agitation (250 rpm) 
at 37°C, overnight, then 2 µL of inoculum from each well of this plate was transferred to a 
second 96-well plate containing 200 µL of 2 x TY with 100 µg ampicillin/mL and 1% (w/v) 
glucose per well, and incubated with agitation (250 rpm) for 2 h at 37°C.  A glycerol stock 
was made with the original plate by the addition of glycerol to a final concentration of 
15% and stored at -80°C until needed.  After 2 h incubation, 25 µL of 2 x TY containing 100 
µg ampicillin/mL, 1% (w/v) glucose and 109 PFU of helper phage KM13 per well was added 
to the plate and grown with agitation (250 rpm) at 37°C for 1 h.  The plate was then 
centrifuged at 3,200 rpm for 10 min and the supernatants were aspirated from each well 
and discarded.  The bacterial pellets were resuspended in 200 µL 2 x TY containing 100 µg 
ampicillin/mL and 50 µg kanamycin/mL, and grown with shaking (250 rpm) overnight at 
30°C.  The following day, the plate was spun at 3,200 rpm for 10 min and 50 µL of the 
supernatant was used in phage ELISA.  
 
2.2.4.6 Phage ELISA 
In a 96-well maxisorb plate, 100 µL of recombinant PSMA protein (10 µg/mL in PBS) was 
incubated overnight at 4°C, or for 2 h at room temperature.  The plate was then washed 3 
times with PBS16 and blocked with 2% MPBS for 2 h at room temperature.  Wells were 
washed as before, and 10 µL of PEG-precipitated phage from each round of selection in 
100 µL 2% MPBS was added, and incubated for 1 h at room temperature.  Phage 
suspension was discarded, and wells were washed 3 times with 0.1% (w/v) Tween 20-PBS, 
then 100 µL of HRP-anti-M13 antibody (1 : 5000, by vol.) in 2% MPBS was added followed 
by incubation for 1 h at room temperature.  After a further wash, 100 µL of substrate 
solution [100 µg 3,3’,5,5’-tetramethylbenzidine (TMB)/mL in 100 mM-sodium acetate, pH 
6, containing 0.006% hydrogen peroxide] was added to each well, followed by incubation 
                                                 
16
 Plates were immersed in a shallow bath containing PBS and all wells were checked to ensure that they 
were filled with wash solution, to avoid creating false positives during later washes. 
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at room temperature for 2-15 min.  Positive reactions were revealed by formation of a 
blue product.  The reaction was stopped by the addition of 50 µL of 1 M-sulphuric acid, 
turning the colour product yellow.  Wells were read on a plate reader at 450 nm.      
 
For scFv ELISA, 3% BSA-PBS [3% (w/v) bovine serum albumin in PBS] was used in place of 
2% MBS.  The plate was handled in the same manner with the addition of Protein A-HRP 
(1 : 10000, by vol.) after incubation with selected scFv.   
 
 
2.2.5 ANTIBODY FRAGMENTS 
 
2.2.5.1 Production of Soluble Antibody Fragments 
Strong binding clones observed in phage ELISA were subsequently sequenced, and those 
bearing unique and complete scFv fragments characterised by ELISA and amino-acid 
sequencing were taken forward to express soluble antibody fragments, and also to 
generate larger volumes of the desired clones.   
 
From each round of selection for which soluble antibody fragments were required, 10 µL 
of eluted phage was taken and added to 200 µL of a culture of E. coli  HB2151 cells, OD600 
= 0.4, growing exponentially at 37°C in a water bath.  (E. coli HB2151 is a non-suppressor 
strain, which, when induced, is able to give soluble expression of antibody fragments).  
After 30 min, serial dilutions were performed on the culture and 50 µL of each of the 
dilutions 102, 104 and 106 was spread on TYE plates containing 100 µg ampicillin/mL and 
1% (w/v) glucose, and incubated overnight at 37°C.  Individual colonies were picked and 
used to inoculate 100 µL 2 x TY 100 µg ampicillin/mL and 1% (w/v) glucose in 96-well 
plates and cultured with agitation (250 rpm) overnight at 37°C.  From each well, 2 µL was 
transferred from each plate to a second containing 200 µL 2 x TY containing 100 µg 
ampicillin/mL and 0.1% (w/v) glucose per well, and cultured with agitation (250 rpm) at 
37°C until OD600 = 0.9 was achieved, whereupon 25 µL 2 x TY containing 100 µg 
ampicillin/mL was added together with isopropyl-β-D-thiogalactoside (IPTG) to a final 
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concentration 1 mM, and the plate was left shaking overnight at 30°C.  The following day, 
the plate was centrifuged at 3,200 rpm for 10 min and the supernatant was assayed by 
performing soluble-scFv ELISA in 3% (w/v) BSA-PBS. 
 
2.2.5.2 Harvesting Fragments from the Periplasm 
E. coli is a popular host for the production of recombinant proteins but it does not secrete 
the proteins into the medium; however in some instances secretion of the proteins into 
the periplasmic space can occur.  Techniques for the recovery of periplasmic proteins 
include treatment with lysozyme-ethylenediaminetetraacetate (EDTA), repeated cycles of 
freezing and thawing, heat treatment, chemical permeabilisation using chloroform, and 
osmotic shock, which is advantageous for large-scale operations. 
 
The periplasmic space is situated between the inner cytoplasmic membrane and external 
outer membrane of Gram-negative bacteria.  It contains a loose network of peptidoglycan 
chains, as well as hydrolytic and degradative enzymes (Figure 2.2).  To achieve osmotic 
shock, cells are first exposed to high concentrations of sucrose supplemented with EDTA, 
then centrifuged and re-suspended in cold water.  As the high osmotic strength causes the 
cells to shrink, periplasmic proteins are released [168].  EDTA functions to release the 
lipopolysaccharides from the bacterial cell envelope, thus increasing the permeability of 
the outer membrane, and the cold water treatment, achieved by holding on ice at 4°C, 
causes a rapid increase in cell size which completes the release of periplasmic proteins.  
The addition of protease inhibitors prevents the degradation of the secreted proteins by 
proteases from the periplasmic space. 
 
Chapter 2  Methodology Part I 
    67 
 
 
Figure 2.2:  Periplasmic space of Gram-negative bacteria.  This constitutes up to 40% of the total cell volume 
of Gram-negative bacteria.  
 
2.2.5.3 Large Scale Production of scFv 
A sample (10 µL) from a frozen stock (before addition of helper phage) was incubated in 
an overnight culture of E. coli HB2151 (1:1000) in 2 x TY containing 100 µg ampicillin/mL 
and 0.1% (w/v) glucose, grown at 37°C to OD600 = 0.9, then induced with 1 mM IPTG and 
cultured overnight with agitation (250 rpm) at 30°C, during which time the antibody 
fragments were secreted into the culture supernatant, which was collected after 
centrifugation at 10,800 rpm for 15 min, passed through a 0.45-µm filter and stored at 4°C 
until purification.  The cell pellets were resuspended in 1/20 the original volume of 30 mM 
Tris, pH 7.0, containing 20% (w/v) sucrose and 1 mM EDTA, adding 1 mL of protease 
inhibitors (1% (w/v)) per 100 mL, and left on ice for 20 min.  The suspension was re-
centrifuged and the clear supernatant containing the periplasmic fraction was set aside for 
purification by column chromatography.  The pellet was further resuspended in 25 mL 5 
mM MgSO4 and held for 20 min on ice.  Following centrifugation, the supernatant (the 
osmotic shock fraction) was collected and combined with the periplasmic fraction, then 
purified immediately or frozen at -80°C until required. 
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2.2.6 PURIFICATION 
 
2.2.6.1 Purification of the Periplasmic Fraction  
Antibody fragments from E. coli periplasm or supernatant can be purified using a range of 
different statagies, the choice of which depends on the type of antibody fragment and the 
tag which is attached to it.  In this case, Proteins A and L columns were used, which 
respectively target variable heavy and light chains, and Ni-NTA and 9E10 columns, which 
selectively bind his-tag and myc-tag.  Purification should be undertaken at 4°C if possible 
or on ice, to prevent proteases from cleaving the antibody fragments. 
 
2.2.6.2 Protein A Chromatography 
Protein A-Sepharose can be used to purify antibody fragments encoded by VH segments 
from the VH3 family [169].  Protein A-Sepharose was pre-swollen overnight and washed 
several times in PBS.  To a 10-mL glass column (pre-washed in concentrated HCl and 
distilled water), a 1-mL bed volume of Protein A-Sepharose beads was added and 
equilibrated with 50 mL sterile PBS.  The periplasmic fraction was applied to the column 
and allowed to pass through, and the emergent fluid was recycled through the column a 
further two times to ensure quantitative binding of scFv to the beads.  The column was 
then washed 5 times with the following filter-sterilised buffers, decreasing in pH:  PBS, pH 
7.0; 0.5 M PBS-NaCl, pH 7.0; 0.2 M glycine, pH 6.0, and finally 0.2 M glycine, pH 5.0.  
Protein was eluted with 3 column volumes of 0.2 M glycine, pH 3.0 (filter-sterilised), 
collecting 1 mL fractions into 200 µL 1 M Tris-HCl, pH 7.4 (filter-sterilised), with immediate 
mixing.  After determining the protein content by measurement of A280, protein fractions 
were dialysed overnight in PBS in Slide-A-Lyzer dialysis cassettes (molecular weight cut-
off, 10 kDa).  SDS-PAGE of eluted fractions was performed on 15% polyacrylamide gels to 
ensure that purification was successful and scFv was not lost.   
 
2.2.6.3 Ni-NTA Chromatography 
Ni-NTA columns exploit the his-tag present on scFv and are used to extract the antibody 
fragment from a protein mixture.  Imidazole is added to buffers to minimise binding of 
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untagged and contaminating proteins, therefore increasing the purity of the target protein 
with fewer wash steps [170].  However, too high a concentration of imidazole can actually 
compete with the binding of the scFv. 
 
The periplasmic fraction was dialysed overnight in Visking tubing (molecular weight cut-
off, 10 kDa) in 1 x native purification bufferM.  Swollen Ni-NTA-agarose (5 mL), washed 
twice in 25 mL of sterile water and again twice with 25 mL of binding buffer, then 
equilibrated in the buffer, was dispensed in 5-mL portions into 50-mL falcon tubes.  After 
adding 40 mL of the dialysed periplasmic fraction, the tubes were placed on a roller either 
overnight at 4°C or for 2 h at 37°C. 
 
After incubation, the suspended beads were transferred into a cleaned glass column, 
collecting the flow-through before passing and collecting five 25-mL fractions of wash 
buffer through the column.  To elute the protein, 15 mL of elution buffer was applied to 
the beads and 1-mL fractions were collected.  To monitor the purification, the eluates, 
together with the flow-through and wash fractions, were submitted to SDS-PAGE on 15% 
polyacrylamide gels, checking for the presence of the expected 25-kDa scFv band.  Protein 
concentrations were determined by measurement of A280 in sterile cuvettes, before 
aliquoting and storage at -80°C. 
 
2.2.6.4 Sequencing 
Strong binding observed by monoclonal ELISA with purified scFvs can be checked, by 
sequencing, for the presence of full-length VH and VL inserts in individual clones.  Primers 
LMB3 and FDSEQ were used (Figure 2.3).   Correct bands were visible at 1018 bp, indicative 
of whole scFv.                   
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Figure 2.3:  LMB3 reads from 3’ end and FDSEQ reads from the 5’ end.  The combined size of the PCR product 
is 1018 bp, the size of the complete scFv fragment. 
 
 
2.2.6.5 Clonal Polymerase Chain Reaction (PCR) 
Individual specific clones were picked from the glycerol stock plate with a sterile pipette 
tip.  Preparation of the PCR master mixture for each reaction was performed on ice (Table 
2.1). 
 
Table 2.1:  PCR components 
 
Components 
Volume 
(μL per  
reaction 
tube) 
10x PCR Buffer 5 
MgCl2 2.5 
LMB3 primer 2.5 
Fdseq primer 2.5 
Deoxyribonucleotide 
triphosphate (dNTP) 
2.5 
water 34.0 
Taq polymerase 1.0 
 
 
Taq polymerase, kept at -20°C until needed, was added last to the master mixture.  Both a 
positive (Original Library) and a negative control (PCR master-mix alone with no clone) 
were included, the negative control being important to ensure that there was no 
contamination of the master-mix during preparation, and the positive control to ensure 
the procedure has been successful. 
 
 
 
LMB3 FDSEQ 
VH VL 
3’ 5’ 
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The following primers were used: 
LMB3: - CAG GAA ACA GCT ATG AC 
Fdseq: - GAA TTT TCT GTA TGA GG 
PCR was run on the following programme: 
95°C – 10 min 
95°C – 1 min 
60°C – 1 min             x 29 cycles 
72°C – 2 min  
4°C – indefinitely 
 
Agarose gel was prepared by heating 1 g agarose powder in 100 mL 1 x Tris/Borate/EDTA 
(TBE) buffer until dissolved.  After cooling, ethidium bromide17 (2 µL) was added prior to 
casting the gel.   Samples (5 μL) mixed with loading buffer (2 μL) were loaded and the gel 
was run at 100 V in 1x TBE solution.  Bands were visualised under UV light to identify 
clones yielding the correct size of band, which were submitted to sequencing. 
 
BigDye 3.1 chemistry with visualisation on an ABI 3700 Automated DNA Sequencer was 
used to generate read-lengths of up to 850 bp. 
 
 
2.2.7 CELL LINES 
 
Table 2.2:  Prostate Cancer (PC) cell lines 
 
Cell line Description Species 
PC3 PC bone metastasis Human 
DU145 PC brain metastasis Human 
LNCaP C42B PC bone metastasis Human xenograft 
LNCaP C81 
PC lymph node 
metastasis 
Human 
 
                                                 
17
 Ethidium bromide fluoresces under UV light when intercalated into DNA (or RNA) 
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Cells were grown in RPMI 1640 / 10% foetal bovine serum (FBS) medium.  Cells were 
handled using standard tissue culture techniques:  briefly, after growth medium was 
removed, the cell layer was rinsed with 5 mL of sterile PBS and 3 mL of 0.25% (w/v) 
Trypsin / 0.53 mM EDTA solution to remove all traces of serum, which contains trypsin 
inhibitor.  Cells were incubated at 37°C for 2 min to facilitate detachment, then RPMI 1640 
medium (10 mL) was added, and gentle pipetting was applied to separate cell clumps so 
as to obtain a single-cell suspension.  Appropriate aliquots of the cell suspension were 
transferred to new tissue-culture flasks, which were then incubated at 37°C under 5% 
(v/v) CO2 /air. 
 
 
2.2.8 FACS ANALYSIS USING PURIFIED SCFV PREPARATIONS ON CELLS 
 
Flow cytometry simultaneously measures and analyses multiple physical characteristics of 
cells as they flow in a fluid stream through a beam of light.  It depends on the use of a 
fluorescent marker, e.g. fluorescein isothiocyanate (FITC), which is conjugated to a 
monoclonal antibody that specifically binds to the primary antibody bound to the target of 
interest (Figure 2.4). 
 
 
Chapter 2  Methodology Part I 
    73 
 
 
 
Figure 2.4:  Schematic diagram of binding steps in FACS analysis.  Washing after each incubation step is   
essential to prevent non-specific binding.   
 
Flow cytometry can measure the relative size of the cells, their relative granularity or 
internal complexity, and their relative fluorescence intensity [171].  The results can be 
represented graphically (Figure 2.5). 
 
 Figure 2.5:  Graphical representation of a FACS analysis from a single population of cells. 
 
 
Histogram A illustrates the entire population of cells present in a sample.  This graph plots 
the side scatter (SSC-H), which is a measure of the cells’ granularity and general shape, 
cells 
Surface antigen of 
interest 
1° antibody  
2° antibody conjugated with 
fluorescent marker e.g. FITC 
Alexa488 
A B 
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against forward scatter (FSC-H), a measure of cell size.  Being able to view the entire 
population enables the gating and separation of sub-populations that one wishes to 
analyse.  Apoptosing cells and cell debris are indicated at the bottom left and can be 
excluded from analysis by the gating system.  
 
Histogram B illustrates the level of fluorescence due to cell-associated FITC (FL1-H), 
measured in the cells that have been gated in histogram A.  With increasing fluorescence, 
the peak will shift from the left to the right, indicating positive cells for the target of 
interest.  Negative cells do not possess the fluorescent marker and thus remain on the 
left-hand side. 
 
Selected cells were detached using Versene18 and then neutralised with fresh medium.  
After centrifugation at 1200 rpm, the supernatant was discarded and the cells were 
washed with cold PBS, then kept on ice throughout the remaining procedure to prevent 
internalisation of the antibodies. 
 
Cells were washed once in FACS bufferM and re-suspended at 4 x 106 cells/mL.  For the 
detection of surface molecules of interest, 50-µL portions of the primary antibody (10 
µg/mL) were delivered into a V-bottomed 96-well plate, avoiding every other well to 
prevent contamination, followed by 50 µL of cell suspension, with gentle tapping to the 
side of the plate to ensure even mixing.  The plate was incubated for 40 min at 4 °C.  A 
non-specific cell line and non-specific antibody were used as negative controls.  Cells were 
washed twice with FACS buffer.  For each wash, cells were centrifuged in a plate-spinner 
at 1200 rpm for 3 min, and the supernatant was gently ejected.  FACS buffer (150 µL) was 
added to each well and mixed with the cells.  After re-centrifugation, the final supernatant 
was ejected and the pellets were each resuspended in 50 µL secondary antibody (1:500) 
conjugated with a fluorescent marker (goat-anti-mouse, alexa488-conjugated).  Due to the 
                                                 
18
 Versene was used instead of 0.25% (w/v) trypsin / 0.53 mM EDTA solution because the latter sometimes 
cleaves the surface markers 
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photosensitive nature of the secondary antibody, cells were incubated for 30 min at 4°C in 
the dark, before washing the plate twice as previously described. 
 
Re-suspended cell pellets in 100 µL of FACS buffer were transferred to FACS tubes pre-
cooled on ice, each containing 400 µL of FACS buffer.  Cells were then analysed with 
single-colour (green) analysis using a CellQuest / LSR-1 Flow Cytometer.   
 
 
2.2.9 PRODUCTION OF DIABODIES 
 
Manipulation of the glycine-serine linker prevents the natural folding of the variable light 
and heavy chains which normally fold and interact with each other to give rise to the 
antigen-binding site of the scFv.  By manipulation or even the complete removal of this 
linker, the variable light and heavy chains are unable to fold and are held in place rigidly, 
which renders the scFv ineffective because the creation of the binding pocket is 
prevented.  It is only by interaction with a complementary scFv to form a diabody that two 
binding sites can be formed (Figure 2.6).   
 
Figure 2.6:  Schematic diagram of scFv and diabody antibody fragment.  Red and green represent variable    
light and heavy chains respectively.  Blue arrows indicate the binding domains which interact with specific 
antigen. 
 
 
 
 
(G4S)3  
scFv Diabody 
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The manipulation of this linker can be effected by the many restriction enzyme sites 
present on the genetic map, which can cut at various places on the vector, depending on 
the endonuclease used19. 
2.2.9.1 Extraction of DNA 
DNA was extracted from overnight cultures of selected clones grown in 2 x TY containing 
100 µg ampicillin/mL and 1% (w/v) glucose, using a Quick Plasmid Miniprep KitM, 
according to the manufacturer’s instructions.  To ensure successful extraction, 5 µL of the 
extracted DNA mixed with 3 µL running buffer was applied to and run on a 0.8% agarose 
gel.  A successful DNA extract revealed two bands, one of supercoiled DNA and the second 
of circular DNA. 
 
2.2.9.2 Restriction Digest 
The complete removal of the linker was achieved using the restriction enzymes XhoI and 
SalI (Figure 2.7), which were selected to cut at points before and after the linker, 
linearising the vector and ensuring complete removal of the linker. 
 
 
 
Figure 2.7:  Schematic representation of the cutting abilities of XhoI and SalI restriction enzymes.   
 
XhoI and SalI cut at various points on the vector, creating “sticky or cohesive ends”, where 
each restriction endonuclease has cut the DNA and caused a four-base overhang in one 
strand and a complementary terminus in the other.  These ends can be joined by a ligase. 
 
                                                 
19
 Appendix I 
                                  3’….. G A G C T                             G …..5’ 
 5’….. C T C G A G …..3’      5’….. G T C G A C ….3’ 
           3’….. G A G C T C …..5’    3’….. C A G C T G ….5’ 
    5’….. C                            T C G A C …..3’ 
5’….. C T C G A C …..3’ 
3’….. G A G C T G …..5’ 
XhoI SalI 
PRODUCT AFTER LIGATION 
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Extracted DNA (10 µL per clone) was incubated with restriction digest mixtureM (20 µL) in 
duplicate at 37°C for 2 h.  Remaining extracted DNA was stored at -20°C as back-up.   To 
verify whether the digestion had been successful, another agarose gel was run, loaded 
with the pooled digestion reaction and 10 µL of loading buffer, split between two wells.  
Bands were visualised under a UV light, and excised and treated with QIAquick gel 
extraction to remove the agarose.  A further verification to check for quantitative DNA 
recovery was performed by running 10 µL of the DNA extract on 1% agarose gel. 
 
2.2.9.3 Ligation 
After removal of the linker the newly-formed sticky ends were ligated.  Reaction mixtures 
containing 5 µL of the digested DNA for each clone were incubated at 16°C overnight; 
negative controls were set up lacking ligase.   
 
2.2.9.4 Preparation of Electroporation-Competent Cells 
To prepare electroporation-competent cells, 1 L of 2 x TY medium containing 100 µg 
ampicillin/mL was inoculated with a 1:100 dilution of an overnight culture of E. coli 
HB2151 and incubated at 37°C with agitation (250 rpm).  An inoculum of 10 mL from the 
overnight culture was added to 1 L of 2 x TY medium containing 100 µg ampicillin/mL and 
incubated again until OD600 = 0.5-0.7 was attained, after which the flask was cooled on ice 
for 15-30 min and centrifuged at 5000 rpm at 4°C.  The pellet was resuspended in the 
original volume of ice-cold sterile 1 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid  (HEPES) buffer, pH 7.0, re-centrifuged, washed again in half the original volume of 
the same buffer, and centrifuged once more.  The cells were resuspended in 20 mL 10% 
(w/v) glycerol, pelleted and finally resuspended in 2-3 mL 10% (w/v) glycerol to a final 
concentration of 3x1010 cells/mL) and stored at -80°C until needed.   
 
2.2.9.5 Electroporation 
For soluble expression of antibody fragments from pIT2, the non-suppressor strain E. coli 
HB2151 was used.  Electroporation-competent bacteria, thawed on ice, (50 µL) were 
transferred to a pre-chilled 0.2-cm cuvette, mixed with 2 µL ligation mixture and left to 
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stand on ice for 1 min.  Using a Gene Pulser machine at 25 µF, 2.5 kV, the reaction mixture 
was irradiated with the pulse set to 200 ohms.  The resultant pores formed in the 
membrane allowed the reformed vector to enter the cells and be replicated. The culture 
was plated in 10-µL and 100-µL portions onto separate TYE plates and incubated overnight 
at 37°C. 
 
Individual colonies were picked and incubated overnight with agitation (250 rpm) in 2 mL 
of 2 x TY with 100 µg ampicillin/mL and 1% (w/v) glucose.  Mini-preps were prepared from 
the cultures, backing up the remainder as glycerol stocks.  Removal of the linker was 
confirmed by performing digestions at various restriction sites, including those used 
originally, the rationale being that if the linker had been removed, the vector would no 
longer possess XhoI and SalI cut-sites, because they would have been lost along with the 
linker.  XhoI and SalI were used in conjunction with two further restriction enzymes that 
would cut the DNA at different sites to yield fragments of differing size; thus two distinct 
bands would be visualised on the gel.  If the linker were absent, XhoI and SalI combined 
with either HindIII or NotI would yield only one band, but two would be generated if XhoI 
and SalI were combined with both HindIII and NotI, or if the linker were present.  Samples 
were analysed as before on 0.8% agarose gel. 
 
 
2.2.10 COLUMN CHROMATOGRAPHY ANALYSIS OF ANTIBODY FRAGMENTS 
 
2.2.10.1 High Pressure Liquid Chromatography (HPLC) 
Size-exclusion HPLC is used to separate soluble compounds of different sizes.  The HPL 
chromatograph consists of a reservoir of mobile phase, a pump, an injector, a separation 
column and a detector.  After injecting a sample mixture onto the column, the different-
sized components in the mixture pass through the column at different rates due to 
differential filtration through the stationary phase, the largest species emerging first.  
Samples were run using mobile phases of 0.1 M phosphate buffer, pH 7.0, containing 10% 
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(v/v) ethanol20, and 0.1 M phosphate buffer, pH 7.0, containing 2 mM EDTA.  Eluates were 
monitored from 220 nm to 280 nm. 
 
2.2.10.2 Fast Protein Liquid Chromatography (FPLC) – ÄKTA ™  
Unlike HPLC, FPLC allows the separation of compounds under low pressure, and can be 
used to determine the molecular weight of the sample injected; but it can also be used as 
a purification method for quantities of proteins that are too large for HPLC to handle.  Gel 
filtration by FPLC was performed using a Sephacryl S-200 high-resolution column with 
spectrophotometric monitoring of the eluate at 280 nm. 
 
Prior to use, the column was washed with filter-sterilised 20% (v/v) ethanol and water, 
and equilibrated with sterile PBS.   Fractions (500 µL) of diabody and scFv fragments 
purified by Protein A chromatography were collected by elution with PBS as per the 
manufacturer’s instructions. 
 
 
2.2.11 RADIOLABELLING OF SCFV AND DIABODY USING SODIUM [125I]-IODIDE   
 
2.2.11.1 Sodium [125I]-Iodide and Iodogen  
Iodine-12521 is used to radiolabel antibody fragments, reacting with tyrosine and some 
histidine residues in proteins or peptides by electrophilic substitution [172].  For efficient 
labelling of antibody fragments, iodinations were conducted in glass tubes (12 x 75 mm) 
coated at the bottom with the oxidant iodogen 1,3,4,6-tetrachloro-3α, 6α-
diphenylglycoluril for the activation of 125I.  One possible drawback of this technique is 
that the iodogen can cause oxidative damage to the sample being labelled. 
 
The procedure was performed in a fume hood.  To the iodogen tube, 50 µL of PBS was 
added, followed by approximately 2 MBq of sodium [125I]-iodide, and finally 20 µg of the 
                                                 
20
 Ethanol improves recovery without affecting retention times 
21 125
I half life = 60 days 
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antibody fragment.  After mixing, the tube was incubated at room temperature for 10 min 
before the addition of 100 µL of PBS and transfer into a storage cryovial, then stored at 
4°C.  Confirmation of successful labelling was achieved by Instant Thin Layer 
Chromatography (ITLC) of the samples. 
 
2.2.11.2 Instant Thin Layer Chromatography (ITLC) 
Samples on ITLC-Silica Gel (ITLC-SG) strips (1 x 8 cm) were developed in duplicate, in 85% 
methanol.  A 1 µL fraction of labelled antibody fragment was spotted onto strips, which 
were developed to within 1 cm of the top.  Strips were removed from the solvent tank, 
dried, and the labelled antibody fragments were visualised using a phosphor imager.  The 
percentage of the radioactivity in each part of each strip was calculated.   
 
2.2.11.3 Radioimmunoassay  
Immunoreactivity can be used either to compare the binding ability of radiolabelled 
antibody with that of the unlabelled starting material, or to measure the proportion of the 
radiolabelled antibody able to bind to the target antigen [172].  Both methods are used to 
assess the antibody’s ability to bind to the target antigen.   
To determine whether the ability of antibody fragments to bind to the antigen has been 
damaged or compromised by the addition of the radioisotope, the ability of the 
radioactive antibody fragment to bind to the antigen-expressing cells was measured. 
 
LNCaP C81 cells (3x107) were trypsinised and resuspended in 5 mL of cold 1% BSA-PBS, 
then washed and resuspended in 3 mL of the same buffer.  After diluting the suspension 
to 8 x 106 cells/mL, 0.5 mL aliquots were transferred into a duplicate series of 5 tubes and 
serially diluted 1:2 with PBS.  Two further tubes each containing 4x106 cells in 0.5 mL were 
labelled as non-specific binding (NSB) samples, and to these, 50 µL of the unlabelled 
antibody fragment was added with brief vortexing. 
 
Radiolabelled antibody was diluted to a final concentration of 50 ng/mL with cold 0.1% 
BSA-PBS, and 250 µL thereof was dispensed to all the tubes and a further two tubes 
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labelled “T” (to measure total activity).  Tubes were incubated with rotation either for 2 h 
at room temperature or for 3 h at 4°C. 
 
After incubation, tubes were centrifuged at 13,000 rpm in a micro-centrifuge for 2 min 
and supernatants were carefully removed and collected into new tubes.  Cell pellets were 
washed twice with 500 µL of cold 0.1% BSA-PBS per tube and re-pelleted by centrifugation 
as before.  The supernatants from the washing steps were also collected and pooled with 
the previous wash samples to determine whether bound antibody was lost by washing.  
Tubes were submitted to the gamma counter, together with those labelled “T”, and the 
immunoreactivity was determined.   
 
 
2.2.12 IMAGING OF SODIUM [125I]-IODIDE-LABELLED ANTIBODY FRAGMENTS IN 
TUMOUR-BEARING MICE 
 
The characteristics and behaviour of the antibody fragments established in vitro needed 
to be demonstrated in vivo to conclude with absolute certainty that the fragments 
targeted and bound specifically to the target antigen – PSMA.  Many new factors, such as 
concentration, pH and affinity, come into play in vivo, and can cause fragments to 
dissociate, rendering them ineffective.  
 
Ten male SCID Beige miceM22 aged 4-6 weeks were each injected subcutaneously on both 
hind-leg flanks with 10 million LNCaP C81 cells mixed with Matrigel23 in a 1:1 ratio by 
volume, in a total volume of 200 µL.  Tumours approximately 5 mm3 in size became visible 
beneath the fur about 5 weeks post injection.  Mice were injected intravenously in the tail 
(100 µL total volume) with 7 MBq (10 µg) of 125I-labelled scFv or diabody, and uptake and 
                                                 
22
 Congenic mice that possess both autosomal recessive mutations SCID(Prkdc
SCID
) and beige (Lyst
BG
).  The 
SCID mutation results in the severe combined immunodeficiency affecting both T and B lymphocytes.  The 
beige mutation results in defective natural killer (NK) cells.  
23
 Matrigel contains structural proteins such as laminin and collagen which provide additional support to the 
cells in a form of a growth matrix, which increases vascularisation.  
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distribution was measured by SPECT24 at various time points;  30 min, 4 h and 34 h after 
injection of the radiolabelled antibody fragments.  Images obtained allowed visualisation 
of uptake and clearance of labelled antibody fragments from the tumours and other 
organs.  Uptake and retention in certain organs helps to understand the behaviour of 
labelled antibody fragments. 
 
2.2.13 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 
 
For CT scans, mice were scanned feet-first for approximately 6-7.5 min/180 projections.  
CT data was reconstructed using CT Reconstruction on the Bioscan InVivoScope (IVS) 
software, using standard reconstruction resolution.  For SPECT images, 1.4-mm pinhole 
collimators were used and mice were scanned feet-first for approximately 30 min/24 
projections.  Images were reconstructed in a 256 x 256 matrix using HiSPECT, a 
reconstruction software package, and were fused with CT images using proprietary 
Bioscan IVS software.   
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2.3 METHODOLOGY 2 
 
This methodology relates to the results section in chapter 4 
 
2.3.1 RADIOLABELLING  
 
2.3.1.1 Radiolabelling Demobesin 4 (DB 4) 
Technetium was provided by the Radiopharmacy Department, St. Bartholomew’s Hospital.  
On the day of the experiment, 99mTc (present chemically as pertechnetate) was eluted 
from the molybdenum-99 generator, from which the isotope 99mTc is continuously formed 
by nuclear decay.  Pertechnetate is separated off from molybdenum-99 by washing with 
isotonic sodium chloride solution. 
 
Almost all technetium-labelled pharmaceuticals are prepared by reducing pertechnetate 
from +7 to a lower oxidation state, usually +4.  Once in this reduced state, technetium will 
readily bind to chelating agents and other compounds.  This reaction can be achieved by 
the addition, with the ligand, of several labelling components that facilitate the reaction, 
together with stabilisers and buffers.   
 
2.3.1.2 Stannous Chloride  
A reducing agent commonly used in ligand binding reactions is stannous (Sn2+) chloride.  
Stannous ions reduce pertechnetate (Figure 2.8) which binds to the ligand.  A short 
incubation at room temperature completes the reaction.  
 
 
Figure 2.8:  Equation for reduction of technetium with stannous chloride [172]. 
 
Stannous chloride is added in excess, so minimising the amount of unbound 
pertechnetate, and the reaction is performed in nitrogen-purged vials to prevent the re-
2 99mTcO4
- + 16H+ + 8Sn2+                            2 99mTc4+ + 8Sn4+ + 8H2O 
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oxidisation of technetium ions, thereby limiting the amount of unbound and reduced 
technetium released by hydrolysis [172]. 
 
2.3.1.3 Binding Components and Labelling of DB 4 
In addition to stannous chloride, other components are added to the reaction mixture 
which facilitate binding of Tc and reduce the formation of unwanted by-products.  
Trisodium citrate is a weak chelator for technetium which chemically stabilises the isotope 
and prevents the formation of Tc-colloids (TcO2 and insoluble hydroxides, formed at 
neutral/alkaline pH).  The reaction is buffered with phosphate and the addition of ethanol 
reduces hydrophobic interactions of Tc compounds with the polypropylene vial used. 
 
Into a lead-shielded polypropylene vial, the following components were added in the 
following order:  100 µL 0.25 M phosphate bufferM, 5 µL 0.1 M trisodium citrate, and 400 
µL 99mTc4+ solution at the desired radiochemical activity.  DB 4 (10 µg) was added prior to 
stannous chloride (60 µg (w/v), in ethanol, freshly prepared), followed by 40 µL ethanol.  
After thoroughly mixing, the reaction was allowed to proceed at room temperature for 30 
min while the labelling took place. 
 
 
2.3.2 QUALITY CONTROL ANALYSIS 
 
2.3.2.1 Instant Thin Layer Chromatography (ITLC) 
Subsequent to the labelling reaction, it is important to determine the radiochemical purity 
of Tc-labelled DB 4, i.e. how much labelled peptide is present in comparison with 
undesirable by-products.  Both ITLC and HPLC analysis can be used to determine the 
success of the labelling.  ITLC is a rapid, simple method of determining labelling efficiency; 
for DB 4, ITLC was carried out using two solvents, acetone and methanol : 1 M ammonium 
acetate (1:1, by vol.) which resolve the radiolabelled peptide from other products (Figure 
2.9). 
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Figure 2.9:  Schematic diagram of ITLC resolved in acetone and methanol:ammonium acetate.  The two 
strips were run concurrently, one in each solvent. 
 
ITLC performed in acetone allows for the resolution of remaining free pertechnetate.  
Using methanol : 1 M ammonium acetate, the radiolabelled peptide is resolved from Tc-
colloids and Tc citrate.  ITLC strips were exposed for varying times to phosphor imager 
screens from which images were obtained by scanning them on a Cyclone Plus Storage 
Phosphor System, using the programme OptiQuant™, which calculates the percentages of 
the labelled peptide and other radiolabelled components present. 
 
2.3.2.2 High Pressure Liquid Chromatography (HPLC) 
There are a number of limitations associated with HPLC analysis of Tc 
radiopharmaceuticals, as the method relies on the complete elution of all the radioactive 
species injected onto the column, which is not possible when the sample contains 
Solvent front 
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colloidal or reduced TcO2, because these components become trapped on the column and 
therefore over-estimations of sample purity occur.  Therefore this method is best used in 
conjunction with ITLC analysis.  HPLC is advantageous over ITLC because it enables 
recovery of the purified fraction. 
 
HPLC was carried out on a reverse-phase column, C18ODS, using a gradient of aqueous 
0.1% (v/v) trifluoroacetic acid (TFA)25 (solvent A) and acetonitrile (solvent B).  UV 
detection was performed at 160-280 nm and radioactivity was detected using an in-line 
gamma-detector. 
 
The gradient system used for analysis was as follows:  40% A : 60% B for 25 min, then B 
was increased linearly to 100% over the next 5 min to elute lipophilic impurities, and 
reduced to 0% (i.e. A was increased to 100%) linearly thereafter over 5 min.  The flow rate 
was 1 mL/min.  Solvent A was passed through the column for ten minutes between 
injections to allow re-equilibration.  The radiolabelled peptide was diluted 1:1 in PBS 
before injecting 20 - 30 µL samples. 
  
Unbound pertechnetate eluted from the column within a few minutes, in 40% A : 60% B, 
followed by the radiolabelled peptide (Tc-DB 4), usually towards the end of the 40% A : 
60% B mixture, at just over 20 min. 
 
 
2.3.3 CELL LINES 
 
Prostate cancer cell lines and negative control cell lines for gastrin-releasing peptide 
receptor (GRP-R) expression experiments are shown in Table 2.3 . 
 
 
 
                                                 
25
 TFA facilitates the release of peptides from solid-phase resins 
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Table 2.3:  Prostate cancer cell lines and negative control cell lines for GRP-R expression experiments.  *GRP-
R negative, ** GRP-R positive. 
 
Cell line Description Species 
Androgen 
Dependence 
PC3 PC bone metastasis Human Independent 
DU145 PC brain metastasis Human Independent 
LNCaP PC Human Dependent 
LNCaP C42B PC bone metastasis Human xenograft Independent 
LNCaP C81 
PC lymph node 
metastasis 
Human Independent 
MKN45 * 
Stomach 
adenocarcinoma 
Human N/A 
AR42J ** 
Pancreatic 
neuroendocrine tumour 
Rat N/A 
 
 
Cells were handled using standard tissue culture techniques26.  In conjunction with these 
cell lines, LNCaP C42B and C81 were also sub-cultured in androgen-deprived media, and 
are denoted as LNCaP C42B and C81 androgen-deprived in future experiments.  RPMI 
phenol red-free medium was used (phenol red can bind to the androgen receptor and 
activate it through the promiscuous pathway27), and supplemented with 8% (w/v) 
charcoal-stripped FBS (CS-FBS) and 2% (w/v) regular FBS.  CS-FBS, which is commercially 
available, is used to elucidate the effects of hormones within media that are used in a 
variety of in vitro systems.  Activated carbon is used to remove non-polar, lipophilic 
materials such as growth factors, hormones and cytokines from the medium without 
affecting the salt, glucose and amino-acid content.  However cells were unable to grow in 
CS-FBS alone, probably due to removal of essential growth factors, therefore they were 
grown in the lowest concentration (8% CS-FBS with 2% FBS) that ensured healthy growth, 
but were switched to total CS-FBS 24 h prior to experiments. 
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 Chapter 2 - Section 2.2.7 
27
 Chapter 1 - Section 1.2.2 
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2.3.4 RADIOLIGAND BINDING ASSAY 
 
Once the peptide has been successfully radiolabelled, it is important to determine 
whether it has retained its receptor-binding affinity, and that this has not been 
compromised in any way.  The ability of the labelled peptide to bind to a receptor 
preparation is measured in a radioligand binding assay (saturation assay; Figure 2.10). 
 
Figure 2.10:  Schematic representation of each step in a radioligand binding assay. C+ and C- = with and 
without the addition of competitor (unlabelled DB 4).  With competitor measures non-specific binding; 
without measures total binding (non-specific and specific binding). 
 
The receptor preparation is normally in the form of cells (or cell membranes), and serial 
dilutions of the radiolabelled peptide are incubated with the cells at either 37 or 4°C for 
1.5 h in order for binding equilibrium to be reached.  As well as specific binding to the 
receptors, non-specific binding can also occur due to hydrophobic and ionic interactions 
with other sites on the cell surface, and it is important to identify the proportions that are 
specific and non-specific from the total binding observed.  
 
 
C+ C+ C+ 
C- C- C- 
 
Competitor 
(unlabelled) DB 4 
99m
Tc- 
DB 4 
Incubate for 1.5 h  
to reach  
equilibrium  
1M NaOH 
Supernatant + 
lysed cells 
Measure 
CPM* using 
Gamma 
Counter 
Scintillation tubes 
Seed 1x10
6 
 
cells/well 
* CPM = counts per minute 
Experiments were performed on all cell lines in triplicate and repeated three times on separate occasions 
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2.3.4.1 Preparation of Cells 
Forty-eight hours prior to the experiment, adherent cells (1x106 per well), in 2 mL of cell 
growth medium (RPMI 10% FBS) per well, were seeded in a 6-well plate.  One plate was 
prepared for each of the following concentrations of radioligand:  25, 10, 7.5, 5, 2.5, 1 and 
0.1 nM. 
 
Prior to experimentation, cells in the plates were checked to ensure they had fully 
adhered to the wells and were not over-confluent.  The medium was aspirated carefully to 
avoid disturbing the cells, which were washed twice in PBS to remove any that were not 
adhering.  Fresh medium (1.2 mL/well) containing 1% (w/v) FBS and 0.1% (w/v) sodium 
azide28 was added and plates were returned to the incubator until needed.  The remaining 
medium was kept at 4°C. 
 
2.3.4.2 Radioligand  
DB 4 was radiolabelled and the radiochemical purity determined29.  The radioligand was 
prepared at 10x the concentration ultimately required.  Assays were performed in 
triplicate, and for each concentration of radiolabelled peptide, a duplicate well containing 
unlabelled competitor was set up.  Competitor wells received, in 1% PBS-BSA, 150 µL of 
unlabelled DB 4 at a final concentration of 1 mM.  The corresponding non-competitor 
wells received 150 µL 1% PBS-BSA to bring the protein concentration and volume to the 
same values.  All wells received 150 µL of the appropriate concentration of labelled DB 4, 
added dropwise to the contents of each well, avoiding contact with the walls to prevent 
non-specific binding to the plastic.  Plates were gently swirled to ensure even dispersion of 
the radioligand, then incubated at 37°C under 5% (v/v) CO2/air for 90 min. 
 
                                                 
28
 Sodium azide prevents the internalisation of the bound radioligand because the uptake is driven by active 
(energy-dependent) transport - which is inhibited.  If the peptide was internalised, the radioisotope would 
be deposited in the cell, the peptide broken down by peptidase action, and the receptor recycled and re-
presented on the cell ready to be bound again.  This would give high readings due to the accumulation of 
the radioisotope rather than to binding. 
29
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After incubation, the medium was aspirated and the cells washed twice in 1% FBS, then in 
medium containing 0.1% (w/v) sodium azide, and finally in ice cold PBS, taking care not to 
disturb the cells.  To each well, 1 mL of 1 M NaOH was added to lyse the cells and left until 
lysis became apparent (10 min). 
 
Thereafter, three 5 µL-aliquots per well were transferred to a 96-well plate for 
determination of protein concentration.  Protein was assayed using the Bio-Rad Protein 
Assay KitM, as per manufacturer’s instructions, and the plate was measured on the plate 
reader at 595 nm.  The remaining supernatant samples were transferred into scintillation 
tubes, together with the washings from two 1-mL fractions of PBS for each well, and the 
tubes were then counted on the gamma counter.  This experiment was performed three 
separate times for each cell line to allow for statistical analysis. 
 
2.3.5 BIODISTRIBUTION 
 
Once successful in vitro experiments have been undertaken, in vivo analysis is essential to 
determine parameters such as biodistribution into tissues, target-to-background ratios, 
and the clearance times from the blood and body.  These factors are determined by the 
stability of Tc- labelled DB 4 complex in vivo.  Animal models, commonly immunodeficient 
mice, are used for these biodistribution studies.  Animals are injected with cancer cells to 
form tumours, then injected with the radiolabelled ligand of interest, and at varying times 
thereafter are culled, the organs are excised and radiochemical activity is measured using 
a gamma counter.   
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2.3.6 IMAGING 
 
2.3.6.1 Single Photon Emission Computed Tomography (SPECT)  
SPECT is a nuclear medicine tomographic imaging technique using gamma rays.  By 
imaging through sections, 3D images can be generated 30. 
 
2.3.6.2 Preparation of Mice 
Groups of 12 male beige SCIDS mice aged 4-6 weeks were used for the imaging and 
biodistribution studies.  Subcutaneous inoculations of the desired cells (106) on both hind-
leg flanks were made with and without Matrigel (1:1) and grown until tumours were 
visible beneath the fur. 
 
DB 4, labelled and verified for radiochemical purity, was drawn up in 100-µL doses into 
identical insulin syringes, one per animal and an additional dose as a control.  The 
radiochemical activity of all syringes was measured in the isotope calibrator, and their 
activity and weights were recorded to enable calculation of the injected dose later.  
Animals were injected via the tail veins, collecting any wipes used to dab the wound into 
individual scintillation counting tubes.  As a control to standardise the experiment, a 100-
μL dose (assuming an injected dose of that volume) was dispensed into a polypropylene 
15-mL falcon tube containing 9.9 mL of 1% PBS-BSA31.  Injection times and the weights of 
empty syringes were recorded.  Groups of 3 or more mice were used per time point, to 
allow for statistical analysis, and were either scanned or culled at 1, 2.5 and 4 h post 
injection, depending whether they were to be imaged or used for biodistribution analysis 
respectively. 
 
The amount of activity varied per experiment, however approximately 40 MBq of Tc-DB 4 
per mouse for imaging, and 2-4 MBq per mouse for biodistribution studies, was injected 
intravenously.  
                                                 
30
 Chapter 2 - Section 2.2.13 
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 BSA was used to minimise non-specific binding to the tube 
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For biodistribution studies, the empty scintillation tubes were weighed with their lids prior 
to the experiment, and reweighed after filling to obtain the weights of the excised tissue.  
Tissue samples (within the scintillation tubes) were counted in the gamma counter 
together with three 1-mL fractions from the 10-mL control sample, neat and after dilution 
(1:10 and 1:100).  The counts obtained from the counted tissues were compared with 
counts obtained from the control standards which were corrected for dilution to obtain 
CPM per mL and the percentage of injected dose per gram of tissue was calculated. 
 
 
2.3.7 AUTORADIOGRAPHY 
 
2.3.7.1 Preparation of Tumours 
Tumours were grown subcutaneously in the same manner as for biodistribution and 
imaging studies, until notable beneath the fur, then excised, mounted onto 2-cm-diameter 
cork discs covered with Optimal Cutting Temperature (OCT) Gel, which when frozen 
becomes a solid white protective layer over the embedded tissue.  The tumour was 
completely covered in OCT Gel before snap-freezing in iso-pentane pre-cooled in liquid 
nitrogen.  Once completely frozen, tumours were cut at 20 µm thickness onto slides and 
stored at -80°C until needed. 
 
Slides were thawed at room temperature for 10 min and photographed over a Perspex 
sheet bearing a small square grid (of size approximately 0.3 mm), in order to orientate the 
location of the tumour after autoradiography (Figure 2.11). 
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Figure 2.11:  Schematic representation of preparation of tumours ready to perform autoradiography. 
 
Slides were pre-incubated in 10 mM HEPES, pH 7.4, for 5 min at room temperature, 
followed by incubation in radiolabelling attachment buffer (RA)M containing radiolabelled 
DB 4 for 1 h at room temperature.  Slides were washed four times in 10 mM HEPES, pH 7.4 
/ 0.1% BSA at 4°C, rinsed twice in ice-cold distilled water for 5 s, and dried fully before 
exposure to the phosphor imager plate for 24 h.  Autoradiography on each cell line was 
performed in duplicate, with and without competitor, to establish specific binding. 
 
Serially-diluted samples of radioligand were spotted in 5-μL fractions onto a glass slide and 
allowed to dry before exposing alongside the tumour sections.  Samples of these dilutions 
were also placed in scintillation tubes and counted on the gamma counter.  
 
 
2.3.8 REAL-TIME PCR (QUANTITATIVE PCR) 
 
Real-time PCR (RT-PCR) or quantitative PCR is a method for determining the amount of a 
target sequence or gene that is present in a sample.  It monitors the progress of PCR as it 
occurs; data is collected throughout the PCR process rather than at the end, allowing a 
more quantitative study of gene expression.  Reactions are characterised by the point in 
time during cycling when amplification of a target is first detected, rather than the amount 
of target accumulated after a fixed number of cycles.    
Cork disk 
OCT over 
tumour 
Liquid nitrogen 
Iso-pentane 
Perspex grid 
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There are two types of RT-PCR; absolute quantification and relative quantification.  In the 
present experiments, the latter was utilised.  Relative quantification determines the 
change in expression of a nucleic acid sequence (target) in a test sample relative to the 
same sequence in a calibrator sample, which in this instance was a non-GRP-R-expressing 
cell line, MKN45.  Also run in parallel was an endogenous control gene, which was the 
housekeeping gene for β-actin.  Its expression occurs in all the samples at consistent levels 
and for this reason is commonly used as a reference in RT-PCR reactions  [173].  The 
endogenous control allows one to normalise quantification of the cDNA target for 
differences in the amount of cDNA added to each reaction. 
 
A singleplex reaction (a single primer pair per reaction) was performed against the target 
(GRP-R) with β-actin as the endogenous control for each of the cell lines.  A two-step 
reaction was performed, whereby total RNA was first transcribed into cDNA, which was 
then amplified by PCR. 
 
The RT-PCR reaction occurs in a four-step process (Figure 2.12).  The oligonucleotide 
probe has a fluorescent reporter dye attached to the 5’ end and a quencher at the 3’ end.  
The quencher greatly reduces the fluorescence emitted by the reporter dye when the 
probe is intact.  When the probe finds the target sequence, it anneals between primer 
sites and is cleaved, removing the probe from the target strand and separating the 
reporter dye from the quencher, thereby increasing the reporter signal.  Cleavage allows 
primer extension to continue to the end of the template strand.  For the GRP-R transcript, 
the TaqMan® Gene Expression Assay was used, an already optimised and ready-to-use 5’ 
nuclease assay.  The probe was labelled at the 5’ end with FAM™ as the reporter dye, and 
a non-florescent quencher combined with a minor groove binder (MGB) moiety32 at the 3’ 
end. 
                                                 
32
 The MGB stabilises the hybridised probe. 
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Figure 2.12:  Four-step schematic representation of the 5’ nuclease chemistry uses a fluorogenic probe to 
enable detection of a specific PCR product.  
 
 
2.3.8.1 RNA Isolation  
Cells were detached from the flask using Versene instead of 0.25% (w/v) Trypsin / 0.53 
mM EDTA solution, to eliminate any possibility that the expressed receptor was cleaved.  
Detached cells were washed twice in PBS and the pellet was taken forward for RNA 
isolation using the RNeasy Mini KitM as per manufacturer’s instructions.  A negative GRP-R 
cell-line served as the control.   The kit comprises a spin column which allows up to 100 µg 
of total RNA of minimum length 200 bases (mainly mRNA) to bind to a silica-gel 
membrane, with the aid of a specialised high-salt buffer.  The addition of ethanol ensures 
the binding of total RNA to the column membrane, and contaminants are efficiently 
washed away.  
 
Briefly; the pellet, comprising 5x106 cells, was homogenised in 350 µL of lysis buffer 
containing guanidine thiocyanate, and β-mercaptoethanol (10% of final volume) to 
inactivate RNase.  Thorough mixture of cells and buffer was achieved by pipetting 
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followed by vortexing for 1 min.  To the homogenised lysate, 350 µL of 70% (v/v) ethanol 
was added and mixed well, before transferring all the lysate, including any precipitate that 
formed, to an RNeasy mini-column equipped with a 2-mL collection tube, and centrifuging 
for 15 s at 8000 g.  The flow-through was discarded, and the column was washed.  DNase I 
was applied to the column membrane and incubated at room temperature for 15 min, 
followed by wash buffer (350 µL).  The column was re-centrifuged, again discarding the 
flow-through, then washed again twice with the appropriate buffer before being 
transferred to a new collection tube.  RNase free-water (50 µL) was applied directly onto 
the membrane and the column was centrifuged for 1 min at 8000 g to recover the eluted 
RNA.  RNA yield and purity was determined spectrophotometrically using a NanoDrop 
spectrophotometer at 260 and 280 nm.  Recovered total RNA gave A260/A280 >1.9.  
Samples were stored at -80°C until needed or taken forward for cDNA synthesis. 
   
2.3.8.2 cDNA Synthesis  
cDNA synthesis was performed using a cDNA synthesis kitM as per manufacturer’s 
instructions.  Briefly, defrosted RNA samples were placed on ice with other kit 
components.  The concentration of RNA was measured again to ensure that the freeze-
thawing process had not damaged it.  In a 0.5 mL tube, the following components (Table 
2.4 ) were mixed to generate the RNA/primer mixture: 
 
Table 2.4:  RNA/primer mixture 
  
Components Volume (μL) 
5 μg total RNA x 
random hexamers 1 
10 mM dNTP mix 1 
RNase free water To a total of 10 
 
Random hexamers are a mixture of oligonucleotides representing all possible sequences 
for a hexamer.  x varied between 1 and 7 μL.   
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After mixture, samples were incubated at 65 °C for 5 min, then placed on ice for a 
minimum of 1 min.  A cDNA synthesis mixture was prepared, adding each component in 
the order shown in Table 2.5. 
 
Table 2.5:  cDNA synthesis mixture.  
 
Components Volumes  (μL) 
10x RT buffer 2 
25 mM MgCl2 4 
0.1 M DTT 2 
RNaseOUT™ 1 
SuperScript™ III 1 
 
RT Buffer comprised of 200 mM Tris-HCl, pH 8.4 / 500 mM KCl, RNaseOUT safeguards 
against degradation of target RNA due to ribonuclease contamination and SuperScript III 
RT is used to synthesise first-strand cDNA. 
 
cDNA synthesis mixture (10 μL) was mixed gently with the RNA/primer mixture, then 
incubated on the thermo-cycler at 25°C for 10 min, followed by 50°C for 50 min, and 
finally 85°C for 5 min, after which samples were chilled on ice.  In parallel, a reverse-
transcriptase control without RNA was also prepared.  Brief centrifugation ensured 
collection of each sample without any air bubbles before the addition of 1 μL of RNase H 
solution to each tube and incubation at 37°C for 20 min.  Samples were used for PCR 
immediately or stored at -20°C in aliquots to minimise repeat freeze-thaw cycles. 
 
2.3.8.3 Real-Time PCR – Experimental Protocol 
RT-PCR was performed by setting up PCR master mix for a 20 μL reaction, for both the 
tested gene and the endogenous (β-actin) control ( 
Table 2.6) 
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Table 2.6:  Master Mix for RT-PCR  
 
Master Mix 
Components 
Tested Gene 
(μL per reaction 
tube) 
Endogenous Control 
(μL per reaction 
tube) 
TaqMan 10.0 10.0 
TaqMan Gene 1.25 - 
β-Actin Gene - 1.25 
Water 4.75 4.75 
 
The PCR master mixture was distributed in 16-μL aliquots into the wells of a RT-PCR plate 
at room temperature.  To this, 4 μL of cDNA template was added and mixed by pipetting.  
The plate was briefly centrifuged to collect the contents at the bottoms of the wells, then 
stored on ice until used. 
 
The plate was placed in the RT-PCR instrument and incubated, using the following settings 
(Table 2.7). 
 
Table 2.7:  RT-PCR Instrument Settings 
 
RT-PCR Settings 
 Repetitions Temperature (°C) Time 
Reverse 
Transcription 
1 50 2 min 
Enzyme 
Activation 
1 95 10 min 
PCR Cycle 
(melt) 
40 95 15 s 
PCR Cycle 
(anneal & 
Extend) 
40 60 1 min 
 
   
An amplification plot for each sample was obtained and further analysis was performed 
on the threshold cycle (CT) values acquired.  An example of an amplification plot (Figure 
2.13) attained in RT-PCR, shows how CT values are derived.  CT is the intersection between 
an amplification curve and a threshold line (automatically determined; it is set above the 
baseline, but sufficiently low to be within the exponential growth region of the 
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amplification curve).  It is a relative measure of the concentration of the target in the PCR 
reaction.  A no-template control (NTC) sample that does not contain template is 
performed to verify amplification quality. 
 
 
 
Figure 2.13:  A representation of an amplification plot.  Rn = the ratio of the fluorescence emission intensity 
of the reporter dye to the fluorescence emission intensity of the passive reference dye. ΔRn = the magnitude 
of the signal generated by the specified set of PCR conditions (ΔRn = Rn - baseline).  
 
 
2.3.9 IMMUNOHISTOCHEMISTRY ON TUMOUR SECTIONS 
 
Immunohistochemistry (IHC), in the present context, is the localisation of antigens in 
tissue sections by the use of labelled antibodies as specific reagents through antigen-
antibody interactions.  These are visualised by use of a marker such as a fluorescent dye, 
an enzyme, a radioactive element, or colloidal gold.  
 
Tumours were processed by the pathology services at the Institute of Cancer, Queen Mary 
University, using the Ventana Discovery™ Immunohistochemistry Unit, which stains 
samples automatically and performs IHC under controlled conditions, minimising 
technique-dependent errors and increasing reproducibility and productivity.  Slides were 
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treated with the Discovery™ DAB Map™ Kit, designed for antigen localisation in cytological 
preparations, frozen sections, or formaldehyde-fixed, paraffin-embedded tissue sections.  
The kit is based on peroxidase detection using 3,3-diaminobenzidine (DAB), an insoluble, 
light-insensitive chromogenic substrate for peroxidase product, which stains antigen-
antibody sites brown, and contrasts well with the blue nuclear counterstain, 
haematoxylin.  It ensures sensitive and specific antibody detection by incorporating 
streptavidin-biotin technology for the detection of antibodies (in a number of 
applications), and reduces background staining.   
 
Optimisation of the commercially available anti-GRP-R antibody (Abcam 39963) was 
performed on human pancreatic tissue.  A range of antibody dilutions were tested and a 
1:100 dilution was found to be the optimal concentration, yielding good staining on tissue 
sections.  Tumour sections were viewed under a standard light microscope. 
 
All tumour sections were stained for GRP-R expression and compared both the positive 
control (pancreatic tissue) and negative control (no antibody).   
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3 PSMA STUDY 
 
3.1 AIMS AND OBJECTIVE 
 
Recognising the shortage of PC radiopharmaceuticals to image and stage PC, it was the 
aim of this study to explore new approaches to identify new ligands as potential targets 
for PC imaging.  
 
PSMA was selected as a promising clinical biomarker target for diagnosis, detection and 
management of PC.  The aim of this project was to develop a PSMA-specific scFv and 
successfully radiolabel to develop a radiopharmaceutical that could image all stages of PC 
growth. 
 
The objectives were to; 
 
1. To screen phage display libraries against both cell-expressed PSMA and 
recombinant PSMA protein. 
2. To construct diabody fragments and assess binding specificity against svFv. 
3. To apply established radiolabeling techniques appropriate for different imaging 
approaches using the selected scFv and diabodies with low and high affinity and 
compare their pharmacokinetics and efficacy to each other. 
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3.2 PSMA STUDY RESULTS 
 
3.2.1 PHAGE DISPLAY  
 
3.2.1.1 Selection for Anti-PSMA Phage on PSMA-Expressing Cells 
Selection for anti-PSMA scFv was performed using phage display.  Two approaches were 
taken to select for anti-PSMA scFv; one performed on cells naturally expressing PSMA, and 
the second approach using in-house-generated recombinant PSMA protein.  The rationale 
behind this was to enable the selection of scFv that bound to the target antigen - PSMA. 
 
Selection on PSMA-expressing cells was considered to be the preferred approach, as 
phage would recognise the naturally-occurring PSMA that bears the typical conformation 
and glycosylation patterns33.  Using the Tomlinson I Library [90], selection for anti-PSMA-
specific phage was therefore performed on the non-PSMA and PSMA-expressing cell lines, 
DU145 and LNCaP C81 respectively34 (Figure 3.1).   
 
 
 
 
                                                 
33
 Glycosylation is an enzymic process which, as well as producing fundamental components of all cells, also 
provides a co-translational and post-translational modification mechanism that modulates the structure and 
function of the membrane and secreted proteins. 
34
 LNCaP C81 and DU145 cells are respectively derived from human lymph node metastasis and human brain 
metastasis. 
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Figure 3.1 Schematic representation of selection performed on cells.  DU145 are PSMA negative and were 
used to subtract non-specific clones before incubation on PSMA-positive cells, LNCaP C81.  A total of 5 
rounds of selection were performed. 
 
The selection of recombinant antibodies using PSMA-expressing whole cells provides a 
means of cloning antibody fragments that react selectively with cell-surface antigens.  One 
drawback of this method is the possibility of selecting for another receptor or marker 
heavily expressed by the LNCaP C81 cells.  Therefore each round of phage display was 
performed on whole adherent LNCaP C81 cells after subtraction of non-specific phage on 
the PSMA-negative cell line (DU145) which lacked the desired target antigen but are 
otherwise similar to the selection cells, thereby greatly increasing selection efficiency.   
Positive phage clones (those that bound to the positive cell line) were eluted from the 
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cells and the whole process was repeated on this enriched population a further four times.  
Selection was monitored using ELISA which was performed after each round, indicating 
the presence of positively-binding phage clones (Figure 3.2).   
 
 A 
  
 
 
Figure 3.2: Monoclonal ELISA after rounds 4 (A) and 5 (B).  Increase in PSMA-specific clones binding to 
LNCaP. 
 
PSMA-positive phage clones were taken forward for further study after the last round of 
panning by expressing the soluble scFv and evaluating the specificity of binding, in 
particular to ensure that the binding seen was specific via the scFv to PSMA, rather than 
non-specific binding to the phage body. Positive scFv clones were therefore subjected to a 
number of verification analysis including FACS, ELISA and immunoprecipitation.  Five 
potential clones were identified; however analysis showed that the specificity and affinity 
of the selected clones was not optimal.  FACS failed to differentiate between positive and 
negative cell lines ( 
Figure 3.3) and ELISA revealed poor binding to recombinant PSMA.   
 
A 
B 
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Figure 3.3: FACS analysis using the 5 positive phage clones on PSMA-positive cells (LNCaP - blue) and PSMA-
negative cells (DU145 - purple).  Binding was not conclusive, as poor binding observed with LNCaP cells. 
 
Clones seemed to weakly bind to PSMA specifically in preference to other proteins (BSA) 
or non-PSMA-expressing cells, but only marginally so, and their affinity was considered 
too low; therefore this approach and the selected scFv were not pursued further. 
 
Selection for anti-PSMA scFv was performed using phage display.  Two approaches were 
taken to select for anti-PSMA scFv; one performed on cells naturally expressing PSMA, and 
the second approach using in-house-generated recombinant PSMA protein.  The rationale 
behind this was to enable the selection of scFv that bound to the target antigen - PSMA. 
 
Selection on PSMA-expressing cells was first investigated and considered to be 
advantageous, as phage would be able to bind in vivo to naturally-occurring PSMA that 
A F I 
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bears the typical conformation and glycosylation patterns35.  Using the Tomlinson I Library 
[90], selection for anti-PSMA-specific phage was therefore performed on the non-PSMA 
and PSMA-expressing cell lines, DU145 and LNCaP C81 respectively36.  The selection of 
recombinant antibodies using PSMA-expressing whole cells provides a means of cloning 
antibody fragments that react selectively with cell-surface antigens.  One drawback of this 
method is the possibility of selecting for another receptor or marker heavily expressed by 
the LNCaP C81 cells.  Therefore each round of phage display was performed on whole 
adherent LNCaP C81 cells after subtraction of non-specific phage on the PSMA-negative 
cell line (DU145) which lacked the desired target antigen but are otherwise similar to the 
selection cells, thereby greatly increasing selection efficiency.   Positive phage clones 
(those that bound to the positive cell line) were eluted from the cells and this enriched 
population was resubmitted to the whole process a further four times.  Selection was 
monitored using ELISA which was performed after each round.  PSMA-positive phage 
clones were taken forward for further analysis after the last round of panning by 
expressing the soluble scFv and evaluating in terms of the stability and specificity of 
binding, i.e. that the binding seen was specific via the scFv to PSMA, rather than non-
specific binding to the phage body.  To do this, positive scFv clones were subjected to a 
number of verification analysis including FACS, ELISA and immunoprecipitation.  However, 
these studies showed that the specificity and affinity of the selected clones was not 
optimal.  Clones seemed to bind to PSMA specifically in preference to other proteins or 
non-PSMA-expressing cells, but only marginally so, and their affinity was considered too 
low; therefore this approach and the selected scFv were not pursued further. 
 
 
 
 
 
                                                 
35
 Glycosylation is an enzymatic process which, as well as producing fundamental components of all cells, 
also provides a co-translational and post-translational modification mechanism that modulates the structure 
and function of the membrane and secreted proteins. 
36
 LNCaP C81 and DU145 cells are respectively derived from human lymph node metastasis and human brain 
metastasis. 
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3.2.2 PRODUCTION OF RECOMBINANT PSMA PROTEIN   
 
3.2.2.1 Baculovirus Expression Vector System 
Using the Baculovirus Expression Vector System, the large extracellular portion of PSMA 
was generated in Hi5 cells37.  Cells were infected with the in-house virus and left at 27°C 
for 3 days.  A negative control flask was left uninfected to allow comparison and establish 
whether infection had been successful (Figure 3.4). 
 
 
Figure 3.4:  Comparison of uninfected and infected Hi5 cell monolayers.  A – Uninfected Hi5 cells, B – Hi5 
cells infected with in-house virus.    
 
Hi5 cells that were incubated with in-house virus were grown to allow for infection, 
production and secretion of the recombinant protein into the medium.  A notable 
difference in morphology was observed in comparison with the uninfected cells which 
grew in parallel.  Infected cells swelled to become much larger than uninfected cells, 
contained enlarged nuclei, stopped dividing, and often became detached from the flask.  
 
3.2.2.2 Verification of Recombinant PSMA Protein Production 
Prior to purification, samples of supernatants were checked by SDS-PAGE to determine 
whether the 90 kDa band was present, corresponding to the large extracellular portion of 
the recombinant PSMA protein (Figure 3.5). 
 
 
                                                 
37
 Chapter 2 - section (Baculovirus)  
A B 
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Figure 3.5:  SDS-PAGE with supernatant harvested 3 days after infection with in-house virus.  Each lane 
(numbered 1-6) was loaded with the material from one of the large 175cm
2
 flasks.   
 
 
The mobilities of the reference standard proteins (lane 1) in SDS-PAGE, plotted against log 
molecular weight, are shown in Figure 3.6. 
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Figure 3.6:  Log molecular weight of markers versus their mobility.   
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Table 3.1:  Molecular weight of the major protein in each sample 
 
Lane 
Mobility (Rf) 
(cm) 
Log Mr Mr (kDa) 
2 6.2 1.989 97 
3 6.4 1.972 94 
4 6.4 1.972 94 
5 6.34 1.977 95 
6 6.34 1.977 95 
7 6.28 1.982 96 
 
 
From this plot, the molecular weight of the major protein in each sample was determined 
(Table 3.1).  Values were slightly in excess of that expected (90 kDa, indicative of the large 
extracellular PSMA portion), due to slight distortion of the banding in the gel, but were 
close to the expected value.  Having confirmed recombinant PSMA protein production by 
SDS-PAGE, Western blot analysis was also performed to check whether commercial anti-
PSMA antibody (1H8H5) recognised the recombinant protein.  Cell lysate (LNCaP C81) was 
used as positive control (Figure 3.7). 
 
 
Figure 3.7:   Western blot of recombinant PSMA protein generated using Hi5 cells.  Bands at 90 kDa were 
seen with each sample of supernatant representative of each flask.  The positive control (cell lysate) 
revealed a band at 100 kDa, confirming that only the large extracellular portion of PSMA protein was 
generated.  Five minute exposure.   
 
Both SDS-PAGE and Western blot analysis substantiated the production of recombinant 
PSMA protein, which was purified from the supernatants using Ni-NTA kits.  The purified 
recombinant PSMA protein was used for selection and verification experiments.  
 
 
100 kDa 
Supernatant 
Cell   
lysate 
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3.2.2.3 Selection For Anti –PSMA Phage on Recombinant PSMA Protein   
Selection on recombinant PSMA protein was initially run in parallel to the presently-
reported work by Dr. Stella Man, who had propagated in-house recombinant PSMA 
protein using the Baculovirus system38 and performed 3 rounds of phage display against 
the recombinant PSMA.  Positive binders were then used in this project and taken forward 
for further analysis.  Using recombinant PSMA was potentially advantageous over 
selection on cells because the Tomlinson phage library was screened against considerably 
higher concentrations of the target protein than that naturally found on cells in vivo.  Also 
the protein was designed to be composed of only the large extracellular portion of the 
PSMA molecule, eliminating the smaller intracellular portion only exposed once cells 
became necrotic or apoptotic39.  A potential disadvantage of this technique was that, 
although the protein was generated using the Baculovirus system which produces proteins 
with similar glycosylation patterns to those found in humans, it may not be exactly the 
same as found naturally in vivo. 
 
Three rounds of phage display on PSMA-coated immunotubes were performed in total40.  
The progress of selection can be readily monitored after each round by measuring phage 
titre; titre was expected to increase with each round of selection as the population was 
being enriched towards the target antigen (Table 3.2).  
 
Table 3.2:  Phage titre after each round of selection 
 
Selection Round Titre 
1 8 x 10
5
 
2 6 x 10
6
 
3 2 x 10
7
 
 
 
Increase in phage titre was a quick validation that each round of selection had been 
successful and the phage population was being enriched towards the target antigen. 
                                                 
38
 Baculovirus system is a versatile method of producing large quantities of biological active and functional 
recombinant protein using cultured insect cells. 
39
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Selection using immobilised recombinant PSMA protein was more successful than that 
performed on cells, and yielded a number of PSMA-specific phage clones that showed 
improved binding in ELISA on recombinant PSMA protein.  These selected clones were 
further subjected to several validating experiments to ensure that the phage selected 
contained a complete, unique scFv sequence, and bound selectively with high affinity to 
PSMA expressed both in vitro and in vivo. 
 
3.2.2.4 Sequencing of Phage Clones  
Phage clones showing high binding in ELISA (results not shown) were chosen and 
sequenced to examine variability and ensure the presence of the complete scFv sequence. 
 
Table 3.3:  Sequencing results of selected phages.  Sequences were read with FDSEQ and LMB3, obtaining 
the CDR2 & 3 for both heavy and light chains.  * represents stop codons in the gene - the sequences below 
are of amino-acids. 
 
 
ScFv sequences were present in all the clones tested.  Sequences with stop codons 
present in the VH-CDR2 sequence indicated possible sequencing errors.  
 
 
 
 
Phage 
Clone 
 
VH-CDR2 
 
VH-CDR3 
 
VL-CDR2 
 
VL-CDR3 
A1 TISYDGSGTAYADSVKG NGSSFDY SASYLQS QQSADNPA 
A5 NIDYAGNYTAYADSVKG TNDNFDY YASSLQS QQSADNPA 
C4 SIAYDGDGTGYADSVKG GTATFDY TASSLQS QQGNYGPA 
C6 YISDNGNATDYADSVKG NTASFDY AASTLQS QQANADPT 
D2 DISSSGSTT*YADSVKG SYSYFDY SASSLQS QQNSANPG 
D4 SIAYDGDGTGYADSVKG GTATFDY TASSLQS QQGNYGPA 
D6 DISSSGSTT*YADSVKG SYSYFDY SASSLQS QQNSANPG 
E3 DISSSGSTT*YADSVKG SYSYFDY SASTLQS QQSTNAPN 
G7 TIAYDGTATSYADSVKG NGASFDY GASYLQS QQANYGPA 
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3.2.3 BINDING STUDIES ON PSMA-EXPRESSING CELLS 
 
3.2.3.1 FACS Using Selected Phage Clones 
Binding studies of those phage clones with a full unique scFv sequence and high binding 
affinity in ELISA were then performed on whole LNCaP and DU145 cells using FACS 
analysis.  An anti-PSMA monoclonal antibody, D2B antibody, kindly provided by a 
collaborative research group at the Department of Experimental Oncology, Instituto 
Nazionale per la Studio e la Cura dei Tumori, Milano, Italy, was used as a positive control, 
and the unselected Tomlinson I library as the negative control.  
 
FACS on selected phage clones was performed as in previous experiments41, with the 
addition of an extra incubation step with anti-M13 monoclonal antibody42 (Figure 3.8). 
                                                 
41
 Chapter 2 - Section 2.2.8 
42
  Monoclonal anti-M13 pIII recognises non-reduced and denatured reduced forms of wild type pIII or pIII 
fusions in ELISA, immunoblotting and FACS. 
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Figure 3.8:  Incubation of selected phage clones on DU145 and LNCaP C81 cell lines differentiating between 
positive and negative anti-PSMA phage.  The identity of the phage clone is denoted on the top left hand 
corner of each graph and cell line tested is identified on the right.  Solid grey: Negative control – Tomlinson I 
Library; Green line: Positive control – D2B anti-PSMA antibody; Red line: Tested phage clone.  
 
Promising results were obtained in FACS:  approximately half of clones tested selectively 
bound more strongly to LNCaP cells than DU145, suggestive of anti-PSMA phage clones.  
No binding with the unselected Tomlinson I library was observed in either cell line, 
A1 A1 DU145 C81 
A5 DU145 
A5 
DU145 C4 C81 C4 
C6 DU145 C81 C6 
DU145 G7 C81 G7 
C81 A5 
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whereas the positive control antibody, D2B, bound selectively to LNCaP C81 cells 
compared to DU145.  The clone names were derived from the 96-well plate, which was 
numbered 1-12 as well as lettered A-H, allowing for the designation of the phage clone to 
a known well. 
 
 
3.2.4 EXPRESSION OF SOLUBLE SINGLE-CHAIN FV 
 
ELISA was performed on secreted scFv supernatant from binding phage clones from both 
rounds 2 and 343 (Figure 3.6). 
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Figure 3.9:  ELISA of soluble scFv tested against immobilised recombinant PSMA protein.  (A) Round 2 of 
selection; (B) round 3 of selection.   
 
Antibody fragments exhibiting high levels of binding to the recombinant PSMA protein 
from both rounds 2 and 3 were selected and put forward for sequencing to ensure that 
the selected scFv was complete and that a diverse repertoire was selected (Table 3.4). 
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Table 3.4:  Sequencing results of high-binding soluble scFv from the results of the ELISA.  Sequences were 
checked to ensure that they were complete and that the scFv were undeleted, as well as representing a 
diverse population from rounds 2 and 3.  ND = no data obtained.  
 
 
scFv 
Clone 
 
ELISA 
(A450) 
 
VH-CDR2 
 
VH-CDR3 
 
VL-CDR2 
 
VL-CDR3 
R3B6 1.853 ATGGSGDATSYADSVKG AATGFDY DASSLQS QQYSAYPT 
R3C5 2.752 SISGYGSTTAYADSVKG NAASFDY TASSLQS QQANSY 
R2E8 2.175 AISTYGSYTSYADSVKG NYTDFDY SASSLQS QQAYNYPS 
R2F3 1.161 SIAYDGDGTGYADSVKG GTATFDY TASSLQS QQGNYGPX 
R3F5 0.761 SIAYDGDGTGYADSVKG GTATFDY TASSLQS QQGNYGPA 
R3G4 1.983 AISTAGAATAYADSVKG NTAAFDY ASYLQS QQTYSTPT 
R2G10 0.686 TISYDGSGTAYADSVKG NGSSFDY SASYLQS ND 
R2H2 0.892 TIAYDGTATSYADSVKG NGASFDY GASYLQS QQANYGPA 
 
The numbering system was set such that R2 or R3 denoted the selection number followed 
by the location on the 96-well plate as with the phage clone number system.  Sequencing 
results obtained revealed that only two identical clones were present (R2F3 and R3F5) and 
the remainder had yielded complete and diverse scFv.  Clone R2G10 sequence had failed 
to read VL-CDR3, possibly due to an error during sequencing, although the A450 reading 
from the ELISA results showed relatively high binding to the recombinant PSMA protein.   
 
 
3.2.4.1 FACS Analysis of Purified Selected Clones 
To further confirm the high binding affinity observed in ELISA, FACS analysis was 
performed.  For this purpose, a small fraction of each clone was purified using Sepharose 
A chromatography (Figure 3.10). 
 
FACS analysis of the purified scFv was performed on both LNCaP C81 and DU145 cell lines 
to determine whether the positive, selective binding observed with the phage clones was 
still present with the scFv alone.   A comparison of anti-his and anti-myc monoclonal IgG 
antibodies as secondary layers was performed; anti-myc demonstrated improved binding 
over anti-his antibody and this was used thereafter.   
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Figure 3.10:  Incubation of purified scFv with LNCaP C81 and DU145 cell lines, differentiating between 
positive and negative anti-PSMA phage.  Solid grey: Negative control – DU145 with D2B anti-PSMA antibody; 
Solid black: positive control - LNCaP C81 with D2B anti-PSMA antibody; Red line: DU145 tested with scFv; 
Blue line: LNCaP C81 tested with scFv.   
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Selective binding was observed with all the tested clones, however R3B6 and R3C5 which 
showed very high readings in ELISA, did not mirror this in FACS and were therefore not 
pursued further.  Remaining lower-binding scFv clones were also examined to ensure that 
improved affinity scFv clones were not lost44.  R2F3, R2G10, R2H2 and R3F5 were selected 
as the most promising candidates with good binding affinity demonstrated in both ELISA 
and FACS.  The two clones with identical amino acid sequences (R2F3 and R3F5) were both 
selected to see whether they behaved in the same manner. 
  
3.2.4.2 Purification of scFv 
Larger scale purification of the selected scFv clones was then performed.  The periplasmic 
fraction obtained during production of the soluble scFv needed to be purified to remove 
other proteins secreted during osmotic shock45.  The purification profile obtained by 
Protein A chromatography46 was compared with that obtained by chromatography on Ni-
NTA47 (Figure 3.11).   
 
 
   
Figure 3.11:  SDS-PAGE of selected scFv antibody fragments recovered after Protein A-Sepharose 
purification.  1 - R2F3, 2 - R2G10, 3 - R2H2, 4 - R3F5 
 
                                                 
44
 Appendix  II 
45
 Chapter 2 - Section 2.2.5.2 
46 
Protein A chromatography can be used to purify antibody fragments encoded by VH segments from the 
VH3 family  
47
 Ni-NTA binds to his-tagged proteins 
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Purification by chromatography on Protein A-Sepharose yielded clean 25 kDa-bands 
indicative of scFv.  Bands could be seen at both higher and lower molecular weights, but 
those observed were faint and considered as inconsequential (Figure 3.12). 
 
 
 
Figure 3.12:  SDS-PAGE of selected scFv antibody fragments recovered after Ni-NTA purification.   
1 - R2F3, 2 - R2G10, 3 - R2H2, 4 - R3F5 
 
Purification using Ni-NTA failed to purify the antibody as efficiently as the protein A-
Sepharose column (Figure 3.12).  Substantial bands of lower molecular weight were 
observed between 15 and 10 kDa, and the 25 kDa-bands looked to be slightly fragmented, 
possibly due to degradation of the antibody fragments. 
 
3.2.4.3 Protein Concentration 
Protein concentrations of the purified scFv were obtained by measurement of A280 nm 
following dialysis (Table 3.5).  Protein concentration was estimated on the basis 1 A280 nm 
unit ≡ 800 µg/mL, an approximation derived from the method of Warburg and Christian 
[174]. 
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Table 3.5:  Concentrations of scFv antibody fragments after Protein A-Sepharose chromatography.  
  
Sample Elution Fraction A280 nm 
Protein 
concentration 
(µg/mL) 
R2F3 
E1 0.1 80 
E2 1.33 1065 
E3 0.39 313 
R2G10 
E1 0.47 374 
E2 2.04 1628 
E3 0.60 481 
R2H2 
E1 0.84 674 
E2 0.53 426 
E3 0.11 89 
R3F5 
E1 0.39 309 
E2 1.09 874 
E3 0.42 366 
 
 
Elution fractions represent 1 mL volumes of eluted protein from the column.  All the 
elution fractions were measured to establish which fraction held the largest concentration 
of protein.  Fractions with similar concentrations were pooled together before aliquoting 
into smaller fractions and for storage at -80°C. 
 
The purified clones were re-tested by FACS to confirm that specific binding observed still 
remained (results not shown).  The most promising clones from ELISA and FACS results, 
R2F3, R2H2, R2G10 and R3F5, were then selected for conversion into diabodies. 
 
 
3.2.5 PRODUCTION AND ANALYSIS OF DIABODIES 
 
ScFv antibodies are genetically-engineered fusion proteins containing variable heavy- and 
variable light-chain domains joined by a polypeptide linker.  To facilitate the formation of 
an intermolecular antigen binding site, artificial linkers such as glycine-serine (G4S)3 have 
been utilised in various scFvs, because such linkers do not contribute to the formation of 
any specific secondary structure [175].  The length of the flexible linker dictates the final 
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structure; linkers longer than 12 residues are predominately monomers, whereas scFvs 
with shorter linkers form dimeric or multimeric molecules [176]. 
 
Manipulation of the glycine-serine linker can therefore be performed to prevent the 
natural folding of the variable heavy and variable light chains48.  The complete removal of 
the linker was carried out by utilising the many restriction sites present in the genetic 
map49. 
 
3.2.5.1 Extraction of DNA 
Extraction of DNA from all four clones (R2F3, R2H2, R2G10 and R3F5) was successful, as 
verified by agarose-gel electrophoresis (Figure 3.13)   In each case, two bands were 
visualised; one representing the circular DNA and the second denoting supercoiled DNA. 
 
 
             
 
Figure 3.13:  Confirmation of successful DNA extraction.  A - D – clones R2F3, R2G10, R2H2 & R3F5 
respectively, M – 1 Kb DNA marker.  Two bands were visualised in all four clones; SC - supercoiled, and C - 
circular, indicative of successful DNA extraction.  
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           Samples 
M 
3.2.5.2 Restriction Digest  
Linearisation of the pIT2 vector was achieved by restriction digestion using SalI and XhoI, 
which act on sites situated either side of the glycine-serine linker.  Digestion was 
performed and verification of successful linearisation was observed by agarose-gel 
electrophoresis, where one clear band could be seen to be recovered from all four clones.  
The removed linker was too small in size to be seen on the gel50.  Bands (linearised vector) 
were cut out and the DNA was extracted using QIAquick gel extraction.  To ensure DNA 
had not been lost during this process, samples were run again.  Single clear bands could be 
seen in all four clones, indicating that the extraction from the agarose had been successful 
(Figure 3.14), although the bands were not as sharp as expected, symptomatic of 
overloading the wells. 
 
 
                                             
 
Figure 3.14:  Linearisation of pIT2 vector in all four clones.  M - 1 Kb DNA ladder run in parallel.  
 
 
     
3.2.5.3 Ligation 
Rejoining of the linear vector was performed by ligation51.  Several methods to confirm 
successful removal of the linker between VH and VL after ligation were investigated to 
ensure that the SalI and XhoI restriction sites had been removed from newly-formed 
vector, indicating complete removal of the linker.  Verification of successful removal was 
seen in several digestions using SalI, XhoI, HindIII and NotI (Figure 3.15).  Digestions with 
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the combination SalI or XhoI (acting on the removed restriction sites) with either HindIII or 
NotI yielded one band, as only one restriction site was present and therefore the cut had 
been made in one place only.  Combination of HindIII and NotI together yielded two 
bands, since both these enzymes were able to cut the DNA in separate places to yield two 
bands.   
 
 
 
Figure 3.15:  Different combinations of restriction enzymes were used to verify that the linker had been 
effectively removed.  HindIII with NotI was selected as the sites for these were present on the genetic map 
and the fragments generated were of different sizes, enabling them to be easily visualised. 
 
Final confirmation was obtained by sequencing, which revealed full and complete removal 
of the glycine-serine linker (results not shown). 
 
3.2.5.4 ELISA of The Dimeric Periplasmic Fraction 
As a rapid means of verifying that dimeric expression was successful, ELISA on 
recombinant PSMA protein was performed on the periplasmic fraction, before 
undertaking purification.  This method gave an indication of the specific binding of the 
dimeric antibody fragments to the target antigen, as well as non-specific binding to BSA 
(Figure 3.16).  
 
 Hind III + NotI                        SalI + NotI                 HindIII + XhoI  
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Figure 3.16:  ELISA performed on recombinant PSMA- and BSA-coated plates.  Periplasmic fractions from all 
four clones were incubated to check for specific binding affinity to the immobilised targets.  Binding assays 
were performed in triplicate.  
 
Clear differences between all four clones could be seen in the extent of binding to PSMA 
protein compared with binding to BSA, with a minimal difference seen between the R2F3 
and R2G10 clones.  A significant difference in the extent of binding was observed between 
R2F3 and R3F5.  Even though these had the same scFv sequence, this could be due to 
different levels of expression.    Encouragingly, the binding observed validated the 
production of the dimeric antibody fragments.  
 
As a means of ensuring that the production of the antibody fragments was successful, the 
levels of expression of the four clones were also measured by adsorbing the periplasmic 
fraction and supernatant material to a Maxisorb plate, and performing an ELISA52 (Figure 
3.17). 
 
                                                 
52
 Chapter 2 - Section 2.2.4.6 
Chapter 3  PSMA Results 
    124 
 
R2F3 R2G10 R2H2 F3F5
0
1
2
3
4
Periplasmic Fraction
Supernatant
Clones
A
4
5
0
 
Figure 3.17:  Expression levels measured of the four clones pre-purification.  The periplasmic fraction 
showed higher levels of expression than the supernatant.  
 
Expression was observed in all the clones.  The periplasmic fraction yielded higher values 
than the supernatant, due to retention of scFv predominantly in the periplasmic space, 
with only a small amount ‘leaking’ into the medium53.  Both ELISA experiments confirmed 
positive production of the dimeric antibody fragments, and showed higher levels of 
expression in the periplasmic fraction over the supernatant; therefore validating the 
purification of the periplasmic fraction, which was performed in the same manner as for 
the monomeric antibody fragments.  Interestingly little difference could be observed 
between the levels of expression between R2F3 and R3F5, indicating the difference in 
binding seen was not due to expression differences. 
 
3.2.5.5 ELISA of Purified Diabodies 
After production and purification of the diabodies (as with scFv purification), a further 
ELISA experiment was performed to ensure that expression and specificity towards PSMA 
protein still remained (Figure 3.18).  Preliminary results revealed an acceptable level of 
expression with moderate specificity for the recombinant PSMA protein. 
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Figure 3.18:  ELISA was performed on decreasing concentrations of adsorbed recombinant PSMA protein in 
order to assess specific and selective binding of purified dimeric antibody fragments 
 
Specific binding was observed in a dose-dependent manner with all four clones.  R2F3 
displayed better binding than the other clones.   
 
3.2.5.6 FACS Analysis of Purified Diabodies  
Specificity of the diabodies to naturally-expressed PSMA was examined by FACS analysis.  
Initial results showed specific binding to PSMA-expressing cells, with differentiation 
between LNCaP C81 and DU145 cell lines (Figure 3.19). 
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Figure 3.19:  FACS analysis using newly generated diabodies (20 µg/mL) showed positive and selective 
binding to PSMA-expressing cells (LNCaP C81).  Black solid:  Negative control - DU145 + D2B anti-PSMA 
antibody; Grey solid: Positive Control - LNCaP C81 + D2B anti-PSMA antibody; Red line: DU145 + tested 
purified dimeric clone; Blue line: LNCaP C81 + tested purified dimeric clone; Green line: Negative control – 
LNCaP C81 + alpha V beta 6 diabody
54
 
 
Selective binding to PSMA on LNCaP C81 by all four generated diabodies was observed 
(blue trace in Figure 3.19 ); however this peak appeared to be broader than the other 
peaks in the trace, possibly due to a the presence of a heterogeneous mixture of both 
monomeric, i.e. scFv, and dimeric i.e. diabody fragments.  The ‘negative’ diabody alpha v 
beta 6 did not appear to be as unreactive as originally thought, which has prompted 
further examination (by another research group). 
 
 
3.2.6 COMPARISON BETWEEN SCFV AND DIABODIES 
 
3.2.6.1 FACS Analysis – scFv vs. Diabodies 
The rationale for forming diabodies was to attempt to increase the affinity of the selected 
clones to the target antigen, PSMA, since the presence of two binding sites should 
increase their ability to bind to the target.  FACS analysis was therefore performed to 
compare the binding affinities of scFv with those of the diabodies.  FACS was performed 
on DU145 and LNCaP C81 with clones R2G10 and R2H2 over a range of antibody 
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 Alpha V beta 6 was provided as a negative diabody control from a colleague, Dr. John Marshall, Tumour 
Biology.  It was believed that it would be unreactive because it predominately binds to skin, mouth and 
breast carcinomas. 
Chapter 3  PSMA Results 
    127 
 
concentrations, viz. 10, 5, 1, 0.5 and 0.1 µg/mL (Figure 3.20).  Overlaying the histogram 
results for all the variables allowed direct, qualitative comparison between the binding of 
scFv and the diabodies. 
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Figure 3.20:  FACS analysis to determine binding affinity between scFv and diabodies.  Grey solid: Negative 
control - DU145 + D2B anti-PSMA antibody; Black solid: Positive control - LNCaP C81 + D2B anti-PSMA 
antibody; Green line: Purified scFv clone; Red line: Purified diabody clone.  A - R2G10 and B - R2H2.   
 
 
A 
B 
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With decreasing concentrations of antibody fragments, binding decreased in a 
corresponding manner.  Greater binding of the diabody than the scFv could be observed in 
both clones; R2H2 still showed noticeably better binding than R2G10 at lower 
concentrations. 
 
Mean fluorescence intensities (MFIs) obtained from the FACS analysis were plotted 
against antibody concentration to allow a more quantitative means of directly comparing 
scFv and diabody binding affinities.   Improved binding with the diabodies was seen for 
both clones, with R2H2 demonstrating improved binding at lower concentrations, 
suggesting enhanced affinity over that of R2G10 (Figure 3.21). 
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Figure 3.21:  FACS analysis showing mean fluorescence intensity for a range of antibody concentrations for 
clones R2H2 (A) and R2G10 (B).  Polynomial (2
nd
 order) regression line fitted. 
 
3.2.6.2 HPLC Analysis of scFv and Diabodies  
The lack of covalent bonds between the two scFv molecules which form the diabodies 
means that diabodies can dissociate, giving rise to a heterogeneous mixture of the two 
molecular species.  However, these scFv can no longer fold as they would naturally, due to 
the removal of the flexible linker, therefore preventing the formation of the antigen 
binding pocket/site, and ultimately rendering them ineffective.  A number of factors can 
contribute to the dissociation of diabodies, such as temperature, the freeze/thawing 
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process, and pH.  Dissociation is not the only factor to take into consideration; because 
scFv and diabodies can also aggregate to form triabodies and even tetrabodies, this will 
subsequently affect their binding abilities and interaction with the target antigen.  It was 
important that the stability of the diabodies was investigated to ensure reproducibility of 
future results.  
 
Since SDS-PAGE dissociates diabodies under the harsh conditions employed, i.e. the 
presence of the detergent sodium dodecyl sulphate (SDS), and heating the samples to 
100°C, Size-Exclusion HPLC was utilised to investigate this problem.  This enabled direct 
comparison between the two types of antibody fragments, and also the size of the 
molecules to be determined by measuring their retention times from a column calibrated 
against known standards (Figure 3.22). 
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Figure 3.22:  Calibration plot constructed for HPLC from standards of known molecular weight. 
 
HPLC analysis yielded multiple peaks for both the scFv and diabody fragments, indicating 
both aggregation and dissociation of the fragments.  To assess reproducibility the analysis 
was repeated several times with and without an internal standard.  The internal standard 
used was an intact antibody molecule of a known size (150-kDa murine antibody PRIAS) 
and stability.  Figure 3.23 shows scFv and diabody chromatograms for R2G10; 
chromatograms for other clones are shown in Appendix IV. 
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Figure 3.23:  HPLC chromatograms for R2G10 scFv (A) and diabody (B).  Left with, and right without, internal 
standard.   
 
HPLC chromatograms of both dimeric and monomeric antibody fragments were obtained 
in combination with the internal standard or alone.  The chromatograms of the antibody 
fragments alone were directly compared with those containing the internal standard, and 
(apart from the extra peak from the standard) very little difference could be seen between 
them, thus showing good reproducibility.  
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The size of the proteins eluting in the various peaks, determined by comparison with the 
retention times of the calibration plot, and the integrated peak areas are shown in Table 
3.6 and Table 3.7. 
 
Table 3.6:  Molecular weight and percentage peak area calculated from all scFv peaks from each run, with 
calculated means.   
 
Sample 
Peak 
Number 
(left to 
right) 
scFv 
Run 1 Run 2 Mean 
kDa 
Integrated 
peak area 
(%) 
kDa 
Integrated 
peak area 
(%) 
kDa 
Integrated 
peak area 
(%) 
R2F3 
1 74 52 72 30 73 41 
2 34 48 34 41 34 45 
3 - - 20 29 - - 
R2G10 
1 80 24 81 28 81 26 
2 45 10 46 9 46 10 
3 28 44 29 42 29 43 
4 15 22 15 21 15 21 
R2H2 
1 76 31 71 33 74 32 
2 31 49 31 47 31 48 
3 17 20 17 20 17 20 
R3F5 
1 72 32 73 32 73 32 
2 32 44 33 46 33 45 
3 19 24 19 22 19 23 
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Table 3.7:  Molecular weight and percentage peak area calculated from all diabody peaks from each run, 
with calculated means.  ND = no data 
 
 
Sample 
Peak 
Number 
(left to 
right) 
Diabody 
Run 1 Run 2 Mean 
kDa 
Integrated 
peak area 
(%) 
kDa 
Integrated 
peak area 
(%) 
kDa 
Integrated 
peak area 
(%) 
R2F3 
1 150 98 92 92 121 95 
2 15 2 15 8 15 5 
R2G10 
1 76 78 73 81 75 80 
2 12 22 13 19 13 20 
R2H2 
1 34 54 36 54 35 54 
2 12 46 12 46 12 46 
R3F5 
1 - - 95 83 - - 
2 15 89 15 17 15 ND 
 
 
The molecular weights calculated from the peaks of the HPLC chromatograms do not 
correlate exactly with their predicted weights; 25 kDa for monomers and 50 kDa for 
dimers.  
 
HPLC analysis thus indicates that both antibody preparations were a heterogeneous 
mixture of several components as indicated by the separation of the sample into 
components that eluted with retention times indirectly proportional to the molecular 
weights (i.e. the higher the molecular weights, the faster the components eluted from the 
column). The diabody preparations for R2G10 appeared to contain approximately 80% 
dimeric fragments and 20% smaller dissociated fragments, whereas the scFv preparations 
contained a mixture of aggregated and dissociated fragments (10 and 21%), 26 % dimeric 
and 43% monomeric fragments.   The peak area determined for the different molecular 
weight components were expressed as a percentage of total integrated peak areas in each 
chromatogram. 
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To confirm these results, size-exclusion chromatography using an alternative methodology 
was used. 
 
3.2.6.3 Fast protein liquid chromatography (FPLC) (ÄKTA ™) on scFv and Diabodies  
ÄKTA™ - FPLC was utilised to analyse the samples and to assess whether the results were 
comparable with the chromatograms obtained by HPLC.  FPLC, unlike HPLC, allows the 
antibody fragments to pass through the column at lower pressures, which would eliminate 
any fear that the antibody fragments were dissociating due to shear forces.   A fresh batch 
of both antibody fragments was generated, and both FPLC and HPLC were performed 
after purification on Protein A-Sepharose beads and prior to freezing, to establish whether 
freeze-thawing process also had an effect on the stability of the fragments (Figure 3.24). 
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Figure 3.24:  R2G10 scFv and diabody were analysed by FPLC (left) and HPLC (right) to enable direct 
comparison between the two techniques.  A:  Dimeric diabody fraction;  B:  scFv fraction.   Dashed circle 
indicating buffer salts.  
 
Chromatograms from both FPLC and HPLC were similar.  HPLC also showed small peaks at 
later retention times caused by buffer salts:  this is more evident in the chromatogram of 
the scFv fraction.  As with HPLC, the sizes of the antibody fragments were determined by 
reference to the calibration plot of known standards (Figure 3.25). 
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To obtain the standard curve for FPLC, calibration of the gel filtration column was first 
performed using a low molecular weight gel filtration kit, which consisted of five individual 
lyophilised proteins ranging in molecular weights and Blue Dextran 2000.  Blue Dextran 
2000 was run separately to determine the void volume of the column.   
 
Figure 3.25:   Calibration plot constructed using standard of proteins of a known molecular weight.  Ve - 
elution volume. 
 
From the calibration plot (Figure 3.25), the molecular weights of both the dimeric and 
monomeric fragments for R2G10 were calculated (Table 3.8). 
 
Table 3.8:  Molecular weights of peaks from FPLC chromatograms of components from R2G10 
 
Sample Ve 
Molecular 
Weight (kDa) 
FPLC  
Molecular 
Weight (kDa) 
HPLC 
Diabody – Peak 1 49.96 59 62 
Diabody – Peak 2 98.82 9 13 
scFv – Peak 1 57.76 39 38 
scFv - Peak 2 69.07 24 29 
scFv – Peak 3 91.92 11 16 
 
 
As observed with HPLC, both diabody and scFv were not a homogeneous preparation but 
they comprised of a mix of differently-sized antibody fragments.  The diabody in Figure 
3.24 (A) analysed by both FPLC and HPLC, revealed two clear peaks, the larger 
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representing 59 and 62 kDa species, and the smaller 9 and 13 kDa species.  In B, the scFv 
yielded three peaks; 39, 24 and 11 kDa species in FPLC and 38, 29 and 16 kDa species for 
HPLC.  Results obtained from FPLC thus gave very similar results to those from HPLC, 
which confirmed the heterogeneity of the antibody samples.  Results compared with 
previous HPLC chromatograms (Figure 3.23) also revealed little difference between the 
chromatograms from samples that had been thawed a number of times, indicating that 
freeze-thawing was not a major contributor to the heterogeneity of the samples. 
 
This, however, gave rise to questions regarding the purity of the samples.  Was the 
heterogeneity observed in both monomeric and dimeric fractions due to the instability of 
the antibody fragments in vitro, or a result of insufficient purification?  Purification of 
these scFv and diabody preparations has been performed by Protein A chromatography 
and post-purification analysis performed by SDS-PAGE.  
 
3.2.6.4 SDS-PAGE Analysis  
In addition to the expected bands at 25 kDa, SDS-PAGE gels often but not always (see 
pages 113) showed some bands at lower molecular weights, but the purity has been 
considered sufficiently high for FACS and ELISA.  The results of HPLC and FPLC analyses 
agreed with these from SDS-PAGE, which also showed the presence of lower molecular-
weight impurities (Figure 3.26).   
                  
 
Figure 3.26:  A:  SDS-PAGE of antibody fragments after Protein A purification.  Samples of eluate from each 
clone (20 µL) were loaded. 1 - R2F3, 2 – R2G10, 3 – R2H2 and 4 - R3F5.  B:  M – molecular weight marker and 
corresponding weights (kDa) both scFv and diabody.   
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Bands at 25 kDa corresponded to scFv; these bands were present even in the samples of 
the diabodies, as the gel was run under reducing conditions, and the diabody subunits 
were not covalently bound.  Bands at 15-10 kDa showed low molecular-weight impurities, 
which were also visible in HPLC chromatograms.  
 
It was therefore necessary to determine whether the lower molecular-weight peaks seen 
on HPLC corresponded to the small bands seen in SDS-PAGE, or whether the antibody 
fragments were themselves dissociating.  It was also considered necessary to achieve a 
higher level of purity of the preparations prior to in vivo use. Therefore a more efficient 
purification method that removed the lower molecular-weight contaminants from the 
antibody preparations was sought. 
 
 
3.2.7 FURTHER PURIFICATION 
 
3.2.7.1 Protein A and Ni-NTA Columns 
Antibodies purified initially by Protein A chromatography were therefore further purified 
by Ni-NTA chromatography.  SDS-PAGE of samples purified using Protein A alone and 
Protein A with Ni-NTA chromatography were compared (Figure 3.27).   
 
                       
  
Figure 3.27:  A:  SDS-PAGE of antibody fragments of two clones R2G10 and R2H2 were purified using Protein 
A with Ni-NTA chromatography, and using Protein A alone.  S – scFv, D – diabody.  B:  M – molecular weight 
marker with corresponding weights (kDa). 
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Bands of lower molecular-weight material detected after purification with Protein A were 
noticeably reduced after chromatography on Ni-NTA; however the intensity of the 25 kDa-
band was greatly reduced, which showed that further Ni-NTA purification of samples 
derived from chromatography on Protein A removed lower-molecular weight bands, but 
also reduced the antibody yield by approximately 50%.  Previous purification experiments 
(results not shown) using Ni-NTA chromatography alone had also generated low yields of 
purified antibody protein, and the procedure had therefore been discounted as a 
potential purification method; these results therefore confirmed the initial findings.  In 
addition to the removal of the lower molecular weight bands, purification using both 
protein A and Ni-NTA also ensured the purification of complete scFv.   
 
3.2.7.2 Protein L Columns 
Protein L55 chromatography was then tested for its ability to remove the low-molecular 
weight fragments and ensure complete scFv purification.  R2G10 scFv and diabody 
purified by Protein A were subjected to a further round of purification using this system, 
and SDS-PAGE was performed as before (Figure 3.28). 
 
                 
 
Figure 3.28:  A: SDS-PAGE of antibody fragments purified by Protein A (PA) and Protein L (PL) 
chromatography.  The wash (W) and flow-through (FT) fractions from protein L chromatography were 
analysed to determine whether protein was lost.   B: Molecular weight marker with corresponding weights 
(kDa). 
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Removal of bands in the lower molecular-weight range was again observed with the scFv 
samples after purification with protein L; however, as with Ni-NTA chromatography, the 
intensity of 25-kDa bands was considerably diminished after protein L chromatography, 
indicating loss of protein.  With the diabody fraction, bands at 15 kDa were still present 
after purification though fainter, but so were the 25 kDa-antibody bands.  Analysis of the 
flow-through sample indicated some diabody loss, but subsequent washes of the columns 
from both scFv and diabody were clear. 
 
As with Ni-NTA, Protein L purification therefore removed the smaller fragments, but 
considerably reduced the yield of the intact antibody fragment.  Although this reduction 
could be attributed to fragmented scFv, the difference was considered too large to be due 
to this alone.  While over half of the antibody present after Protein A purification was lost 
after Protein L purification, very little was seen in either the flow-through or wash 
samples, indicating that the protein was most probably still attached to the Sepharose 
beads.  With this in mind, a sample of the beads was removed from the column, boiled in 
20 µL of SDS-PAGE running buffer, and the supernatant was analysed by SDS-PAGE.  
Intense bands for both the scFv and diabody were visible, confirming that protein had 
remained bound to the beads, and but not eluted (Figure 3.29, lane H). 
 
3.2.7.3 Elution Strategies  
Various elution buffers were therefore investigated in an attempt to improve the elution 
efficiency of the antibody fragments from Protein L-Sepharose beads.  The buffers 
selected were those previously used in other applications [169, 177] to elute protein from 
various columns and beads, and were considered to provide conditions that were 
stringent enough to elute the protein, but mild enough not to damage the antibody 
fragments.   
 
Varying concentrations of NaCl were first examined.  In addition, 10% (w/w) SDS and 6 M 
guanidine were tested to see whether the protein could be removed from the beads 
under denaturing conditions.  SDS-PAGE was performed on all eluted products, and a 
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sample of the beads was boiled in running buffer as a control representing total bound 
protein. 
                   
Figure 3.29:  (A) SDS-PAGE of samples recovered using various elution buffers of high pH and/or high salt 
concentration.  Beads (10 µL) were incubated for 10 min with buffers at room temperature.  A - 10% (w/v) 
SDS B - 6 M guanidine, C - 125 mM sodium borate, pH 10 / 0.5 M NaCl, D - 125 mM sodium borate, pH 10 / 1 
M NaCl, E - 125 mM sodium borate, pH 10 / 2.5 M NaCl, F - 250 mM sodium borate, pH 10, G – 0.2 M 
glycine, pH 3.0, H – Antibody protein from beads boiled in SDS-PAGE running buffer.  B:  M – molecular 
weight marker and corresponding weights (kDa) both scFv and diabody.   
 
 
The selected elution buffers all failed to elute scFv protein from the Protein L beads.  SDS 
(10% w/w) and 6 M guanidine did elute protein, but would have denatured it, and were 
therefore not considered suitable for purification.  Since sodium borate pH 10, did not 
seem to be effective, other buffers were investigated in an attempt to elute as much of 
the antibody as possible from the Sepharose beads without damaging it (Figure 3.30).   
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Figure 3.30: A: SDS-PAGE of protein eluted from Protein L beads bearing attached R2G10 scFv.  A - Boiled 
protein (antibody) from beads, B - 0.1 M glycine, C - 0.5 M glycine, D - 1 M glycine, E - 100 mM 
triethylamine, F - 200 mM triethylamine, G - best elution from a Protein L purification.  Glycine buffers were 
pH 2.0, and triethylamine buffers pH 11.0. B:  M – molecular weight marker and corresponding weights 
(kDa) both scFv and diabody.   
 
 
The gel revealed weak bands with all elution buffers used; however none of the buffers 
used yielded a band of the same intensity as from the boiled beads, indicating that most 
of the scFv was still retained on the beads.  Band F, obtained with 200 mM triethylamine, 
pH 11, appeared to contain some eluted scFv.  This buffer is commonly used in cell 
selection to elute phage bound to cells [94] and is thus believed not to damage the 
antibody fragment, therefore it was further investigated.  It was possible that by 
increasing the concentration, this buffer might elute more of the protein (Figure 3.31). 
 
      
 
Figure 3.31:  A:  SDS-PAGE of protein eluted from Protein L beads binding R2G10 scFv.  Beads were 
incubated with increasing concentrations of triethylamine.   A -  Boiled beads, B -100 mM, C - 200 mM, D- 
500 mM, E - 1 M, F- 2 M, G - 3 M.  B:  M – molecular weight marker and corresponding weights (kDa) both 
scFv and diabody.   
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The use of increasing triethylamine concentrations appeared to elute more scFv from the 
beads, with the optimal concentration between 0.5 and 2 M.  As very little difference 
could be seen between the two concentrations, 500 mM triethylamine, pH 11 was used to 
elute the scFv and diabody from Protein L after Protein A purification. 
 
A summary of the range of buffers used during the attempt to elute the scFv bound to 
Protein L is shown in Table 3.9. 
 
Table 3.9:  Elution of scFv and diabody from Protein L-Sepharose beads using a number of solvents of 
varying pH and sodium ion concentration 
 
Elution Buffer Concentration Previous application Eluting protein 
Glycine 
             pH 2 
0.1 M 
Elution from Protein A 
Sepharose beads 
Faint bands were observed, but 
these buffers failed to elute the 
protein 
0.5 M 
1 M 
Sodium Borate 
pH 10 
250 nM NaCl 
Elution of protein from 
Proteins A and G 
Increasing concentrations of salt 
failed to elute the protein 
0.5 M NaCl 
1 M NaCl 
2.5 M NaCl 
Potassium 
thiocyanate 
1 M and 3 M 
Disrupting antibody - 
antigen interactions 
Failed to elute protein 
Guanidine 
hydrochloride pH 3 
6M  
To clean Protein G - 
Sepharose beads 
Eluted protein, but high pH 
probably damaged antibody 
fragments 
10% (w/v) SDS  
Reducing agent in SDS-
PAGE 
Eluted a moderate amount of 
protein;  probable damage to 
antibody fragments 
Triethylamine  
pH 11 
 
100 mM 
Used in phage display to 
elute bound phage from 
cells 
Weak elution of protein 
200 mM 
500 mM 
Strong elution of protein, close to 
that eluted from boiled beads  
1 M 
2 M 
3 M 
Weak elution of protein; 
probable damage to antibody 
fragments 
 
 
In conclusion from these experiments, scFv and diabody periplasmic fractions were 
purified using Protein A, followed by Protein L chromatography, and eluted with 500 mM 
triethylamine, pH 11.  This method ensured complete purification and removal of all lower 
molecular-weight contaminants, although it also compromised the yield of protein eluted. 
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3.2.8 RADIOLABELLING OF SCFV AND DIABODY USING SODIUM [125I] IODIDE  
 
3.2.8.1 Labelling antibody fragments with Sodium [125I] Iodide using Iodogen tubes 
Both monomeric and dimeric antibody fragments were radiolabelled with sodium [125I]-
iodide56.  ITLC, performed to measure the percentage bound, showed radiolabelling 
efficacy always to be greater than 90%. 
  
3.2.8.2 Radioimmunoassay  
Cell-binding assays were carried out on both LNCaP C81 and DU145 cells with [125I]-iodine-
labelled R2G10 scFv and diabody.  These assays were repeated several times whilst 
varying the incubation time and temperature; however no assays showed specific binding 
to the LNCaP C81 cells.  This raised questions as to whether radiolabelling interfered with 
the binding sites on scFv and the diabody, and prompted analysis of the binding of 
antibody fragments labelled with non-radioactive (stable) iodine (127I) by FACS (Figure 
3.32).  Stable isotope 127I was used to allow analysis by FACS which would not be possible 
with its radioactive counterpart.  As the stable isotope behaves chemically in the same 
way as radioactive iodine, if conjugation of the isotope to the antibody fragment was 
interfering with the binding domain, this would be highlighted in the FACS analysis.  It was 
also a safer and more economical method; limiting the experimenter’s exposure time and 
utilising a more readily available product. 
 
3.2.8.3 FACS Analysis to Test for Oxidative Damage 
The antibody fragments were labelled as before, substituting 125I- with the stable isotope 
127I- to ascertain whether labelling interfered with the antigen binding site.  The antibody 
fragments were also incubated in the iodogen tubes alone, to assess whether the 
oxidative environment damaged them.  FACS analysis was performed with 127I-labelled 
antibody fragments and ‘oxidised’ antibody fragments, and their binding affinity was 
compared with that of the antibody fragments alone. 
                                                 
56
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Figure 3.32:  FACS analysis on PSMA-expressing cells LNCaP C81.  Overlay of histograms using 5 µg of 
diabody.  Negative control – no antibody fragment, just secondary antibody
57
 and FITC, positive control – 
commercially-available anti-PSMA antibody. 
 
Usually, the labelling process does not damage the antigen-binding ability of the antibody, 
but occasionally oxidative damage may occur during binding or attachment of the isotope 
to the antigen-binding site if the latter is tyrosine-rich.  The experiment was carried out 
under the same conditions as in previous FACS analysis58.  The binding affinity of the 
dimeric antibody fraction was compared with that of unlabelled diabody, and oxidised 
diabody resulting from treatment in the iodogen tube in the absence of iodine.  Very little 
difference was seen between the behaviour of any of the samples treated under all the 
conditions.  The unprocessed diabody showed a slight improvement in binding, but this 
difference was not regarded as significant. 
 
This experiment was also performed on scFv fractions and, as with the dimeric fractions, 
little difference in binding efficacy was seen, suggesting that the labelling process, 
oxidation and the substitution of the radioisotope did not affect the binding site.  The 
reason for the apparent decrease in antibody binding after labelling with sodium [125I]-
iodide was unknown and an in vivo experiment was performed in one last attempt to test 
the antibody fragments’ specificity.  
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3.2.9 IN VIVO BINDING 
 
Although radioimmunoassay failed to show any specific antibody binding to LNCaP C81 
FACS showed that 127I-labelled diabody selectively bound to PSMA-expressing cells, with 
no significant difference observed between the labelled and unlabelled species.  Therefore 
it was thought worthwhile to assess the behaviour of the antibody fragments in vivo.  Five 
weeks prior to the experiment, 10 male SCID beige mice were injected subcutaneously 
with 106 LNCaP C81 cells in a 1:1 mix with Matrigel in the left hind leg at the level of the 
pelvis, and left to grow until tumours became visible under the skin.  R2G10 scFv and 
diabody were selected for the initial in vivo experiment, and were radiolabelled with 
sodium [125I]-iodide.  The percentage radiolabelling efficiency, determined by ITLC, was 
greater than 98%.  
 
Radiolabelled antibody fragments were administered by intravenous tail injections, and 
scanned using SPECT at several times post injection; 30 min, 4 h and 24 h (Figure 3.33).  
These times were chosen to allow monitoring of the distribution and both specific and 
non-specific uptake of the radioligand.  
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A 
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Figure 3.33:  SPECT images of mice 4 h after injection.  A – 7 MBq of [
125
I]-iodine - labelled R2G10 diabody; B 
– 7 MBq of [
125
I]-iodine - labelled R2G10 scFv. 
 
The tumours grew to approximately 5 mm in diameter and were readily apparent in the 
CT images in both mice, in longitudinal and transverse sections.  In the SPECT images, the 
thyroid was clearly visible due to the uptake of [125I]-iodine, as well as the kidneys, liver 
and gall bladder; however, no uptake of either scFv or diabody by the tumour was seen in 
injected mice at any of the sampling times, raising questions about the specificity of the 
antibody fragments and the labelling technique employed.  
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3.3 DISCUSSION 
 
3.3.1 PSMA ANTIBODIES 
 
3.3.1.1 PSMA Antibodies 
Monoclonal antibodies (mAb) are highly specific and versatile for targeting cells and in the 
last decade much research has been undertaken for treating a range of human diseases 
including cancer.  PSMA has attracted a lot of interest due to its potential at being both a 
diagnostic and therapeutic target  [45, 66]. 
 
3.3.1.2 Selection for Anti-PSMA Phage on PSMA-Expressing Cells 
In the present investigation, the use of phage display technology to generate anti-PSMA 
antibody fragments represented a promising and quick alternative to the conventional 
immunisation approaches employed to produce polyclonal and monoclonal antibodies.  
The use of a synthetic phage library in this work enabled the isolation of scFv specific to 
PSMA, without the need for immunisation. 
 
Selection for anti-PSMA scFv was first performed on the cell line LNCaP C81, which 
naturally expresses PSMA.  The rationale behind this approach was that the scFv raised 
against PSMA would recognise the naturally expressed PSMA, because the selection was 
being performed on the form of PSMA found in vivo, bearing the typical conformation and 
glycosylation patterns, rather than that of synthetically generated PSMA.  Five rounds of 
selection performed on the cells yielded 5 clones that were deemed PSMA-specific and 
were taken forward for a number of validating experiments.  However, this approach 
ultimately did not yield high-affinity PSMA-specific scFv, and was subsequently 
abandoned. 
 
A possible modification of this approach, which might have been more successful, would 
have been to alternate selection between the PSMA-expressing cells and the recombinant 
PSMA protein developed in-house in parallel to cell selection.  That would enhance the 
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enrichment of the phage population to PSMA because of the greater concentration of 
PSMA protein, and yet still ensure specificity toward the naturally-expressed PSMA.  
Conversely this approach could equally be emulated by transfecting either the LNCaP or 
DU145 cell line with PSMA, to enable selection to be performed on cells that expressed 
PSMA in considerably higher concentrations.   
 
 
3.3.2 PRODUCTION OF RECOMBINANT PROTEIN 
 
Recombinant PSMA protein was generated using the Baculovirus Expression Vector 
System in insect (Hi5) cells.  The advantage of generating the protein in this way 
(established by Dr. Stella Man) enabled only the large, extracellular portion of the 
molecule (the ectodomain) to be generated, without the smaller intracellular portion, 
which is only exposed once the cell has undergone apoptosis.  Using this system, high 
yields of PSMA were obtained.  A his-tag having been inserted next to the ectodomain, 
purification was then facilitated by chromatography on Ni-NTA Sepharose, which shows 
high affinity and selectivity for 6xHis-tagged recombinant fusion proteins; and purity was 
confirmed by Western blot analysis, which revealed bands at the expected molecular 
weight of 90 kDa. 
 
3.3.2.1 Selection using Recombinant PSMA Protein 
The three rounds of selection performed on the recombinant protein were considered 
sufficient, because selection was performed using considerably higher concentrations of 
PSMA than that naturally expressed on cells, and performing too many rounds risked 
amplifying only a few highly-expressed phages, with the potential to lose less-prevalent 
but higher-affinity phages. 
 
This procedure might have been improved by biotinylation of the protein at the N-
terminus, so that during subsequent assay in immunotubes or 96-well plates coated with 
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streptavidin, the protein would have been bound so as to maximise exposure to binding, 
rather than adhering in a randomised manner to the plastic. 
 
3.3.2.2 Sequencing of Phage Clones 
Amino-acid and nucleotide sequence alignments have been compiled for all functional V, 
D and J segments of the immunoglobulin in the program V Base, The Database for Human 
Genes Medical Research Council (MRC).  Using this program, sequences from selected 
clones were analysed against the corresponding VH and VL sequences, DP47 from VH3 and 
DP-k9, respectively.   Here, comparison of the fixed framework was used to find the scFv 
sequence and verify it by analysis of the CDRs 2 & 3 of both the heavy and light chains, to 
determine whether the selected phage clones possessed unique and complete sequences.  
Sequences from screened phage clones revealed a diverse range of PSMA-specific scFv. 
 
During phage enrichment and amplification to PSMA, deletions in antibody gIII fusions can 
occur which result in the surface expression of only part of the antibody fragment.  Such 
species are often “sticky”; they can interact non-specifically with the solid phase and can 
co-elute with antigen-specific phages [178].  It is therefore important to perform PCR on 
single bacterial colonies infected with eluted phage and then to sequence them to 
determine the proportion of phages containing the full scFv insert.  This, combined with 
ELISA and phage titration, allows monitoring after each round of selection and provides a 
first hint of progress. 
 
3.3.2.3 FACS Using Selected Phage Clones 
It was crucial, at an early stage of screening, to determine whether PSMA-specific phages 
shown to bind the recombinant PSMA protein also bound to PSMA naturally expressed on 
cell surfaces, thereby confirming similarities in conformation between the recombinant 
protein and PSMA expressed in vivo.  FACS analysis enabled measurement of the binding 
of the positive phage clones and their ability to discriminate between the PSMA-positive 
and -negative cell lines, respectively LNCaP C81 and DU145, and ensured that clones 
bound PSMA specifically, not by “sticky” interactions.  The Tomlinson I Library [90] was 
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employed as the negative control, to ensure that binding was not due to the reactivity 
towards the PSMA of an enriched  population of different PSMA-binding phages present in 
the original library. 
 
FACS analysis revealed that 50% of the phage clones from selection rounds 2 and 3 bound 
specifically to LNCaP C81, and not to DU145.  Accordingly, cells of the non-suppressor 
strain E. coli HB2151 were infected with these clones to prompt the expression of the 
soluble scFv alone, but the binding affinity of these phage clones never approached that of 
the positive control D2B.  
 
 
3.3.3 EXPRESSION OF SOLUBLE SINGLE-CHAIN FV 
 
Soluble scFv expression was carried out on clones from both rounds 2 and 3 because a 
diverse scFv population giving both high expression and strong binding was required for 
further analysis.  Soluble scFv was expressed and secreted by the non-suppressor strain, E. 
coli HB2151, instead of the originally-used strain, E. coli TG1, because although a small 
proportion of soluble scFv is produced by this organism (since suppression is never fully 
achieved), HB2151 cells secrete soluble antibody fragments quantitatively into the 
periplasm59 and the supernatant because an amber stop codon is present at the junction 
of the antibody gene and gIII60.  The lacZ promoter drives the expression of the scFv gene, 
which is induced by IPTG.  Due to expression sometimes occurring in the absence of IPTG, 
glucose is added to the growth medium to inhibit expression of the scFv gene until IPTG is 
added, which is why the glucose concentration is reduced from 1% (w/v) to 0.1% to 
ensure that it has been completely metabolised by the time IPTG is added [179, 180].  
Recovery of the scFv fragments is then easily achieved. 
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3.3.3.1 FACS Analysis of Purified Selected Clones 
FACS analysis on the purified, secreted scFv was performed again to determine whether 
the selected scFv retained the binding and specificity towards PSMA of the original phage 
clones, and the ability to discriminate between PSMA-expressing and non-expressing cells.  
The results confirmed that selection to the target PSMA had been successful, and that the 
observed binding was indeed due to specific interactions between scFv and PSMA, and 
not to non-specific interactions via the phage body.   
 
As well as ascertaining the PSMA-specificity of the scFv, optimisation of the secondary 
antibody was also performed, by targeting both the myc- and his-tags using anti-myc and 
anti-his monoclonal antibodies respectively.  These tags, incorporated into the vector, 
offered a range of sites for assay and purification procedures [181, 182].  For reasons 
unknown (perhaps stronger affinity), anti-myc yielded better results than anti-his, and was 
thereafter used routinely. 
 
The peaks obtained in the FACS histograms (Figure 3.10) for the scFvs were not as sharp as 
those of the positive and negative controls.  Their breadth suggested heterogeneity, 
possibly indicating the formation of di-, tri- or even tetrabodies by interaction of the 
fragments with one another. 
 
3.3.3.2 Purification of scFv 
Purification of scFvs from the periplasm and supernatant can be achieved by use of a 
number of different columns, depending on the choice of target, viz. the myc- and his-tags 
incorporated into the pIT2 vector, or the VH3 family and VL chains of the scFv, which bind 
to Proteins A and L, respectively.  Compared with Ni-NTA chromatography, initial 
purification on Protein A-Sepharose gave high yields of purified scFv from the periplasmic 
and supernatant fractions, as verified by SDS-PAGE, and was therefore selected as the 
method of choice. 
 
Chapter 3  PSMA Discussion 
    154 
 
Four scFv clones were selected for further analysis; R2F3, R2G10, R2H2 and R3F5.  These 
all exhibited good binding both to PSMA naturally expressed in cells (as shown by FACS) 
and also to the recombinant protein (shown by ELISA).  Analysis showed that R2F3 and 
R3F5 possessed the same scFv sequence, and were at first selected in error; however, 
both clones were retained as it was thought interesting to see whether differences in 
binding or expression were nonetheless observed (see below). 
 
3.3.3.3 Production of Diabodies  
Diabodies were produced in an attempt to increase avidity for the target antigen by 
combining two antigen-binding sites.  Diabodies are known to have an advantage over 
scFvs for in vivo applications due to this increase in avidity, and because dimerisation 
reduces the rate of clearance from the circulation [180].  Complete removal of the flexible 
glycine-serine linker was performed by exploiting the two restriction sites, SalI and XhoI3, 
on either side of the linker.  After cutting and ligation, removal of the linker was verified 
by using other restriction sites present on the vector, viz. HindIII and NotI.  As expected, 
digestions with the combination SalI or Xhol (acting on the removed restriction sites) with 
either HindIII or NotI yielded only one band, since only one restriction site remained.  The 
combination of both HindIII and NotI resulted in two bands, due to both sites being cut on 
the vector (Figure 3.15).  
 
Diabody production was confirmed by ELISA using immobilised recombinant periplasmic-
fraction PSMA protein, and BSA as a non-specific control.  The results were encouraging; 
all the diabodies generated discriminated between PSMA and BSA, indicative of specific 
binding.   
 
Diabodies from the supernatant and periplasmic fractions were also compared by 
performing ELISAs in Maxisorb 96-well plates61, which revealed dimeric antibody 
fragments in both fractions.  Removal of the glycine-serine linker resulted in the 
attachment of the C-terminal residue of the VH domain directly to the N-terminal residue 
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of the VL domain, so sterically preventing the two sites from coming together to form the 
natural antigen binding site of which scFv fragments were capable; therefore the observed 
binding could only occur with dimeric molecules (possibly also with triabodies and 
tetrabodies [180]). 
 
Hudson et al (1999) [180] showed that when the linker is reduced in length to a small 
number of residues, it is possible to predict the interactions and aggregation of antibody 
fragments.  Reduction to two glycine residues increases the probability of triabody 
formation, whereas limiting the linker to 3-5 residues usually favours diabody production 
[180].   
 
As well as confirming successful diabody production, ELISA also showed that the 
periplasmic fraction contained two or three times more soluble antibody material than 
the supernatant, therefore confirming the value of purifying the periplasmic fraction 
rather than the supernatant.  
 
3.3.3.4 ELISA of Purified Diabodies 
Diabody purification was performed (as with scFvs) using Protein A-Sepharose, and 
binding analysis was likewise performed on the purified fractions to ensure that the 
specificity remained.  Purified diabodies specifically bound to the recombinant PSMA in a 
concentration-dependent manner; minimal binding was observed with the same 
concentrations of BSA (Figure 3.16).   
 
3.3.3.5 FACS Analysis of Purified Diabodies 
The four diabodies were further examined to see whether they retained the specificity of 
the parent scFvs to PSMA naturally expressed by cells.  As with purified scFvs, FACS 
histograms again showed broad peaks, possibly due to heterogeneity of the dimer 
fractions that may have also contained triabodies and tetrabodies.  Nonetheless, selective 
binding took place with LNCaP C81 cells, compared to DU145, confirming specificity 
towards PSMA.  This, together with the ELISA results obtained with recombinant PSMA 
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protein, confirmed successful manipulation of the linker to drive the formation of dimeric 
fragments. 
 
It was also important to determine whether diabody binding showed greater avidity over 
that achieved with scFv.  A range of concentrations of both scFv fragments and diabodies 
was compared by FACS, taking the mean fluorescence intensity for both scFv and diabody 
clones as the measure of binding.  For all clones, significantly improved diabody binding 
was seen compared with the parent scFvs.  Binding decreased in a concentration-
dependent manner, with R2H2 exhibiting the greatest avidity.  The apparent improvement 
in binding shown by the diabodies may have partly been due to the two myc-tags present 
on the VL chain of each scFv molecule (Figure 3.20), each of which bound more of the 
secondary antibody via the anti-myc sites, thereby enhancing the fluorescence signal.  
However, if the enhanced fluorescence were due to this amplification alone, then there 
would maximally have been a two-fold increase in fluorescence yield over that of the 
corresponding scFv, but the increase with R2H2 diabody was three-fold. 
   
Due to its rigid structure and small size, it is unlikely that the diabody could bind two 
PSMA ligands simultaneously [183].  The antigen binding sites of diabodies lie at opposite 
ends of the molecule, but unlike normal antibodies and Fab antibody fragments, in which 
binding sites can take up a range of orientations and spacings, the structure of diabodies is 
more compact and rigid due to the shortening or complete removal of the linker, which 
separates the binding sites by 6.5 nm and limits possible movement from their mean 
position to only 30° [183, 184]. 
 
Nevertheless, FACS analysis confirmed successful manipulation of the scFv fragments to 
drive the formation of dimers, which still exhibited PSMA-specific binding.  The benefits of 
diabody formation would be more evident in in vivo applications than in vitro, as the 
increase in size of the antibody fragment would diminish the rate of antibody clearance 
from the circulation, thereby maintaining a higher concentration at the target site [180].  
Diabodies are known to possess significantly lower dissociation rates (Koff) than the 
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parental scFv molecules, and are therefore more attractive molecules for in vivo imaging 
of tumours [184]. 
 
3.3.3.6 HPLC and FPLC Analysis of scFv and Diabodies  
The two scFv molecules that form a diabody are not linked covalently, hence they can 
readily dissociate when changes in environmental conditions such as pH or temperature 
occur, or during freeze/thawing. The regenerated scFv molecules cannot themselves bind 
to antigen due to the rigidity resulting from the removal of their linker. 
 
HPLC analysis was employed to examine the heterogeneity of diabody and scFv 
preparations consequent on their tendency to aggregate to generate diabodies, triabodies 
and even tetrabodies, which display different binding abilities and interactions with the 
target antigen.  Therefore it was important that the stability of the diabodies was 
investigated to determine whether they would behave reproducibly in future 
experiments, or in the long term.  Size-exclusion chromatography revealed a mixture of 
molecules ranging from small fragments to species the size of triabodies (Figure 3.23, 
Table 3.6 and Table 3.7).  To ensure comparability of the results, samples were run with an 
internal standard, an intact antibody of mol. wt. 150 kDa, that did not interact with other 
proteins in the mixture and was adequately resolved from them during elution [185].   
 
Chromatograms were reproducible and demonstrated a mixture of scFv and diabody 
fragments.  Molecular weights did not correlate exactly with their predicted values (25 
kDa for scFvs and 50 kDa for diabodies), but manipulated proteins such as engineered 
antibody fragments have a more open tertiary structure than naturally-produced proteins 
of the same molecular weight [186] because the environment in which a protein is 
synthesised and allowed to fold is a significant determinant of its final shape. Therefore, in 
size-exclusion chromatography, such proteins pass through at a faster rate than those 
with more compact structures and register higher apparent molecular weights than 
expected, which is a limitation of the method [187].   Lower molecular-weight 
contaminants may have persisted because of inefficient purification, or could have arisen 
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due to degradation by proteases because protease inhibitors were not added during 
purification, which in hindsight may have been advantageous.     
 
The integrated areas of the chromatography peaks shown below (Figure 3.34) 
demonstrate the heterogeneity of the samples. 
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Figure 3.34:  Heterogeneity of scFv and diabody preparations demonstrated by HPLC analysis.  Mean 
integrated peak areas were calculated for both antibody preparations for all the clones.   
 
 
These results showed a decidedly heterogeneous mix of antibody fragments.  Small 
molecules of less than 15 kDa, present in both diabody and scFv preparations, were 
possibly generated by protease action.  The antibody preparations from the R2G10 clone 
had already been established as the most promising, having shown selective binding with 
both recombinant and naturally-expressed PSMA, respectively by ELISA and FACS analysis, 
and size-exclusion chromatography showed that the R2G10 diabody generated the most 
stable dimeric preparation.  It is not known why the other clones yielded so little dimeric 
material, perhaps due to the instability of the dimers, disaggregation driven by protease 
action on intact diabodies, or to the complete removal of the linker favouring triabody 
formation over diabody [180]. 
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The behaviour of R2G10 diabody and scFv fragments on HPLC was also compared with 
their elution pattern on FPLC, because it was possible that the shear forces applied during 
HPLC were causing loosely-associated dimeric fragments to dissociate.  The 
chromatograms of both the scFv and diabody obtained by FPLC were very similar to those 
obtained by HPLC, showing very little difference in the proportions or sizes of 
components, further confirming the stability of the dimeric fragment, and demonstrating 
that the heterogeneity of the antibody preparations was not an analytical artefact.   
 
3.3.3.7 Purification 
Throughout the analysis, several new batches of antibodies were generated and divided 
into smaller portions in preparation for further analysis.  Each new batch was purified 
using Protein A-Sepharose and then analysed by SDS-PAGE.  Although sometimes this 
procedure resulted in high purity, on other occasions significant levels of fragments of size 
<15 kDa remained.  It was important, firstly, to achieve the highest level of purity for in 
vivo applications, and secondly to see if the low molecular-weight fragments seen in HPLC 
analysis corresponded to these seen in SDS-PAGE.  It was not clear whether these small 
molecules originated in the periplasmic fraction and had not been fully removed during 
the purification step, or whether they resulted from enzymatic degradation of antibody. 
 
Other purification techniques were explored to remove the small fragments whilst 
ensuring high yields of purified protein.  Ni-NTA chromatography proved inefficient at 
removing these contaminants and also reduced the yield of purified protein by 50%, so 
was therefore discounted.  Protein L-Sepharose, which has an affinity for kappa-light 
chains, was trialled after initial purification using Protein A-Sepharose, but although the 
lower molecular-weight fragments were removed, the yield of protein was diminished.  
The loss of protein prompted further analysis to establish the cause.  Neither the flow-
through samples nor the washes contained any protein, which indicated that it still 
remained on the beads, from which it can be released by boiling in buffer, as 
demonstrated by subsequent SDS-PAGE analysis.  The reason for the failure to elute from 
the beads is unclear.  In an attempt to release the antibody without damaging it, a range 
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of elution buffers was explored in which NaCl concentration and pH were varied.  
Normally, during affinity chromatography, proteins bind to beads when they have a 
greater or significantly lower charge than the bead, therefore elution buffers must alter 
this charge in order to release the protein efficiently; this can be done either by 
decreasing the pH or by increasing the NaCl concentration [188]. 
 
These buffers failed to elute the protein, so others were employed.  Triethylamine, a 
moderately strong base, also used previously in cell selection to elute bound phage, was 
thought to be sufficiently basic to disrupt the interaction between the antibody fragment 
and the beads, and was known not to denature the antibody itself [178].  The optimal 
triethylamine concentration for successful elution was 500 mM, pH 11, which was used 
thereafter for elution from Protein L, in conjunction with the purification step using 
Protein A-Sepharose. 
 
 
3.3.4 RADIOLABELLING OF SCFV AND DIABODY USING SODIUM [125I]-IODIDE 
 
Radiolabelling of both the monomeric and dimeric R2G10 antibody fragments was 
achieved using sodium [125I]-iodide in iodogen tubes62, with an efficiency of >90%. 
 
To determine whether the binding affinity of R2G10 antibodies had remained unaffected 
by labelling, a direct radioimmunoassay was performed to measure the immunoreactivity 
of the labelled fragments, i.e. the proportion of radioactive antibody fragments having the 
ability to bind the antigen [144].  However this failed to yield any positive results; no 
specific binding to LNCaP C81 cells was observed, implying that radiolabelling had 
interfered with the antigen binding site.  [125I]-Iodide reacts with tyrosine residues by 
electrophilic substitution in the phenolic side-chain63, therefore if the antigen-binding site 
is rich in tyrosine, [125I]-iodide might bind and interfere with the avidity of the fragment, 
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however the sequence that makes up the binding site is known, and contains no tyrosine 
residues, thus eliminating this possibility.  Alternatively the antibody-binding ability of the 
fragments could be damaged by the labelling procedure itself, notably during the period 
of residence in the oxidative environment of the iodogen tube.  This possibility was 
explored by FACS analysis.  R2G10 antibody was accordingly either labelled with stable 
iodide [127I-], using iodogen, or incubated in iodogen tubes alone to determine whether 
the oxidative environment was the cause.  The resultant preparations showed no 
significant difference in behaviour from untreated dimeric antibody.  Although the 
labelling procedure was shown not to affect the immunological activity of the fragments, 
it remains unclear why binding ability was lost after radiolabelling.  Labelling experiments 
with both sodium [125I]-iodide and stable iodide [127I] were repeated on several occasions 
and with new R2G10 scFv preparations, but all failed to reveal the cause of the loss of 
binding. 
 
It is however important to consider the differences between the two assays which could 
account for the differences in binding behaviour.  Although the radioimmunoassay was 
performed at 4°C to prevent internalisation, the binding buffer did not, unlike the FACS 
buffer, contain sodium azide.  If the radiolabelled antibody were internalised, it would be 
metabolised, the iodide released and secreted from the cell into the supernatant, so that 
subsequent analysis would reveal no evidence of binding.  To ensure that the loss of any 
weakly-binding material in the wash steps was detected, the washes were also collected 
and assayed, but no activity was found, therefore no bound material was lost during these 
steps.  
 
Furthermore, binding studies conducted by FACS analysis were routinely performed with 
approximately 800-fold greater antibody concentrations than those used in the 
radioimmunoassay, which could explain why no binding was observed. Although 
concentrations were later increased, they still fell well short of the normal values used in 
FACS and a low binding affinity of the antibody fragments could explain the lack of 
observable binding by radioimmunoassay.   
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Although the labelling procedure appears not to have been responsible, other techniques 
could be employed to radiolabel the antibody fragments effectively, such as the enzyme-
catalysed methods using lactoperoxidase or glucose oxidase, which proceed under much 
milder conditions, though with diminished labelling efficiency.  Alternatively, one could 
employ a reaction that attaches the iodine to a different amino-acid; e.g., the Bolton and 
Hunter reagent [N-succimidyl 3-(4-hydroxyphenyl) propionate] results in iodination of 
lysine residues [144], but again with lower labelling efficiencies than using iodogen tubes. 
 
125I was employed initially to verify binding efficiency of the antibody fragments once 
radiolabelled.  The benefits of iodination with this radionuclide include the relative ease of 
the methodology, the long half-life of the isotope which allows repeated study on the 
same preparation, minimal losses of protein, and most importantly, it allows the 
radiolabelling of low protein concentrations, which was crucial as antibody production 
was only performed on a micro-scale.   
 
An intrinsic drawback of iodination is the possibility of deiodination resulting in the 
generation of free iodide. Deiodination of the radiolabelled antibody fragments in vivo 
would result in iodide being taken up by the thyroid and other iodide-transporter 
expressing tissues.  More importantly, as PSMA is internalised into the cell, deiodination 
could occur once inside and be released from the cell, resulting in poor images due to high 
background or even complete loss of the released iodide which would fail to generate any 
images of uptake.   Deiodination could also occur in-vitro if the radioligand is internalised 
by PSMA-expressing cells after which the free iodine can be released from the cell 
resulting in poor retention of the radiolabel. To ensure that this did not happen in the in 
vitro experiments described above and to assess the whether the extent of deiodination, 
TCA precipitation of the supernatant was performed to ensure that the majority of the 
radioiodine remained in a protein-bound form with minimal free iodide, this however 
cannot be performed for in vivo analysis. 
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3.3.5 IN VIVO STUDIES 
 
Despite negative results from the cell-binding studies, a limited exploration of in vivo 
targeting was undertaken, however no uptake in the tumour was observed. 
 
The failure of this in vivo study with tumour-bearing mice to demonstrate any specific 
binding of radiolabelled antibody could have been due to a number of factors.  The 
stability of the labelled antibody as a function of temperature was not fully examined to 
determine whether the binding ability of the complex remained stable at 37°C for a time 
period matching that of the experiment.  Binding capacity can be diminished by up to 25% 
over 24 h [61].  Plasma stability analysis, whereby radiolabelled antibody is incubated in 
human or murine blood at 37°C and then analysed by reverse-phase HPLC [189], would 
have determined whether the labelled preparation remained intact in vivo long enough to 
target the PSMA expressed on the tumour cells.  However it was concluded that although 
PSMA-specific, positive binding had been seen in vitro by FACS and ELISA, the binding 
efficacy of the antibody fragments appeared to be too low to justify further analysis. 
 
 
 
 
 
3.4 SUMMARY & CONCLUSION 
 
3.4.1 Generating scFv Antibody Fragments 
Using phage display technology two attempts to generate PSMA specific scFv were made; 
firstly on PSMA expressing cells and secondly on in-house generated recombinant PSMA 
protein. 
 
Attempt one 
 
A total of 5 rounds of selection were performed and 5 ‘positive’ candidates were selected 
and taken forward for further validating experiments, using a range of techniques viz. 
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FACS, ELISA and immunoprecipitation.  Results however did not show high affinity to 
PSMA and questions arose to their specificity to the PSMA target, subsequently, this 
approach was abandoned. 
Attempt two 
 
In-house recombinant PSMA protein provided a high concentration of target to which 3 
rounds of selection was performed.  Several PSMA-specific clones were selected and 
soluble scFv molecules expressed.   
 
Binding specificity was measured by ELISA and FACS and the 4 selected clones were able 
to discriminate between the target with non-specific proteins and non-PSMA expressing 
cells. 
 
To increase avidity, the formation of diabodies was performed on the selected clones, 
molecular biology techniques allowed for the complete removal of the flexible linker, 
driving the spontaneous formation of dimeric molecules.  Improved binding could also be 
observed over the scFv antibody fragments.  
 
The stability and heterogeneity of the fragments were also measured using both HPLC and 
FPLC.  Dimeric fragments were not as unstable as feared and results from HPLC were 
reproducible and further confirmed in FPLC. 
 
Optimisation of purification techniques were also studied and issues overcome.  High 
purity of both the scFv and diabodies was established by combination of Protein A and L 
chromatography, with the use of optimal elution buffer to elute the protein without 
damage to the antigen binding site. 
 
Radiolabelling of the antibody fragments yielded in excess of 90% efficiency, however the 
specific binding previously observed was lost.  Investigation into why binding was lost did 
not reveal a conclusive answer; with antibody preparation concentration and binding 
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affinity a possible cause, however it confirmed that labelling of the radiotracer did not 
interfere with the antigen binding site and the antibody fragments were not damaged by 
oxidative stress during the labelling procedure. 
 
In vivo analysis to tumour bearing mice did not reveal specific binding to the PSMA 
expressing cells and although PSMA specific clones were successfully selected using phage 
display, both the scFv and diabodies did not posses high enough affinity to justify further 
radio-imaging studies. 
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4 DEMOBESIN 4 STUDY 
 
Small peptides are currently being investigated for their ability to bind to cell surface 
receptors, over-expressed in a wide variety of malignant tissues.  They are potentially 
useful for radionuclide-mediated detection and therapy, and could serve as ideal delivery 
vehicles for toxins or drugs to act against tumours.  The clinical utility of using 
radiolabelled receptor-avid peptides is readily exemplified by the current use of [111In]-
DTPA-octreotide (Octreoscan® Mallinckrodt Medical Inc. USA)64 [190] and other 
radiolabelled octrotide analogues that bind cancer cells expressing somatostatin 
receptors. 
 
GRP and somatostatin receptors share some similarities and there is increased interest in 
GRP-R expression in a number of cancers, including prostate cancer.  The incidence of 
GRP-R and its density on prostate cell surfaces was investigated in this project using 
Demobesin 4 (DB 4), an analogue of Bombesin, to establish its clinical potential and 
application as a radiopharmaceutical. 
 
 
4.1 AIMS 
 
The aims of this project were four-fold: 
1. Compare methods for the measurement of GRP-R expression by prostate cancer 
cell lines 
2. Compare expression levels in vitro vs. in vivo  
3. Determine whether imaging in-vivo is able to quantify the level of GRP-R 
expression 
4. Assess the relationship between androgen status and GRP-R expression 
 
 
                                                 
64
 ["'I]-DTPA-pentetreotide (Octreoscan®) - a somatostatin receptor radiopharmaceutical, for the detection 
of somatostatin-positive tumours.    
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4.2 DEMOBESIN 4 STUDY RESULTS 
 
4.2.1 IN VITRO STUDIES WITH 99MTC – LABELLED DB 4 
 
4.2.1.1 Radioligand Binding Assay 
Assays were performed at various concentrations of 99mTc-labelled DB 4 to measure the 
specific radioligand binding to cells at equilibrium, and to determine both the receptor 
numbers (Bmax) and the binding affinity (Kd). 
 
Bmax and Kd were determined for all cell lines.  Before the advent of non-linear regression 
programmes, data obtained from these experiments was transformed into a linear form, 
such as a Scatchard plot (more accurately attributed to Rosenthal) (Figure 4.1 (A)). 
  
 
Figure 4.1:  Schematic diagram of Scatchard plot (A) and non-linear regression plot (B) [191].   
 
The Scatchard plot allows the estimation of Bmax and Kd; respectively the x intercept and 
negative reciprocal of the slope [191], however the Scatchard transformation distorts the 
experimental error and may transform data far from their true values, therefore non-
linear regression is now widely used.  Graphpad Prism 5, a statistical program was used to 
perform non-linear regression plots.   
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The ligand binding assay was first performed on AR42J rat pancreatic cells, the positive 
control known to express GRP-R [192] .  Non-specific binding, measured using unlabelled 
DB 4 as the competitor, was subtracted from the total binding to obtain the specific 
binding (Figure 4.1 (B)).  Non-specific binding is almost always a linear function of the 
ligand concentration, so a straight line can be drawn that best fits the non-specific values 
without the need to measure non-specific binding at every radioligand concentration.  A 
range of radioligand concentrations was investigated to obtain the full curve and reach 
saturation; when most of the receptors are occupied by the radioligand.  Radioligand 
concentrations of 0.1, 1, 2.5, 5, 7.5, 10 and 25 nM were investigated; normally saturation 
is reached prior to the highest concentration (Figure 4.2). 
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Figure 4.2:  Non-linear regression graph of radioligand binding assay for AR42J cells.  Experiment performed 
in triplicate on 3 separate occasions (n=9)    
 
Specific binding levelled off at higher radioligand concentrations after incubation for 1.5 h 
at 37°C, by which time the reaction had reached equilibrium. 
 
The results of the radioligand binding assay on all cell lines65, including LNCaP C81 and 
C42B, grown in androgen-reduced media66, are shown in Figure 4.3.  Bmax and Kd were 
calculated for each cell line tested (Table 4.1). 
                                                 
65
 Appendix V 
66
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Figure 4.3:  Results of radioligand binding assay for all prostate cancer cell lines tested.  AR42J - positive 
control known to highly express GRP-R.  Experiments were performed in triplicate on 3 separate occasions 
for each cell line (n=9).    
 
Elevated levels of GRP-R were observed in PC3 and DU145 above that of the positive 
control AR42J.  LNCaP, the only androgen-dependent cell line, also showed GRP-R 
expression but to a lesser extent than that of PC3 and DU145.  LNCaP C81, LNCaP C81 
(androgen-deprived) and C42B (androgen-deprived) [results not displayed in Figure 4.3] 
did not show receptor expression, or the level of expression was below the sensitivity of 
the assay. 
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Table 4.1:  Bmax and Kd values with standard deviations for all PC cell lines obtained from radioligand-binding 
assays.  N/A - not applicable (AR42J is a rat pancreatic cell line). 
 
Cell line 
Androgen 
Dependence 
Bmax 
(fmol/mg protein) 
     Kd 
(nM) ± SE 
AR42J N/A 1108 ± 477 1.361 ± 0.183 
PC3 Independent 8345 ± 426 0.356 ± 0.108 
DU145 Independent 4182 ± 624 2.24 ±  2.200 
LNCaP Dependent 104 ± 70 1.509 ± 0.814 
LNCaP C81 Independent No specific binding observed No specific binding observed 
LNCaP C42B Independent 57 ± 19 1.229 ± 0.517 
LNCaP C81 
(androgen-reduced 
medium) 
Independent No specific binding observed No specific binding observed 
LNCaP C42B 
(androgen-reduced 
medium) 
Independent No specific binding observed No specific binding observed 
 
A range of Bmax and Kd values was obtained for the cell lines tested.  Some androgen-
independent cell lines showed receptor expression, with some at levels greater than that 
of the positive control.  The androgen-dependent cell line LNCaP showed GRP-R 
expression but at lower levels than the independent cell lines PC3 and DU145.  GRP-R 
expression thus seemed to be up-regulated with later stages of cancer (Figure 4.4).   
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Figure 4.4:  Comparison of Bmax values obtained for all tested cell lines.  AR42J - positive control cell line. 
Experiments were performed in triplicate on 3 separate occasions for each cell line (n=9).    
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Very similar Kd values were found, with minimal differences observed between cell lines; 
any differences observed were found not to be significantly different when t-test analysis 
was performed with a P value = >0.05.  
 
4.2.2 HIGH- AND LOW-PASSAGE NUMBERS IN THE LNCAP C42B CELL LINE 
 
4.2.2.1 Increased Passage Number 
Over-subculturing in vitro is widely known to change cell lines’ properties over time.  Cell 
lines that have been passaged too many times experience alterations in cell morphology, 
responses to stimuli, growth rates, protein expression, transfection and signalling 
compared to cells that have been passaged fewer times [193, 194].  LNCaP cells are known 
to display markedly divergent responses to androgens, which can drive androgen-
dependent cells to become androgen-independent.   
 
With this in mind, it was important to ascertain whether the in vitro results obtained and 
relationships inferred were in fact a true representation of the natural behaviour of these 
cells in vivo.  Although there is considerable literature to support the fact that over-
subculturing cells has an effect on their growth and behaviour, not much is known as to 
why and how this occurs.  Nutrient stress is one possibility which might account for this 
phenomenon.  Selecting LNCaP C42B as a representative example, a comparison of 
radioligand binding was made between cells that had been passaged a few times and cells 
passaged many times.  Passage numbers below 30 were classed as low-passage number; 
numbers greater than this were classed as high-passage number (Figure 4.5). 
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Figure 4.5:  Radioligand binding assay on high- and low-passage LNCaP C42B cells.  The experiment was 
performed in triplicate on 3 separate occasions (n=9).  
 
Results obtained revealed a notable difference between high- and low-passage LNCaP 
C42B cells, which confirmed the hypothesis that cells with a higher passage number 
behaved in an abnormal way, and although there is no gold standard that defines an 
upper limit to passage numbers (since passage levels considered high for one cell line may 
not give rise to abnormal effects in another) all the cell lines used in both in vitro and in 
vivo experiments were limited to those of passage numbers <30. 
 
4.2.2.2 RT-PCR – Relative Quantification  
A quantification assay using RT-PCR was performed to measure the amount of GRP-R 
mRNA present in the range of cell lines studied (representing both early and late stages of 
prostate cancer growth) and to see whether similar expression levels observed with 
radioligand binding assays were found.  This experiment sought to determine the extent 
to which each cell line (representing different stages of PC growth and thus of androgen-
dependence) expressed the GRP-R gene, and also whether external factors such as 
passage number and culture conditions influenced the expression in comparison with a 
non-expressing cell line.   
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Total RNA was extracted from the cell lines of interest, from which cDNA was generated 
for the acquisition of Ct
67 values which were quantified and compared with those derived 
from a calibrator, here the non-GRP-R expressing cell line, MKN45.  Results were 
expressed in terms of the ratio of the level of expression of the base sequence in a given 
cell line to that found in the calibrator. 
 
The comparative Ct method is also known as the 2
–ΔΔCt method68, where:  
ΔΔCt = ΔCt sample - ΔCt reference 
 
Here ΔCt,sample is the Ct value for the tested cell line normalised to the endogenous 
housekeeping gene (Beta-actin-ACTB), and ΔCt, reference is the Ct value for the calibrator also 
normalised to the endogenous housekeeping gene.  
 
For the ΔΔCt calculation to be valid, the amplification efficiencies of the target and the 
endogenous reference must be approximately equal. This was established by observing 
how ΔCt varied with template dilution
69.  Relative quantification RT-PCR was performed on 
all the PC cell lines, and GRP-R expression was compared with that from the calibrator 
(Figure 4.6). 
 
                                                 
67
 Ct (threshold cycle) - the intersection between an amplification curve and a threshold line.  Chapter 2 - 
Section 2.3.8.3 
68
 For 100% efficient PCR, doubling of product is obtained at every cycle, which is raised to the negative 
power of the ΔΔCt in order to transform these ΔΔCt values into a -fold change. 
69
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Figure 4.6:  Quantitative RT-PCR for GRP-R expression over MKN45 (calibrator) in all prostate cancer cell 
lines.  The expression level of MKN45 was set equal to 1.  Values are the mean ± standard error for three 
separately performed studies (n=3). 
 
All cell lines tested expressed GRP-R mRNA significantly more than MKN45.  The highest-
expressing cell line was PC3, which gave levels considerably greater than any other line.  
The remaining lines all expressed GRP-R within a four-fold difference among them.  This 
experiment confirmed the expression of GRP-R in all the lines tested, especially in the 
androgen-independent PC3. 
 
Further investigations were performed to elucidate the effects of androgens on the 
expression of GRP-R in cells by reducing the levels of androgens and growth factors in the 
growth medium, and to examine the effects of over-subculturing the cells on the 
expression of the receptor (Figure 4.7).   
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Figure 4.7:  Quantitative RT-PCR on LNCaP lines grown under different conditions.  The expression level of 
MKN45 was set equal to 1.  *LNCaP C42B underwent <30 passages; **LNCaP C42B underwent >50 passages.  
A. deprived means androgen-deprived, ie. grown on reduced levels of androgen; Re-supplemented means 
growth in medium supplemented with androgen after androgen deprivation.  Androgen-deprived medium 
was supplemented with 8% CS-FBS and 2% FBS, and was re-supplemented with 10% FBS.  Values are the 
mean ± standard error for three separately performed studies (n=3). 
 
Cells grown in 10% FBS were subcultured in 8% CS-FBS with 2% FBS70, and back into 10% 
FBS, remaining in each growth medium for 1 week.  Significant differences were seen in 
the level of GRP-R expression in cells cultured in the different types of medium, and 
between cells of high- and low-passage number.  LNCaP C42B lines of high- and low-
passage numbers both showed a reduction in expression after androgen deprivation, and 
over-expression of the target receptor once supplementation was restored.  High-passage 
LNCaP C42B showed a smaller reduction than did the low-passage line, as seen in Figure 
4.6, a relationship previously observed in the radioligand binding assay71 whereby low-
passage LNCaP C42B revealed a higher receptor density (Bmax = 101 fmol/mg protein) 
compared with high-passage LNCaP C42B (Bmax = 47.1 fmol/mg protein).   A considerably 
increased level of expression of GRP-R was observed in all three cell lines after re-
                                                 
70
 The use of CS-FBS alone caused cells to die, probably because essential growth nutrients were withheld, 
therefore an 80:20 mix of CS-FBS and FBS was used. 
71
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supplementation of the standard FBS, indicating a physiological change within the cells 
which caused an up-regulation of GRP-R expression. 
 
4.2.2.3 GRP-R Expression by FACS 
GRP-R expression in vitro was examined by FACS analysis using the commercially-available 
rabbit-polyclonal anti-gastrin-releasing peptide receptor antibodies (Novus Biologicals 
NB100-74434 and Abcam Ab39963) on all the prostate cancer cell lines.  Varying 
concentrations (10, 5, 2.5, 1 and 0.1 µg of GRP-R/mL) were evaluated.  No binding with 
either was observed with any of the cell lines.  
 
Cells were detached from tissue culture flasks with Versene instead of 0.25% (w/v) Trypsin 
/ 0.53 mM EDTA solution to reduce any possibility of cleaving the receptor during the 
detachment process.  Neither antibody was recommended for FACS and it was concluded 
that they were unsuitable for this purpose.   
 
 
4.2.3 EX VIVO STUDIES 
 
4.2.3.1 Autoradiography Optimisation Study with 99mTc 
The methodology for autoradiography used throughout this thesis was developed and 
refined using 99mTc-DB 472.  Radiolabelling components, technique and phosphor imager 
screens were all standardised or calibrated in order to optimise procedures. 
 
The radiolabel content of tissue samples was quantified using phosphor screens, which 
store energy in photostimulable crystals.  There are several types of screen available, 
ranging in sensitivity.  Sensitivities to 99mTc of the super resolution screens (formulated 
from fine-grain crystals) and the durable multipurpose screen were measured and 
calibrated. 
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To determine the comparative responses of these screens, twelve 5-µL spots of serially-
diluted samples of the isotope were spotted onto a glass cover slip.  Each type of screen 
was exposed to the source for 30 min and scanned in a Cyclone Plus Phosphor Imager at 
600 dpi resolution.  Quantification of the responses was performed using OptiQuant 
software, which recorded the readings in terms of digital light units (DLU)73.  Identical 
elliptical regions were drawn around each spot of radioactivity, and a series of identically-
sized regions were similarly circumscribed in background areas; the measurements from 
these were subtracted from those of the standards.  In parallel, duplicate spots of the 
serial dilutions were measured in a gamma counter to quantify these standards in terms 
of CPM. 
 
The radioactivity (CPM) was plotted against the phosphor-imager output (DLU) (Figure 
4.8).  This relationship was linear, therefore the slope of the line was used as the 
conversion factor from DLU to MBq. 
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Figure 4.8:  Correlation of DLU values and CPM readings as recorded using the multipurpose and super 
resolution screens after 30 min exposure to various quantities of 
99m
Tc. 
 
 
                                                 
73
 A measure of luminosity  
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Sections of tumour xenografts which had been incubated with 99mTc-DB 4 (see Section 
2.3.7) were then exposed to the phosphor imaging plates using the same experimental 
conditions.  However, poor results were obtained, as shown in Figure 4.9, because of 
insufficient contrast between sample and background.  In order to overcome this problem 
and increase the level of specific binding, the effects of increasing exposure times and 
radioactivity levels on the calibration were studied.  The results are shown in Figure 4.10.  
It can be seen that the linear relationship between radioactivity and the DLU generated 
was lost, and that the plates became saturated under these conditions. 
 
 
 
Figure 4.9:  Autoradiography performed on PC3 tumour sections using 
99m
Tc-DB 4 with and without the 
addition of the competitor, unlabelled DB 4, showing the impossibility of successfully orientating the 
location of tumour sections mounted on the glass slide.   
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Figure 4.10:  Overnight exposure (10 hours) of multipurpose and super-resolution screens to 
99m
Tc.  Binomial 
regression was plotted for each screen. For the mulipurpose screen, R
2
 = 0.9892; for the super resolution 
screen, R
2
 = 0.9927. 
 
 
Autoradiographic analysis using radionuclides with short half-lives is difficult because their 
rapid decay restricts sensitivity unless very high activities are used, which in turn gives rise 
to the problems shown.  Long exposure times heighten the contrast between sample and 
background, but over-exposure reduces sensitivity.  For this reason, the use of sodium 
[125I]-iodide as a radiolabel was explored because longer exposure times to tumour 
sections could potentially be achieved with lower levels of radioactivity, due to its longer 
half-life (60 days). 
 
4.2.3.2 Autoradiography Optimisation Study with [125I]-Bombesin Analogue [[125I]-D-Tyr6, 
β-Ala11, Phe13, Nle14-Bombesin 
Optimisation with two screens were therefore performed using a commercially available 
[125I]-D-Tyr6, β-Ala11, Phe13, Nle14-Bombesin. Exposure times of 24 and 48 h were tested 
(Figure 4.11). 
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Figure 4.11:  (A) 24 h exposure and (B) 48 h exposure to [
125
I]-Bombesin Analogue [[
125
I]-D-Tyr
6
, β-Ala
11
, 
Phe
13
, Nle
14
-Bombesin of the multipurpose and super resolution screens. 
 
 
As with 99mTc, the multipurpose screen showed greater sensitivity than the super 
resolution screen.  Exposure times longer than 24 hours saw saturation of the phosphor 
imager screens (B), whereas exposure for 24 hours maintained a linear relationship (A).  
The multipurpose screens were therefore used in subsequent autoradiographic studies, 
with a maximum exposure of 24 h. 
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Sample preparations of all prostate cancer tumours, as well as a non-GRP receptor-
expressing tumour were incubated with [125I]-Bombesin Analogue [[125I]-D-Tyr6, β-Ala11, 
Phe13, Nle14-Bombesin in the absence and presence of an excess of the competitor, 1000 
µM-unlabelled DB 4, for 1 h.  Unbound and non-specifically bound radioligand was 
removed by wash steps prior to exposing samples to the multipurpose phosphor imager 
screen for 24 h (Figure 4.12). 
 
 
 
Figure 4.12:  Example of autoradiography on PC3 tumour sections using [
125
I]-D-Tyr
6
, β-Ala
11
, Phe
13
, Nle
14
-BB, 
with and without competitor, unlabelled DB 4.  Regions of interest were drawn around the tumour sections 
and DLU obtained.   
 
Compared with 99mTc-DB 4, autoradiography performed with [125I]-D-Tyr6, β-Ala11, Phe13, 
Nle14-BB showed improved binding and contrast between sample and background, as 
shown in Figure 4.12.  Autoradiography was therefore performed on the other excised 
tumours to see whether the binding observed correlated with the binding seen both in 
vitro and in vivo. 
 
Slides directly cut one after the other were used to prepare a series of sections as similar 
as possible to each other.  Serial dilutions of the stock radioligand were used as standards, 
spotted onto a glass slide and placed side-by-side with the tumour sections, which were 
then autoradiographed together.  Duplicate dilutions of the standard were also measured 
on the gamma counter to obtain CPM values.  Prior to exposing to screens, slides and 
standards were dried completely to minimise contamination. 
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Specific binding was determined by subtracting the non-specific binding (measured in the 
presence of the competitor) from the total binding (measured without competitor) (Figure 
4.13).  The following equation was used to calculate the percentage of [125I]-Bombesin 
Analogue [[125I]-D-Tyr6, β-Ala11, Phe13, Nle14-Bombesin specifically bound: 
 
100
x
yx
 
Where x is the total bound (without competitor) and y is the amount bound non-
specifically (with competitor). 
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Figure 4.13:  Autoradiographic studies performed tumours derived from a range of prostate cancer cell lines, 
varying in stages of development.  MKN45 is a negative (non-expressing) GRP-R cell line.  A. Deprived means 
androgen-deprived, ie. grown on reduced levels of androgen.  Values are the mean ± standard error for 
three separately performed autoradiography studies (n=3). 
 
 
Among the cell lines, PC3 tumours yielded the highest GRP-R expression, followed by 
those from LNCaP androgen-dependent and LNCaP C42B. 
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LNCaP C42B and C81 cells grown in reduced levels of androgen74 were also subjected to 
autoradiography.  Cells injected into male, non-castrated mice took substantially longer to 
establish tumours, compared with their parent cell line grown in regular FBS medium, but 
were of course exposed to circulating androgens once within the body.  This experiment 
was performed to see whether the results would concur with those obtained in vitro, 
where a difference in GRP-R expression was observed.  There was a definite decrease in 
expression of GRP-R in LNCaP C42B, but no significant difference between LNCaP C81 and 
LNCaP C81 androgen-deprived cells was detected. 
 
4.2.3.3 Immunohistochemistry  
Prior to the analysis of GRP-R expression by immunohistochemistry, optimisation of the 
use of the commercial antibody rabbit polyclonal anti-GRP-R (Abcam 39963) was 
performed.  Human pancreatic tissue, donated by Pathology Services, Institute of Cancer, 
Queen Mary, University of London, was used as the positive GRP-R-expressing tissue, and 
a range of anti-GPR-R antibody concentrations was tested to select for the optimal 
concentration (Figure 4.14). 
 
 
 
Figure 4.14:  Optimisation study performed on human pancreatic tissue.  (A) Stained in the presence of a 
1:100 dilution of anti-GRP-R antibody; (B) without primary antibody.  Slides were imaged under a light 
microscope at x40 magnification.  Bar = 1 μm. 
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Weak positive staining for GRP-R expression was seen as indicated in Figure 4.14 (A), 
where the chromogenic substrate stained the antigen-antibody interactions brown 
throughout the tissue section, indicating antibody binding.  Little or no non-specific 
binding occurred in the tissue stained without primary antibody [Figure 4.14 (B)].  A 1:100 
dilution was selected as the optimum antibody concentration from a range of 
concentrations tested [1:10, 1:30, 1:50, 1:500, 1:1000 and 1:10,000].  Tumour sections of 
all the PC cell lines were then stained for GRP-R expression (Figure 4.15 and Figure 4.17). 
 
 
 
 
 
Figure 4.15:  PC3 tumour sections stained (A) with and (B) without anti-GRP-R antibody.  Slides were imaged 
under a light microscope at x40 magnification.  Bar = 1 μm. 
 
Results obtained with PC3 revealed a similar level of weak staining for GRP-R expression, 
with a distribution of the chromogenic substrate similar to that seen in human pancreas.  
Without primary antibody (Figure 4.15 B), there was little or no staining, confirming that 
binding was due to the primary antibody (Figure 4.15 A).  However, in addition to staining 
of the tumour, staining also occurred in skeletal muscle, which does not express GRP-R, 
therefore indicating non-specific binding (Figure 4.16). 
 
 
 
 
 
A  B 
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Figure 4.16:  Different areas within a section of PC3 tumour.  Non-specific staining of skeletal muscle is seen 
in the finger-like projections (arrowed) which were not GRP-R positive.  Dashed arrows indicate tumour 
tissue. Faint staining on blood vessels was also observed (not shown).  Slides at x 40 magnification. 
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Figure 4.17:  Immunohistochemistry performed on all the remaining cell lines to investigate GRP-R 
expression.  (A) - MKN45 (GRP-R-negative cell line), (B) - LNCaP androgen-dependent, (C) LNCaP C42B 
(androgen-deprived), (D) - LNCaP C81 (androgen-deprived), (E) - LNCaP C42B (androgen-independent) and 
(F) - LNCaP C81 (androgen-independent).  Slides at x20 magnification.  
 
A B 
C D 
E F 
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No significant staining was observed in the other tumour lines, although compared with 
the negative cell line, MKN45, there was some minimal brown, granular cytoplasmic 
staining, which was generally neither convincing nor significant, especially in comparison 
with the high degree of non-specific binding observed in the PC3 tumour sections.   
 
 
4.2.4 IN VIVO STUDIES 
 
4.2.4.1 Radiolabelling and 99mTc - Quality Control Analysis 
 
ITLC  
After radiolabelling, it is important to ascertain the percentage of radiolabelled peptide, 
free pertechnetate and 99mTc by-products.  For quality control purposes, labelling 
efficiency was measured using both ITLC and HPLC. 
 
Using acetone as the mobile phase, unreduced and free pertechnetate, which migrated 
with the solvent front, was resolved by ITLC from other radiolabelled components, 
including unwanted by-products, which remained at the origin.  Acetone, however, was 
unable to resolve further the radiolabelled components; these were separated using 
methanol : 1 M ammonium acetate as the mobile phase.  Here 99mTc-colloids remained at 
the origin while the radiolabelled peptide and unreduced pertechnetate travelled up the 
strip.   
 
Figure 4.18 shows an example of ITLC analysis of [99mTc]-DB 4 after the labelling 
procedure, together with data obtained from the phosphor imager.  Data acquired was 
subtracted from background readings, and analysis performed by OptiQuant enabled the 
percentage of radiolabelled DB 4 to be calculated. 
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Figure 4.18:  Analysis of the radiolabelled product using ITLC-SG strips run in acetone and methanol: 1 M 
ammonium acetate. 
 
The quality of this sample was particularly good; no free pertechnetate was present in the 
radiolabelling mixture.  In Table 4.2, ITLC results obtained from a representative selection 
of other radiolabeling procedures demonstrate the stability of the product and the 
reproducibility of the labelling procedure. 
 
Table 4.2:  ITLC analysis from a number of quality control procedures performed after radiolabelling.  Data 
were obtained by exposure of ITLC-SG strips to phosphor imager screens for 30 s. 
 
 
 
 
 
 
 
 
 
 
 
HPLC 
ITLC Analysis 
% Free  
Pertechnetate   
% 
99mTc-Colloids 
% 
99mTc-DB 4 
1 0 5 95 
2 2 4 94 
3 0 4 96 
4 1 6 93 
5 2 7 91 
6 0 2 98 
7 0 8 92 
8 3 3 94 
9 2 5 93 
10 0 4 96 
All 
labelled 
products 
Labelled 
DB4 
99m
Tc 
colloids Methanol: 
1 M 
ammonium 
acetate 
Acetone 
Acetone Methanol: 
ammonium 
acetate 
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To further confirm results obtained by ITLC, reverse-phase HPLC was run in parallel.  The 
HPLC chromatogram in Figure 4.19 shows a successful labelling procedure, in which one 
clean, sharp peak of 99mTc-DB 4 has eluted at approximately 21 min, and no additional 
peaks of free or unreduced pertechnetate have appeared near the solvent front.  The 
absence of peaks eluting before or after 21 min indicate that the peptide has not 
undergone complexation or dissociation.  
 
 
 
Figure 4.19:  HPLC chromatogram of radiolabelled DB 4.  [
99m
Tc-DB 4] eluted from the column in the region 
of 21 min.  Circled section indicates the position of unbound pertechnetate.  This chromatogram indicates 
excellent labelling with >99% labelling efficiency. 
 
The circled region on the graph indicates where unwanted soluble impurities such as 
unreduced pertechnetate would elute.  It is essential that significant amounts of free 
pertechnetate are not present in the preparation, to optimise the targeting of the 
radionuclide.  As with ITLC analysis, HPLC analysis showed that the reproducibility of the 
radiolabelling procedure was good (Table 4.3). 
 
 
 
 
Table 4.3:  HPLC analysis of a number of chromatograms performed after the radiolabelling procedure.  
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HPLC 
Chromatograms 
% 
99mTc-DB 4 
Soluble 
impurities 
1 99.5 0.5 
2 99.4 0.6 
3 100.0 0 
4 100.0 0 
5 100.0 0 
6 98.0 2.0 
7 99.5 0.5 
8 99.0 1.0 
9 99.3 0.7 
10 99.5 0.5 
 
 
4.2.4.2 Biodistribution Studies on PC3 Tumour-Bearing Mice 
In vivo analysis was performed on all the cell lines tested to see whether the relationships 
and specific binding observed in vitro were replicated in vivo.  Groups of tumour-bearing 
mice were therefore tested to examine the distribution, specific uptake and clearance of 
99mTc-DB 4.   
 
For in vivo analysis, mice were injected subcutaneously on both hind-leg flanks with 10 
million cancer cells, in the right flank with cells alone, and in the left flank with cells mixed 
in a 1:1 ratio by volume with Matrigel, which was used to promote tumour growth.  With 
certain cell lines, tumour formation was particularly difficult to achieve; PC3 and AR42J 
were faster growing cell lines (approximately 2 weeks) LNCaP cells alone took 
approximately 8 weeks and androgen deprived up to 12 weeks. 
 
Initially biodistribution studies were performed in mice bearing PC3 tumours at three time 
points; 1, 2.5 and 4 hours post injection.  These time points were thought to provide a 
sufficient window of observation as to how the radiotracer was behaving within the 
mouse.  Groups of 3-4 mice were used per time point, since it is important to note that 
there is a degree of variability when using these biological models. 
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At each time point, mice were culled, and organs and tissue were excised and collected 
into pre-weighed scintillation tubes to be measured on the gamma counter.  The counts 
obtained were then used to calculate the uptake of radioactivity per g of tissue (% ID/g)   
(Figure 4.20). 
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Figure 4.20:  Biodistribution of [
99m
Tc]-DB 4 in PC3 tumour-bearing mice.  The average amount of radiotracer 
measured in three mice, per time point, is shown with standard deviations.  % ID/g = % uptake of injected 
dose per g of tissue.  Left tumour - with Matrigel, right tumour without Matrigel. 
 
 
Relatively high uptake was seen in those tissues with known GRP-R expression, in 
particular tumour, intestine and pancreas.  Increased binding was observed in the right 
tumour (no Matrigel) over the left tumour (with Matrigel).  Growth rates in the flanks 
differed significantly with time, with the left flank showing palpable tumours before the 
right, due to the addition of Matrigel.  At times the mice were left an additional day or two 
for the tumour to form in the right flank, therefore it is probable that the higher binding 
observed is due to the right tumour still being within the exponential growth phase and 
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cellular metabolism being more active than in the left tumour.  Lower levels of uptake 
were seen in receptor-negative tissue such as heart, lungs and muscle.  The highest uptake 
was observed in the kidney, which provides the major excretory route for this hydrophilic 
radiopharmaceutical.  A decrease in uptake was seen in all tissues between 1 h and 2.5 h, 
with little change thereafter.  
 
4.2.4.3 Blocking Study 
To determine whether the uptake in GRP-R positive tissue observed was specific and not 
as a result of non-specific binding or hydrophobic interactions, a blocking study was 
performed. 
 
PC3 tumour-bearing mice were split into two groups of four.  One group was injected with 
99mTc-DB 4, and the second with 99mTc-DB 4 in the presence of excess competitor, 
unlabelled DB 4, at 10 µg per mouse, sufficient to bind and occupy/block all the GRP 
receptors.  Mice were culled at 4 h post injection, and organs were excised for 
biodistribution analysis (Figure 4.21). 
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Figure 4.21:  Biodistribution analysis of the blocking study, 4 h post injection.  % ID/g = % uptake of injected 
dose per g of tissue.  * t-test showed no significant difference between blocked and unblocked samples for 
all tissues, apart from the tumour and pancreas, which showed a significant difference (P >0.05). 
 
A reduction in binding was observed within the GRP-R-expressing tissues viz. tumours, 
intestine and pancreas.  The percentage differences between the blocked and unblocked 
tissues were respectively 58, 46 and 28%, however t-test analysis showed the difference 
to be statistically significant only in tumour and pancreas.  Bombesin-binding sites have 
been identified throughout the small and large intestine [120].   Smaller differences were 
seen between the groups in any of the other tissues examined, indicating low levels of 
specific binding in them.  Some reduction was seen in kidney uptake but the level of 
uptake varied greatly in this organ, perhaps as a result of differing rates of excretion 
between the animals.  This experiment confirmed that a significant proportion of uptake 
initially observed with PC3 tumours was indeed due to specific binding to expressed GRP-R 
but also that a significant level of non-specific uptake also occurred. 
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4.2.4.4 Biodistribution Studies on Other Cell Lines 
Biodistribution studies were also performed with the remaining PC cell lines to assess the 
uptake of 99mTc-DB 475 by these tumours.  Uptake seen in tumours was compared with 
that in non-expressing tissue (muscle) and also clearance via kidneys (Table 4.4). 
 
Table 4.4:  Biodistribution studies on prostate cancer cell lines.  *AR42J is the rat neuroendocrine cell line.   
 
Tissue 
Time 
(h) 
Ar42J* PC3 
LNCaP 
Androgen- 
dependent 
LNCaP 
C81 
LNCaP 
C81 
(androgen- 
deprived) 
LNCaP 
C42B 
LNCaP 
C42B 
(androgen- 
deprived) 
% ID/g ± SD 
Tumour 
1 1.89 ± 0.56 1.55 ± 0.36 1.98 ± 1.16 0.86 ± 0.33 2.16 ± 0.48 0.78 ± 0.49 0.41 ± 0.17 
2.5 1.31 ± 0.44 0.52 ± 0.08 2.41 ± 0.39 0.75 ± 0.36 1.72 ± 1.03 0.62 ± 0.66 0.14 ± 0.12 
4 1.88 ± 0.47 0.48 ± 0.22 1.35 ± 0.58 1.02 ± 0.36 0.36 ± 0.04 0.43  ± 0.16 0.44 ± 0.52 
Kidney 
1 
13.58 ± 
1.44 
7.37 ± 2.05 
16.92 ± 
1.44 
11.11 ± 
3.12 
8.46 ± 2.47 3.82 ± 1.89 5.87 ± 2.51 
2.5 8.53 ± 0.50 3.34 ± 0.39 
10.10 ± 
3.22 
7.77 ± 2.48 8.10 ± 4.55 5.10 ± 1.50 1.67 ± 1.27 
4 9.65 ± 2.74 2.83 ± 0.35 3.96 ± 1.32 4.43 ± 1.12 3.42 ± 0.67 5.11 ± 0.37 6.42 ± 3.70 
Muscle 
1 0.11 ± 0.03 0.46 ± 0.31 0.22 ± 0.04 0.19 ± 0.10 0.29 ± 0.15 0.09 ± 0.01 0.07 ± 0.02 
2.5 0.16 ± 0.12 0.05 ± 0.01 0.12 ± 0.02 0.14 ± 0.04 0.21 ± 0.06 0.13 ± 0.09 0.01 ± 0.00 
4 0.08 ± 0.04 0.06 ± 0.02 0.02 ± 0.01 0.11 ± 0.04 0.06 ± 0.05 0.03 ± 0.01 0.23 ± 0.38 
 
Tumour uptake and specific binding was observed in the majority of the cell lines tested, 
but minimal or no significant binding was observed in both LNCaP C81 and C42B.  The 
greatest level of uptake was observed by the androgen-dependent LNCaP line which, like 
the positive control AR42J, showed uptake at just under 2%, which was retained for up to 
4 h post injection.  PC3 tumours also showed a high uptake, and interestingly, specific 
binding was increased in androgen-deprived LNCaP C81, but not androgen-deprived C42B 
(Figure 4.31 on page 210). Uptake levels in the PC tumour cell lines were variable but were 
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always significantly greater than in muscle.  In general, uptake declined with time, but not 
always.   
 
4.2.4.5 Imaging with 99mTc-DB 4 in all Prostate Cancer Cell Lines 
As well as biodistribution studies, mice were also imaged using a Nano SPECT/CT scanner.  
 
 
 
Figure 4.22:  Transverse images of a PC3 tumour-bearing mouse.  (A) CT image - arrow shows the dense 
vertebra, indicating the back of the mouse.  Dashed arrow indicates the right PC3 tumour.  (B) Combined CT 
and SPECT images.  (C) SPECT image alone - arrows indicate the left kidney (larger area) and intestine 
(smaller area) uptake.  Dashed arrow indicates the right PC3 tumour.  
 
CT imaging facilitates the location and orientation of the tumour [Figure 4.22 (A)]:  as the 
cancer cells were injected subcutaneously, tumour formation occurred just beneath the 
skin, and a solid mass was easily identified in the CT image, which could be overlaid on the 
SPECT image, ensuring that the activity measured was due to uptake by the tumour, and 
not other adjacent tissues (Figure 4.22 B & C).  Although activity was observable in the 
SPECT image alone, without the CT image it was difficult to orientate and attribute the 
uptake. 
4.2.4.5.1 Dynamic Acquisition 
Dynamic acquisition was performed on an AR42J tumour-bearing mouse.  [99mTc]-DB 4 
was injected intravenously into a mouse, which was scanned continuously by the Nano 
SPECT/CT over the next hour to allow visualisation of the distribution, clearance, and 
specific and non-specific binding of the radiopharmaceutical (Figure 4.23).  Dynamic 
CT CT & SPECT Combined SPECT 
A B C 
Chapter 4  Demobesin 4 Results 
    196 
 
acquisition showed the total spread of the radiopharmaceutical throughout the body and 
a rapid clearance from the blood and receptor negative tissues.  High levels of uptake 
were seen in the kidneys and bladder, due to the hydrophilic nature of the peptide and its 
rapid renal clearance.  Heterogeneous uptake was observed in the tumour tissue.  
 
 
Figure 4.23:  Dynamic acquisition of an AR42J tumour-bearing mouse, injected with [
99m
Tc]-DB 4 and 
scanned continuously for 1 hour.  White arrow indicates tumour, dashed arrow, indicates gall bladder. 
 
4.2.4.5.2 Static Imaging 
Static images of the mice were acquired 1, 2.5 and 4 h after injection of [99mTc]-DB 4.  High 
levels of activity were observed in the ventral body cavity in the mice at all time points, 
mainly due to clearance via the kidneys and the bladder, as well as some uptake in the 
intestines, but this activity diminished over time as the radiotracer was excreted (Figure 
4.24).  Uptake was seen in the gall bladder of earlier time points, suggesting a small 
proportion cleared via the liver. 
 
Time  
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Figure 4.24:  Coronal images of PC3 tumour-bearing mouse no. 1 of three imaged over the three time points.  
Uptake and clearance by the various organs and tissues was observed.  Arrows indicate the PC3 tumour on 
the right flank.  Images were scaled the same to allow for direct comparison. 
 
 
Heterogeneous specific binding (not a uniform distribution of uptake) was observed in the 
right tumour, with several small ‘hot spots’, which were retained there in excess of 4 h.  
No obvious sites of necrosis, which would appear as black non-specific regions in the 
centres of tumours, were observed.  Imaging data was obtained for all PC cell lines, at all 
the time points tested76.  Uptake also occurred into the left tumour, but a lesser extent 
than the right. 
 
4.2.4.5.3 Quantification 
From SPECT data, it is possible to obtain quantitative as well as qualitative information.  
Using the SPECT-analysis programme, In Vivo Scope™, elliptical regions of interest (ROIs) 
were manually drawn around target tissue from imaged mice.  Tumours on both the left 
and right flank were measured as well as the kidneys for all three time points (1, 2.5 and 4 
h) post injection (Figure 4.25).   
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Figure 4.25:  Example of the acquisition of quantification data, using the In Vivo Scope™ SPECT-analysis 
programme.  White dashed arrow - indicating the tissue of interest (right tumour).  White arrow - 
highlighting the ROI (green) which was manually drawn around the tumour. 
 
 
The ROI was manually drawn around the tumour or kidney in the transverse section, 
although all views were used to locate the tissue of interest.  Data obtained from the ROIs 
drawn was expressed in terms of MBq/mm3, and the percentage of the injected dose in 
the total ROI was calculated by dividing this by the total radioactivity injected. The uptake 
obtained from the imaged data was compared with that obtained from biodistribution 
analysis for PC3 tumours.  Data was normalised to correct for decay, to ensure that results 
were directly comparable. 
 
Difficulties were encountered in drawing the boundaries around ROIs of the tumours and 
kidneys without including unwanted surrounding tissue, especially at the 1 h time point.  
With the tumours, unwanted muscle tissue was sometimes selected; however as minimal 
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radioactive uptake was observed in muscle, this was not seen as a significant problem. The 
kidneys however are in close proximity to a number of organs which also showed uptake 
of 99mTc-DB 4, such as the intestines, stomach and liver, so great care was taken to ensure 
that the ROI of the kidney was defined without incorporating any unwanted tissue (Figure 
4.25). 
 
1 2.5 4 
0.0
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Figure 4.26:  Comparison of % ID values in tissues obtained via quantification from imaged data and 
biodistribution data for the PC3 line.   
 
 
Figure 4.26 compares the averaged % ID values obtained from the imaging and 
biodistribution data.  Only the 4-h time points are directly comparable, as the mice 
imaged at this point were culled for the 4-h biodistribution point.  The % ID values of the 
tumours were similar for the later time points, but not for the 1 hr time point, when the 
uptake from the imaging data appeared to be much higher at 1 h. This is thought to be 
due to a higher background in normal tissues giving tumours a larger appearance than in 
the later images, therefore resulting in a higher estimation of uptake.  Significant 
differences in kidney uptake between the two methods can also be observed which may 
be attributable to difficulties in obtaining an exact ROI without including the activity from 
the intestine.  A smaller ROI could be drawn within a region of the selected tissue and 
then multiplied to derive a value for the total tissue mass; however although that would 
eliminate the issue of taking in unwanted surrounding tissue, it also makes the assumption 
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that the uptake and binding was homogenous, which examination of the images showed 
was not the case. 
 
Another way of graphically representing these results was to compare the activity 
recorded by the two techniques and to observe whether there was a linear relationship 
between them (Figure 4.27). 
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Figure 4.27:  Comparison of tissue uptake in MBq:  biodistribution versus quantification. 
 
It is clear that there is a linear relationship between the uptake values obtained by 
biodistribution and those determined by image quantification.  The line of best fit shows a 
good correlation between the two methods. However the slope of the line is 0.3382 
rather than 1 as would be expected from a perfect correlation. This suggests that the 
differences are not due to experimental variability but to a fundamental flaw in one or 
both of the calculation methods.   
 
In order to overcome the problem of drawing the ROI on the early, 1-hour image, ROIs 
were drawn from the CT image rather than SPECT image, which ensures that the ROI was 
drawn round the tumour only, eliminating any possible background activity (Figure 4.28). 
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Figure 4.28:  Comparison between tumour uptake obtained from biodistribution measurements and imaging 
procedures.  ROI were drawn on CT and SPECT images to compare the difference.  Data taken from right PC3 
tumours from 3 imaged mice, 1 h post injection. 
 
It can be seen that there is a closer correlation between the data obtained from the CT 
ROIs than the SPECT ROIs, indicating that assigning accurate ROIs may be a source of 
error. 
 
4.2.4.5.4 Specific Activity 
Specific activity was investigated as another cause of this discrepancy, since as the binding 
capacity of receptors in vivo can be as low as a few nanomoles, a low concentration of 
labelled ligand is essential.  It was considered important to determine the effect of 
changes in specific activity because the non-radioactive substrate (DB 4) may 
competitively bind to the GRP-R and thus prevent the binding of the labelled ligand. 
 
The differences in uptake were measured in PC3 tumour-bearing mice, mice were split 
into two groups; half of which were administered with an imaging dose of approximately 
1000 pmol, and the other half with a biodistribution dose of 50 pmol; a 20-fold difference.  
Biodistribution was carried out 2.5 h post injection and organs and tissues were excised 
and measured (Figure 4.29). 
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Figure 4.29:  Biodistribution of PC3 tumour-bearing mice injected with either a biodistribution dose (50 
pmol) or an imaging dose (1000 pmol).  The average amount of label bound in three mice, taken per group 
at 2.5 h post injection, is shown with standard deviations.  % ID/g = % uptake of injected dose per g of tissue. 
 
A difference in uptake can be observed between the mice receiving the biodistribution 
and the imaging doses.  Differences were seen in GRP-R expressing tissue such as tumour, 
intestine, pancreas and stomach.  However differences were also seen in lungs, heart, 
liver and spleen, non-GRP-R expressing tissues. 
 
4.2.4.5.5 Quantification of Other Cell Lines 
The data shown above was obtained from mice bearing PC3 tumours. Quantification was 
also performed on mice bearing tumours from the other PC cell lines.  A comparison of % 
ID/g values obtained from imaging and biodistribution analysis was performed.  Data was 
again normalised to correct for decay and the 4 h time point was analysed to allow for 
direct comparison between the datasets (Figure 4.30). 
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Figure 4.30:  Comparison of % ID/g values in tumours obtained via quantification from imaged data and 
biodistribution data.  Cell lines C42B & C42B androgen-deprived did not grow any tumours on the right flank. 
 
 
The results obtained show a similar % ID/g uptake by the tumours in some of the cell lines 
tested, with LNCaP androgen dependent showing highest GRP-R expression in both 
imaging and biodistribution.  However LNCaP C42B showed greater variability between 
the two methods. 
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4.3 DISCUSSION 
 
Interest in radiopharmaceuticals has increased considerably over the last decade, with 
radiolabelled receptor-binding peptides emerging as a new class of radiopharmaceuticals.  
Peptides show a number of favourable characteristics; they are readily synthesised, 
inexpensive, and can withstand harsh chemical conditions for modification and 
radiolabelling.  Furthermore, they offer several advantages over antibodies, being less 
likely to induce immunogenic responses, having improved pharmacokinetic profiles 
inherent in fast blood clearance, better tissue penetration, higher tumour uptake and 
therefore offering a more favourable tumour-to-background ratio [195]. 
 
The transition from androgen-dependent to androgen-independent (hormone-refractory) 
metastatic tumour type poses a major challenge for PC treatment.  Molecules that are 
differentially expressed throughout this transition are likely to play important roles in 
imparting PC cells with the ability to grow in a hormone-deprived environment, and are 
therefore likely targets for diagnostic and therapeutic intervention.  GRP-R expression has 
been reported in early stages of PC when tumour-growth is androgen-dependent as well 
as in prostatic intraepithelial neoplasia, a possible precursor to PC [9].  Expression levels at 
later stages of PC especially androgen-independent have been investigated and reports of 
receptor expression have been observed in androgen-independent PC3.  During the 
emergence of an androgen-independent cancer, molecular changes occur and cancer-
specific surface receptors and ligands are upregulated [196].  Imaging 
radiopharmaceuticals can potentially exploit these changes, allowing an insight to the 
development of the cancer, and also its response to treatment [116].  DB 4, a peptide 
binding to GRP-R was used to study GRP-R expression in a range of PC cell lines (from 
androgen-dependent to independent) in order to explore its potential as a 
radiopharmaceutical. 
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4.3.1 Prostate Cancer Cell Lines 
The LNCaP cell line is one of the most widely studied cell lines in prostate cancer research 
because the cells express AR and behave much like early prostate cancer by being 
androgen-sensitive and having the ability to be transformed into androgen-independent 
cell lines both in vivo and in vitro [197].  LNCaP C42B and C81, cell lines derived from 
LNCaP show features of progressed disease such as metastatic capabilities and androgen 
independence, although androgen-sensitivity is also sometimes observed [198]. 
 
The two “classical” cell lines DU145 and PC3 are reported to be androgen insensitive and 
have been used extensively as a model for androgen-independent PC.  They are however 
not regarded as optimal PC cell lines as they lack androgen receptor expression despite 
the presence of an apparently normal androgen receptor gene [199, 200]. Contradictory 
reports in the literature concerning the expression of AR mRNA and protein have been 
observed in these cells by a number of research groups [200, 201].  It remains an area of 
uncertainty as to whether these cells are AR negative or not, however it must be 
considered as a possibility. 
 
De Visser and co-workers addressed this issue by measuring GRP-R expression in a range 
of human prostate tumour xenograft models [202].  A unique panel of human prostate 
tumour xenograft models had been established and reviewed by Van Weerden et al [203] 
which represented the various aspects of human PC and De Visser et al were therefore 
able to study the PC progression from androgen-dependence to androgen-independence 
stages.  They found GRP-R expression in androgen-dependent PC, but minimal to no 
binding observed in androgen-responsive and androgen-independent PC, suggesting that 
GRP-R expression is regulated by androgens.  
 
This aims of this project were to measure GRP-R expression in a number of PC cell lines 
ranging in androgen sensitivity by a number of different techniques and to compare 
expression both in vitro and in vivo with [99mTc]-DB 4.  It was considered important to see 
whether results were comparable over a range of different techniques.     
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4.3.2 Radioligand Binding Assays 
Radiolabelled peptides must retain their receptor-binding capacity if they are to function 
as effective radiopharmaceuticals and this was confirmed on the positive control cell line 
AR42J, a rat pancreatic tumour.  Radioligand binding assays were then performed on all 
the PC cell lines in order to obtain both the receptor number (Bmax) and the binding 
affinity (Kd) of DB 4, by analysis of non-specific binding and total binding. 
 
Non-specific binding, importantly, occurs in many types of binding assay.  In addition to 
specific binding to target receptors, radioligands may also bind non-specifically to other 
sites, notably the cell membrane.  The details of the molecular interactions remain 
unclear, but charge and hydrophobicity of the ligand are involved, more so than 
sequence-specific structure.  Non-specific interactions may also occur to other receptors 
and transporters expressed on the surface of the cell membrane, and is usually directly 
proportional to the concentration of the radioligand (the addition of twice the 
concentration of radioligand doubles the amount non-specifically bound) [191].  
 
Unlabelled DB 4 was used as the competitor to measure non-specific binding to ensure 
that all the target receptors were occupied, so that any binding observed would be to 
other receptors, or be due to interactions with the cell membrane.  The concentration 
used (1000 μM) was adequate to block all the receptors.  
 
Measurable Bmax and Kd values were obtained for PC3, DU145, LNCaP (androgen-
dependent), LNCaP C42B and AR42J but LNCaP C81 and androgen-deprived LNCaPs C81 
and C42B failed to generate any conclusive data, possibly due to lack of expression of 
GRP-R; or more likely, expression at levels below the sensitivity range of the assay.    
 
Although androgen-dependent lines, showed a high level of expression of GRP-R, the 
androgen-independent lines, PC3 and DU145 revealed substantially higher levels of 
expression, even greater than of AR42J, the positive control (Table 4.1). 
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Aprikian and co-workers [204] found Bmax values for GRP-R of 47600, 1500 and 1000 fmol  
in PC3, DU145 and LNCaP respectively using [125I]-Tyr4-bombesin.  These values differ 
considerably from ours (8345, 4182 and 104 fmol respectively) but the order of level of 
expression (PC3>DU145> LNCaP) remains the same.  This discrepancy may be explained by 
the effects of passage number and culture conditions described below. 
  
Others have also shown GRP-R expression in these cell lines [204, 205] including increased 
expression in more advanced cancer [118].  The Bmax values obtained from the cell lines 
thus demonstrated expression of the GRP receptor over a range of different stages of 
prostate cancer growth, especially in some of the more advanced androgen-independent 
forms; but they also show a reduction or loss of expression levels in the androgen-
independent strains of LNCaP.  Kd values were obtained for DB 4 from the tested cell lines 
and fell between a range of 0.3 – 2.2 nM, similar to those observed with a BN-analogue, 
[125I]Tyr4-bombesin on the PC3, DU145 and LNCaP, respectively 1.5, 1.1 and 3.6 nM [206].  
 
The radioligand binding assay thus confirmed the expression of GRP-R in some of the 
prostate cancer cell lines tested, including androgen-independent PC3 and DU145 but 
with no receptor expression being observed in 3 lines. 
 
 
4.3.3 High- and Low-Passage Numbers in LNCaP and C42B cell line 
 
4.3.3.1 Increased Passage Number   
It is essential to handle cell lines in a manner that maintains their usual phenotype.  
Androgen-dependent LNCaP cells that are used in experimental analysis should be 
maintained at as low a passage number as possible, and grown in media that maintain 
their growth and androgen dependency for as long as possible.  The use of charcoal 
stripped-FBS (CS-FBS) is preferred, and media should be free of phenol red, since this  
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indicator is known to bind to androgen receptors [207] and elicit the same responses as 
do androgens, via the promiscuous pathway [9].   A main focus of research is aimed at 
understanding why after androgen ablation there is a switch in cell growth from a 
paracrine pathway to a newly-emergent autocrine pathway.  A number of hypotheses and 
possible explanations concerning the role of androgen receptor expression and behaviour 
have been advanced to account for this [12, 208, 209].  One should also consider that the 
levels of expression of other receptors may also be up- or down-regulated in vitro due to 
factors such as increased passage number and nutrients within the media.  
 
This change in behaviour was observed with high- and low-passage LNCaP C42B cells.  All 
cell lines were passaged, and media changed in accordance with each line’s requirements; 
however, working stocks of cells were regularly replaced with cells from frozen stocks of 
lower passage number to maintain a supply with as low a passage number as possible.   
Radioligand binding assays were performed on both low- and high passage-number stocks 
of LNCaP C42B which had been handled in the same manner.  The difference observed 
between the two confirmed that passage number had an effect on the levels of expression 
of GRP-R, and validated the need to continue maintaining cell lines at low passage 
numbers.  The precise reason for this effect is unclear, but perhaps the stress associated 
with the passaging of cells is causing the cells to evolve and behave differently from what 
is normal, or the gradual adaptation to their artificial environment, which is different from 
what naturally occurs in vivo. This observation was further confirmed in a comparison 
between high- and low-passage LNCaP C42B mRNA by RT-PCR.  High-passage C42B 
expressed significantly lower levels than low-passage cells (explained in further detail in 
section 4.2.2.1). 
 
 
4.3.4 RT-PCR – Relative Quantification  
GRP-R expression was determined in androgen-dependent and -independent PC cell lines 
by relative quantification and -fold expression compared with MKN45, the non-expressing 
cell line.  All cell lines tested revealed expression of GRP-R mRNA; in PC3 considerably 
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more than in any other cell line.  It was not possible to obtain a value for GRP-R expression 
by the rat pancreatic cell line AR42J due to the use of probes and primers designed for 
human transcripts. The results obtained were comparable in some respects to those from 
the radioligand binding assays, PC3, DU145 and LNCaP showed the highest level of 
expression and the androgen-independent LNCaP lines the lowest.  However the order of 
expression was PC3>LNCaP>DU145>C42B>C81 compared to 
PC3>DU145>LNCaP>C42B>C81 for the radioligand binding assays.  Similar patterns of  
GRP-R expression have been observed in PC3 and DU145 as well as LNCaP using standard 
PCR [210].  
 
To assess whether androgens and the AR had an affect on GRP-R expression as previously 
observed by De Visser et al, LNCaP cells were transferred from regular FBS into CS-FBS and 
back into regular FBS.  These exhibited changes in GRP-R expression.  Decreased 
expression was first observed when the medium was supplemented with CS-FBS (lacking 
androgens and growth factors), however once cells were transferred back to standard 
FBS, recovery of GRP-R expression and sometimes enhanced-expression was observed in 
all the cell lines.  
 
Schroeder et al [211] have also observed this effect in androgen-dependent prostate 
cancer in vivo.  The authors investigated GRP-R regulation in 3 androgen-dependent 
human PC xenograft models representing the early androgen-responsive state of PC.  RT-
PCR of mRNA from the tumour tissue was performed to evaluate the changes in mRNA 
expression of GRP-R during androgen manipulation.  After androgen ablation, the relative 
level of GRP-R expression dropped considerably, but partially recovered after re-
supplementation with testosterone.  Autoradiographic analysis also revealed reduced 
binding after androgen ablation by up to 95% reduction in androgen-dependent cell lines.  
Biodistribution studies demonstrated a similar response, but to a lesser extent.  
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Future work would beneficially be directed at attaining fundamental knowledge of the 
hormonal regulation of GRP-R; essential information for the clinical use of GRP-R-based 
technologies. 
 
4.3.5 GRP-R Expression Examined using FACS 
FACS analysis of GRP-R expression was not successful using either of the commercially 
available anti-GRP-R antibodies (Novus or Abcam) on the PC cell lines.  As no positive 
control antibody was available, optimisation of the assay was not possible, therefore it 
was difficult to know for certain whether the negative results obtained were the result of 
the absence of binding, or a fault of the assay method.  Neither of the commercially 
available antibodies had been optimised for FACS, and currently there is no FACS data 
published on GRP-R expression. 
 
 
4.3.6 Autoradiography 
Autoradiography was performed as another means of measuring GRP-R expression, but 
also to assess whether the levels of expression observed in vitro were maintained ex vivo.     
 
Autoradiography was first attempted with 99mTc but was found to be not an ideal isotope 
for this procedure.  99mTc is not a β-emitter, therefore autoradiography depends on the 
activity of Auger and internal conversion electrons, which have a lower and broader 
energy spectrum than β-particles.  When an electron is removed from an atom leaving a 
vacancy (leaving the atom in an energetic ionised state), an electron from a higher energy 
level may fall into the vacancy, which results in a release of energy; this energy can be 
emitted in either the form of a photon or an Auger electron [172].  Internal conversion is a 
radioactive decay process where an excited nucleus is de-excited by interaction with an 
electron from one of the lower atomic orbitals, causing an internal conversion electron to 
be emitted from the atom [172]. 
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Because of difficulties in obtaining reproducible results using 99mTc, optimisation studies 
were performed.  Due to the small tumour sections used, a high specific activity was 
required to label the DB 4 peptide, to limit competition between unlabelled and labelled 
DB 4 for the GRP-receptors.  High levels of activity are also necessary to detect a signal in a 
short exposure time because of the short half-life of 99mTc, however, use of higher activity 
levels of 99mTc was found to cause saturation of the screens.  For these reasons, results 
obtained were of poor quality and it was not possible to clearly differentiate between 
tumour sections incubated with and without competitor (unlabelled DB 4), due to low 
tumour-to-background signal ratios.  Since the use of 99mTc-DB 4 failed to give conclusive 
answers, the technique was adapted for use with the [125I]-Bombesin analogue [125I] -D-
Tyr6, β-Ala11, Phe13, Nle14 BB in place of 99mTc. 
 
This radioligand yielded much clearer results, facilitating the distinction between non-
specific and total binding, which allowed specific binding to be measured.  The relatively 
long half-life allowed for longer exposure times, which heightened the contrast between 
the tumour and the background.  The results obtained from this assay mirrored those 
obtained by in vitro analysis (radioligand binding assays and relative quantification by RT-
PCR), and showed that the PC3 cell line gave the greatest level of GRP-R expression, 
followed by LNCaP androgen-dependent, LNCaP C42B and LNCaP C81.  No sites of necrosis 
were observed, confirming good vascularisation of the tumours.  Autoradiography of GRP-
R has also been performed by Maddalena and co-workers in both LNCaP and PC3 cells 
confirming receptor expression ex vivo [135]. 
 
Autoradiography studies of GRP-R expression in a range of prostatic tissue from patients 
with PC have been performed by Marwalder and Reubi [118].   Four types of tissue were 
investigated:  invasive prostatic carcinoma; high-grade PIN; prostatic hyperplasia, in which 
prostatic stroma and GRP-R frequency and intensity were measured.  Their main findings 
were a high incidence and high density of GRP-R in not only invasive prostatic carcinomas, 
but also in the earliest phase of neoplastic transformation.  Little to no expression was 
seen in non-neoplastic prostatic tissue, such as benign prostatic hyperplasia.  The 
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autoradiography results obtained in the present work are similar to these documented 
findings, in that high levels of GRP-R expression were observed in early PC growth (in 
LNCaP androgen-dependent), when cells proliferate and differentiate via a paracrine 
pathway.  High levels of GRP-R were also observed in advanced PC such as in the PC3 cell 
line.   
A slight drop in GRP-R expression was observed when cells were grown in androgen-
deprived medium, however autoradiographic study of these tumours does not provide a 
true representation of the effects of complete androgen removal, as cells were injected 
into intact male mice, and therefore were exposed to circulating androgens, thus 
nullifying the effect of the androgen-deprived environment that the cells were previously 
grown in.  Nonetheless, androgen deprivation did have an effect on the growth of the 
tumours, because compared with the same cell lines grown in 10% FBS, the androgen-
deprived line took 2 to 3 times longer to grow in vivo, suggesting a possible link between 
the level of GRP-R expression and rate of cell proliferation. 
 
4.3.7 Immunohistochemistry 
Immunohistochemistry failed to fully reveal specific GRP-R binding in the prostate cancer 
cell lines studied.  PC3, was the only line that stained positively, visually nearing that of 
pancreatic tissue, the positive control.  However upon closer inspection, other types of 
non-expressing cell, such as skeletal muscle, also appeared to exhibit positive staining. 
Therefore PC3 probably displayed a certain degree of non-specific binding, though a 
proportion of the staining may still be attributed to specific binding. 
 
The remaining prostate cancer cell lines all failed to reveal any specific binding with anti- 
GRP-R antibody.  Diffuse staining was observed with all lines, and although it was not 
observed with the negative line MKN45, that was not sufficient evidence to corroborate 
specific binding. 
 
The minimal level of specific binding seen in all the sections of tumour tissue tested could 
be attributed to a number of possible causes;  firstly, the antibody, which had to meet the 
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requirements of both IHC and FACS analysis. There are very few commercially-available 
human anti-GRP-R antibodies.  The first antibody considered, Novus Biologicals NLS830, 
failed at the optimisation stage of the experiment.  No specific binding even to the 
positive control, pancreatic tissue, was seen.  The second, Abcam 39963, yielded better 
results, however the specificity of the antibody may still have been the cause of the little 
specific binding observed in the range of cell lines.  It was possible that this antibody was 
not optimal for this procedure, and the levels of expression in these cells were lower than 
the sensitivity of the assay and that only the high expressing PC3 tissue sections was 
stained successfully.  Secondly, the epitopes on the receptors may also have been 
damaged during the processing, embedding and sectioning of the paraffin samples.    
 
Schultz and co-workers were successful in positively staining GRP-R in a number of GRP-R 
expressing cancer cell lines, such as prostate and breast with their novel antipeptide 
antibodies [212].  GRP-R protein has also been successfully detected in colon cancer by 
immunohistochemisty [213] and with weak and diffuse staining in breast cancer tissue 
with a commercially available antibody [214].  Both the results obtained and data in the 
literature indicate that commercially available antibodies towards GRP-R give a diffuse 
positive-staining which is open to interpretation. 
 
 
4.3.8 Imaging 
 
4.3.8.1 Radiolabelling with 99mTc - Quality Control Analysis  
Radiolabelling efficency was measured for each batch of labelled DB 4 by ITLC and 
confirmed by HPLC analysis; an important step before commencing any experiment to 
ensure the quality of the labelled product.  Both ITLC and HPLC routinely indicated a 
labelling efficiency >98%, therefore further purification was not necessary.  
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4.3.8.2 Biodistribution Studies on PC3 Tumour-Bearing Mice 
The jump in experimentation from the in vitro to the in vivo environment is considerable, 
and many new factors come into play, such as the stability of the radiotracer, 
pharmacokinetics, temperature (stability at 37 °C), pH, non-specific binding to proteins 
and its general ability to interact with the biological environment [215]. 
 
Both left and right flanks of the mice were injected with PC3 cancer cells, the left with a 
50:50 mix of Matrigel77, and the right with cells alone.  Matrigel was used to encourage 
tumour growth; however it was not known whether this would affect the imaging and 
biodistribution studies.  In both imaging and biodistribution studies, the Matrigel tumours 
did not show as high levels of specific binding as observed with the tumours grown with 
no Matrigel.  This could be for one of two reasons; either a direct effect on GRP-R 
expression or, more probably, on the rate of tumour growth.  Matrigel tumours always 
grew much more rapidly than non-Matrigel tumours, so it is possible that they outstripped 
their supply of nutrients and became senescent or underwent apoptosis and necrosis. 
  
Biodistribution studies in PC3 tumour-expressing mice showed increased levels of uptake 
in both left- and right-flank tumours, with right tumours exhibiting higher binding than the 
left.  Rapid clearance from the circulation was observed with minimal 99mTc-DB 4 
background seen after 1 h post injection.  Very little non-specific binding was observed in 
non-GRP-R-expressing tissue including muscle, heart and lungs.  Activity observed in the 
stomach could be due to the degradation of the 99mTc-DB 4 complex or to possible low 
levels of GRP-R expression [216].  A degree of binding would also be expected in the 
intestine and pancreas, which express lower levels of GRP-R.  High uptake by the kidneys 
was due to the hydrophilic nature of this radiopharmaceutical, which was accordingly 
excreted renally.  The decrease in uptake observed at later time points was indicative of 
washout from the tissue and clearance from the body. 
 
                                                 
77
 Matrigel contains structural proteins such as laminin and collagen which provide additional support to the 
cells in a form of a growth matrix, which increases vascularisation 
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4.3.9 Blocking Study 
Prior to the commencement of the in vivo imaging study, it was important to ensure that 
the binding observed was specific, therefore a blocking study was performed to validate 
this.  Some degree of non-specific binding is expected due to hydrophobic and ionic 
interactions with other sites on the cell surface [144]; however this percentage must be 
low enough to allow specific binding to be observed. 
The results showed a decrease in binding of 99mTc-DB 4 when blocked with 10 µg of 
unlabelled DB 4.  A reduction of only ~50% was observed.  This residual uptake may be 
non-specific or possibly due to GRP-R not being fully blocked by unlabelled DB 4.  A 
blocking dose of 10 µg was used, considerably lower than other groups who used a dose 
of 250 µg and showed a reduction in PC3 tumour uptake of DB 4 from 5.19 to 0.55 %ID/g 
at 4 hours [206].  The 10 μg blocking dose chosen was influenced by toxic effects seen 
after injection of higher doses of bombesin analogous in these mice. 
 
Cescato [206] have also studied the distribution of 99mTc-DB 4 in PC3 tumour-bearing 
mice, and found higher uptake by the tumour, with better retention extending over longer 
periods of time, with % ID/g values for tumour uptake of 9.37, 5.19 and 2.67 at 1, 4 and 24 
h respectively post injection was observed.  However, they also showed greater uptake by 
the pancreas at 38.90, 34.80 and 14.43%; substantially higher (pancreas at 1, 2.5 and 4 h 
showed 2.49, 1.51 and 1.41%) than the uptake observed in any of the cell lines tested in 
the present work.  Although the experimental conditions were the same, significant 
differences were observed between the two sets of data which can perhaps be attributed 
to differences in cell culturing techniques, which may affect GRP-R expression in tumours, 
but not pancreas.  Other factors which may account for these differences are the age, sex 
and strain of murine models used.   All our biodistribution studies were performed on 
male, SCID mice aged 6-8 weeks.  Although Cescato et al also used SCID mice, the age and 
sex is not known.  Administered dose could not be a contributing factor, since these were 
the same, and the reason for this high pancreatic uptake remains unclear.   
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4.3.10 Biodistribution Studies on Other Cell Lines 
Biodistribution studies were performed on the remaining PC cell lines to assess their GRP-
R expression and to see whether they followed the same level of expression as previously 
observed in both in vitro and ex vivo analysis.  These results are summarised in Figure 
4.31. 
 
A range of uptake across the cell lines tested was seen, with LNCaP androgen-dependent 
showing higher uptake than all the other lines, including PC3.  No correlation was 
observed between in vivo uptake and the level of receptor expression shown by in vivo 
and ex vivo analysis.  However, the results are difficult to interpret, because in some 
instances the uptake observed did not always decrease with time, and in some cell lines 
(AR42J, LNCaP C42B androgen deprived and LNCaP C81) increases in uptake were 
observed at later times (Figure 4.31). 
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Figure 4.31:  Biodistribution of % ID/g uptake of [
99m
Tc]-DB 4 in a range of PC cell lines over 1, 2.5 and 4 h in 
muscle (non-specific binding), tumour (specific binding) and kidneys (renal clearance).  Values are the mean 
± standard error for each tested tissue (n=3). 
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A possible reason for the lack of correlation is the fact that the different tumours were 
often of quite different sizes.  The use of Matrigel-assisted and non-Matrigel-assisted 
tumours in opposite flanks often resulted in a non-ideal combination of tumour sizes, with 
the Matrigel-tumours being too large and the non-Matrigel tumours being too small.  This 
meant that factors such as the level of necrosis (in large tumours) or variations in blood 
supply (in small tumours) could have an influence on the level of uptake independent of 
the level of receptor expression. 
 
4.3.11 Specific Activity 
The effect of the difference in specific activity between the biodistribution and imaging 
studies was evaluated.  A difference in uptake can be observed between the mice 
receiving the biodistribution and the imaging doses, probably due to a proportion of 
competing unlabelled DB 4, blocking the GRP-R in the imaging dose mice.  However, 
although this trend was observed in all the GRP-R-positive tissues such as tumour, 
intestine and stomach, non-GRP-R expressing tissues also showed a blocking effecti such 
as the spleen, blood, heart and lungs, which would not be expected.  This anomaly needs 
to be clarified by further work, but the difference between the two doses may explain in 
part the poor correlation between biodistribution and quantification shown in Figure 4.27, 
where the slope of the line of best fit does not equal 1. 
 
4.3.12 Imaging with [99mTc]-DB 4 in all Prostate Cancer Cell Lines 
Imaging provides both qualitative and quantitative information allowing the visualisation 
of the uptake, clearance and interaction with biological systems in real-time.  It also 
reduces the numbers needed in animal studies.  Two to three mice bearing each tumour 
type were selected for imaging.  It was considered important to select mice with tumours 
that were not too advanced (too large), because it was important to try to capture growth 
in the initial growth phase, with good vascularisation but minimal necrotic sites.  These 
mice were injected at 40-min delay intervals to allow for Nano SPECT and CT analysis, and 
were subsequently scanned at 1, 2.5 and 4 h post injection.   The images showed uptake in 
the tumour in all the cell lines to varying degrees, LNCaP C81 androgen-deprived showed 
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the least visual uptake, with AR42J, PC3 and LNCaP androgen-dependent showing greater 
uptake than the other cell lines78.  As well as uptake at the sites of tumour, imaging 
allowed an assessment of how long the radiopharmaceutical was maintained at the 
tumour sites, as well as an indication of any uptake in other tissues.  Kidney uptake 
decreased over time as the radiopharmaceutical cleared from the system, but was also 
dependent on the rate of excretion by individual mice.  Uptake was also observed by the 
intestines partly due to the GRP-R expression present there and partly, perhaps to 
excretion[119]. 
 
The behaviour of [99mTc]-DB 4 was encouraging as the radionuclide:peptide complex 
appeared to remain intact, since no activity was observed in the thyroid, which would 
have indicated the presence of free pertechnetate, and the spleen, which would have 
accumulated [99mTc]-colloids. 
 
4.3.13 Quantification 
ROI analysis was performed to obtain quantitative information from the SPECT images and 
to see whether the results obtained by Nano SPECT/CT were comparable with the 
biodistribution data.  Quantification analysis was performed on the PC3 images at the 
three time points studied and compared with the biodistribution data for the same time 
points.  However, only the 4-hour time point was directly comparable because the imaged 
mice were the same as those used for the 4 h biodistribution time point.  Figure 4.26 
shows that similar uptakes for both left and right tumours were obtained for the time 
points 2.5 and 4 h.  Uptakes at 1 h were not as similar, possibly because of the greater 
background uptake in normal tissues.  This gives the tumour a larger appearance on the 
SPECT images than the CT scans (Figure 4.28).  Uptake in kidneys was not comparable 
either due to difference in excretion between the two sets of mice or the difficulties in 
drawing accurate ROIs round the tissues of interest. 
 
                                                 
78
 Appendix X 
Chapter 4  Demobesin 4 Discussion 
    220 
 
When the imaging results were plotted against the biodistribution results, a linear 
relationship was observed, but the slope of the line was not equal to 1, suggesting a basic 
flaw in one or both of the methods used.  This could be either due to a real difference in 
uptake caused by differences in the experimental protocols or by apparent differences 
due to errors in the analysis.  At least two possible reasons could explain these observed 
differences: (1) specific activity may be one possible reason as differences were observed 
in uptake between imaging doses and biodistribution doses in GRP-R expressing and non-
expressing tissues (Figure 4.21).  (2) Definition of the ROI could also introduce errors.  It is 
important to ensure that the ROI is obtained correctly.  The widest part of the tumour is 
generally selected and the ROI drawn, as shown in Figure 4.32.  The analysis programme, 
then gives a value for the volume of the tumour in cm3.  Errors can arise if the ROI is 
drawn around a narrower region, eliminating sections of the tumour which fall outside 
this region and thus will not be recorded.  As previously explained, it can be difficult to 
obtain by this technique the correct volume of the desired tissue/organ, without also 
acquiring surrounding unwanted tissue.  However, since tumours on the flanks of hind 
legs are surrounded by tissue (muscle) showing these would not be expected to result in a 
large difference in the total %ID calculated with the ROI.  
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Figure 4.32:  Schematic representation of the importance of drawing ROI round the widest part of tissue.  
Dashed white circle highlights the region from which the ROI is drawn.  MBq values from tissue within the 
cylinder are taken; values for any tissue which falls outside the cylinder are not recorded and are therefore 
lost.  Red dashed line indicates the diameter of the cylinder drawn which contains the ROI.  Blue area 
indicates surrounding tissue which is also included in the reading; therefore if the tissue being measured is 
in close proximity to other positive tissue, minimal surrounding tissue must be taken, otherwise they affect 
the MBq readings.  
 
 
Quantification in the other tested cell lines (Figure 4.30) showed a close similarity 
between the two procedures in C81, PC3 and LNCaP tumours, but with C42B and C42B 
androgen-deprived showing greater variability.  These differences may be attributed to 
the causes discussed above. 
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4.4 SUMMARY & CONCLUSION 
 
4.4.1 GRP-R Expression in Prostate Cancer Cell Lines 
Using a range of in vitro, ex vivo and in vivo techniques, GRP-R expression was measured 
and compared over a range of PC cell lines representing different stages of cancer growth.  
GRP-R was expressed in all the cell lines tested.  The highest values were observed in the 
androgen-independent cell lines PC3 and DU145, followed by LNCaP androgen-dependent 
which were much lower; Bmax values were respectively 8345, 4182 and 104 fmol/mg.  Kd 
values for 99mTc-DB 4 fell within the range 0.3 – 2.2 nM, indicating a high affinity for the 
receptors.  
 
RT-PCR further showed a very similar trend in GRP-R expression in vitro as seen in the 
radioligand binding assay, with the PC3 line showing the highest level of expression.  
Changes were observed in GRP-R expression when cells were deprived of and 
resupplemented with androgens.  Passage number, cell culturing techniques and handling 
were shown to affect the behaviour and subsequent level of expression of GRP-R.  The 
reason for this remains unclear, but nutrient stress, passage number and handling 
technique have been shown by others to affect GRP-R expression significantly [217].  
Androgen deprivation was seen to decrease the expression level slightly, but after 
resupplementation with androgens, there were significant increases in expression, 
exceeding the base-line values obtained.  This phenomenon was also observed by 
Schroeder and co-workers [211], and further investigation is needed elucidate the 
mechanism responsible.   
 
FACS analysis failed to show any specific and selective binding to any of the GRP-R-positive 
cell lines in comparison with the negative line MKN45.  Failure to observe binding was 
attributed to the two commercial antibodies used, neither of which proved to be suitable 
for FACS analysis. 
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Ex vivo analysis of tumours from the cell lines tested was performed in an attempt to 
bridge the gap between the jump from in vitro to in vivo.  Technical difficulties were 
encountered by using [99mTc]-DB 4 for autoradiography but successful results were 
obtained with [125I]-Bombesin Analogue [[125I]-D-Tyr6, β-Ala11, Phe13, Nle14-BB.  Specific 
binding was observed in all the PC cell lines tested, at significantly higher levels than the 
binding observed in the GRP-R-negative cell line, MKN45. 
 
Binding trends seen in radioligand binding assays, and the relative quantification afforded 
by RT-PCR were also reflected in the data obtained from autoradiography, further 
strengthening and validating the results and patterns previously observed.  
Autoradiography also revealed a decrease in receptor expression when cells were 
androgen-deprived, showing a reduction of 35% in LNCaP C42B, but no significant 
difference in LNCaP C81.  Further investigation using castrated mice is needed to confirm 
these initial findings. 
 
As with FACS, immunohistochemical studies using the commercially-available anti-GRP-R 
antibodies failed to reveal any binding.  Even pancreatic tissue, the positive control, did 
not demonstrate strong binding, and only diffuse staining was observed in PC3 sections.  
As GRP-R expression had been revealed by autoradiography, the lack of demonstrable 
binding was not thought to be due to the absence of receptor expression, but rather to 
deficiencies in the antibodies used, or perhaps the processing, embedding and sectioning 
of the sections.   
 
In vivo analysis of the uptake of 99mTc-DB 4 in tumour-bearing mice did not mirror in vitro 
findings.  The androgen-dependent cell line LNCaP showed the highest uptake (% ID/g = 
1.98), greater than PC3 (% ID/g = 1.55) at 1 h post injection, and with improved retention 
at the tumour site even at 4 h post injection, in vitro analysis had shown greater GRP-R 
expression in PC3.   
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The interpretation of in vivo imaging is made difficult because of its questionable 
reproducibility.  Procedural protocols and the approach to the measurement of tumour 
vascularisation need to be standardised, experimental error needs to be reduced and the 
relationships between tumour size, uniformity and uptake, need to be better understood,  
prior to ascertaining whether imaging can provide the same quantitative information as 
biodistribution studies. 
 
Dose and specific activity issues could partially explain the differences observed between 
imaging and biodistribution data and would need to be further investigated.  Differences 
in quantification between biodistribution and imaging data were partly attributed to 
errors in measurements of volume which arose when obtaining the ROI, and further 
investigation may be needed. 
 
99mTc-DB 4 successfully bound to GRP-R expressed in a range of PC cell lines. The level of 
expression was quantified by a variety of different techniques in vitro, which showed high 
levels of expression in the androgen-independent cell lines PC3 and DU145, as well as in 
LNCaP androgen-dependent, but lower expression in the androgen independent strains of 
LNCaP C42B and C81.  Androgen appeared to have an effect on GRP-R expression; 
deprivation reduced the levels expressed and resupplementation appeared to drive over-
expression.  99mTc-DB 4 has proven to be a successful candidate for imaging PC in a range 
of PC cell lines, and could potentially be used as a targeting radiopharmaceutical. 
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5 THESIS DISCUSSION AND CONCLUSIONS 
 
The aim of this work was to design, syntheise and test two poteintial targets to develop 
into new radiopharmaceuticals which could be easily radiolabelled and to specifically 
target PC.  As PC switches from androgen-dependence to independence, new 
radiopharmaceuticals for imaging and therapy would need to target ligands or receptors 
ideally expressed on all stages of growth, but not in healthy tissue. 
 
Two appropriate molecular targets were developed as potential imaging 
radiopharmaceuticals for PC.  The first target was PSMA, a ligand which is highly expressed 
in PC with lower expression in healthy tissue and its expression is upregulated with cancer 
progression.  PSMA is a large surface marker, which is not released into the circulation and 
is internalised after antibody binding.  
 
A number of groups have developed mAb and scFv against PSMA [62, 63, 71] but few have 
undergone clinical application.  ProstaScint® is commercially available, however a 
drawback to this radiopharmaceutical is its ability to target only the internal domain of 
PSMA; and is thus only able to detect its target when cells are dying and is not ideally 
suited to image the early progression or reoccurrence of the disease [65].  To overcome 
this problem, recombinant PSMA protein was generated for this project in which the 
internal domain was deleted and phage display was performed on the protein encoding 
only for the large, extracelluar portion of the PSMA ligand. 
 
The aims of this study were partially met.  Using a semi-synthetic phage display library, a 
number of potential scFv clones were selected and syntheised and shown to specifically 
bind to PSMA.  This was confirmed by FACS analysis whereby both positive phage clones 
and purified scFv preferentially bound to PSMA expressing cells (LNCaP) over non-
expressing cells (DU145). 
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In a bid to increase the affinity, production of diabodies was performed, as they are 
known to have an advantage over scFv’s in vivo.    The manipulation of the linker can drive 
the formation of diabodies or even triabodies as shown by Hudson et al [180] and the 
successful production of diabodies was achieved by the complete removal of the linker, by 
exploiting the many restriction sites on the phagemid vector.  Binding efficacy by ELISA 
and FACS was studied to ensure production of diabodies, as removing the linker prevents 
the natural folding of the scFv and prevents the fragment from forming the paratrope.  
Binding efficiency was compared between the scFv and diabodies by ELISA and FACS to 
ensure successful production of diabodies which still retained their binding ability; 
improved binding was observed with the diabodies for all the clones.  FACS histograms 
showed broad peaks, suggesting heterogeneity of the dimeric samples containing 
diabodies, triabodies and even tetrabodies.  Nonetheless, they were able to selectively 
bind to LNCaP over DU145, confirming specificity to PSMA.  These results together with 
the ELISA results confirm successful manipulation of the linker to drive the formation of 
dimeric fragments. 
 
HPLC and FPLC confirmed the heterogeneity of the both the monomeric and dimeric 
preparations, but also confirmed stability of the fragments reducing the possibility of 
dissociation. 
 
Radiolabelling of both the monomeric and dimeric R2G10 antibody fragments was 
achieved using sodium [125I]-iodide in iodogen tubes, with an efficiency of >90%.  However 
no binding of radiolabelled antibody fragments to cells was observed in radioligand 
binding assays.  Studies were undertaken to see if this was due to chemical changes to the 
antibody during the labelling procedure but it seemed that this was not the case.  It was 
concluded that the differences in binding observed between the FACS and radioligand 
binding analysis was due to the differences in antibody concentrations employed and that 
it was likely that the antibodies were binding to PSMA with only low affinity.  Binding both 
in vitro and in vivo was unsuccessful using the radiolabelled antibody fragments, however 
this as well as the antibody fragments themselves, other factors such as the choice of 
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radioisotope and methodology used, could have played a crucial role in this failure to 
show binding with the PSMA-specific antibody fragments. 
 
The second target GRP-R is highly expressed neuropeptide receptors in PC.  GRP-R is 
known to be expressed in early stages of PC; however recent studies have questioned its 
expression in advanced, androgen-independent PC.  Expression in the androgen 
independent PC3 cell line has been observed in a number of research groups [116, 136], 
however in human prostate xenografts of advanced androgen-independent PC, expression 
was not observed [134, 202].  
 
GRP-R expression was successfully designed, synthesised and evaluated in vitro and ex 
vivo by a number of techniques (radioligand binding assay, RT-PCR, autoradiography and 
immunohistochemistry) and results obtained were comparable showing an level of 
expression in the order PC3>DU145>LNCaP>LNCaP C42B>LNCaP C81 using these different 
analytical methods.  Expression was then studied in vivo by injection of the radiolabelled 
peptide 99mTc-DB4 into xenograft bearing mice and results compared with those obtained 
in vitro.  Although specific uptake of the radiopharmaceutical by the tumours was 
observed there was not a good correlation between uptake in vivo and expression levels 
observed in vitro; with expression being observed predominately in LNCaP and PC3.  
Quantification of imaged data was performed and compared to in vitro findings, but again 
were found not to be directly comparable. 
 
Androgen dependence and GRP-R expression was also assessed to determine a possible 
relationship between the two.  It was found that androgen ablation appeared to cause the 
down-regulation of GRP-R expression in LNCaP cells but when resupplemented with 
androgens the levels of expression not only recovered but expression were increased 
considerably.  This confirmed findings from Schroeder et al who also observed this 
relationship [134]. 
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The majority of the aims of this project were met. 99mTc-DB 4 successfully bound to a 
range of PC cell lines; the level of expression was quantified by a variety of different 
techniques in vitro.  Androgen appeared to have an effect of GRP-R expression as 
deprivation was seen to reduce the levels expressed and resupplementation appeared to 
drive over-expression.  99mTc-DB 4 has proven to be a successful candidate for imaging PC 
in a range of PC cell lines, and could appears to have the potential for clinical application. 
 
The hypothesis for this work is that PC can be imaged by using a suitably designed 
radioligand directed against an appropriate molecular target such as PSMA or GRP-R.  This 
project to a large extent confirms this hypothesis.  99mTc-DB 4 was successful designed, 
synthesised and showed a good level of binding and uptake in in vivo analysis and high 
quality images were produced.  Anti-PSMA antibody fragments although were successfully 
radiolabelled, the radiolabelled product could not be shown to bind PSMA, this could be 
attributed to the chosen isotope and methodology employed and with further 
investigation could potentially also be a good imaging radiopharmaceutical. 
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6 FUTURE WORK 
 
6.1 PSMA PROJECT 
 
6.1.1 Optimisation of Radioimmunoassay and in vivo imaging  
Further investigation with the positive control antibody D2B, in both the 
radioimmunoassay and in vivo imaging procedure would allow issues with these assays to 
be addressed, as the D2B binds to PSMA-expressing cells with a higher affinity than any of 
the positive selected clones from the phage display selection (Figure 3.19).  It would also 
be advantageous to explore an increase in the concentration of the antibody preparation 
when performing radioimmunoassay, equal to the concentrations used in FACS to enable 
the results of the two assays to be more directly compared, 
 
If positive data was attained with D2B, this would allow validation of these assay 
conditions (antibody concentration, incubation time and temperature) with which it 
would then be beneficial to re-test the four scFv and diabody clones (including analysing 
R2G10) to see whether improved binding could be observed. 
 
In addition, it may prove advantageous to perform assays on other PSMA-expressing cell 
lines, such as PSMA transfected PC3 cell line. 
 
6.1.2 Stability Analysis 
Analysis of the stability of the antibody preparations would also be important to ensure 
that the radioisotope and antibody fragments remained intact in vivo for long enough to 
target the expressed PSMA.  Analysis in both plasma and PBS at 37°C should be 
performed.  
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6.1.3 Radiolabelling with Other Isotopes 
Alternative chelate-based radiolabelling chemistry could be investigated such as 111In and 
99mTc to see whether improved binding could be observed using these radioisotopes over 
125I.  
 
Proteins cannot be labelled with 111In directly and a multi-stage approach is required, 
using a bifunctional chelating agent, capable of covalently binding to the protein.  The 
most commonly used is diethylene-triamine-penta-acetic acid (DTPA).   Both isotopes 
have a much shorter half-life and are more appropriate for imaging applications.  
 
One draw-back of substituting 125I with another radioisotope is that radiolabelling requires 
considerably larger concentrations of protein, requiring an increase of the production in 
the scale and techniques currently employed. 
 
6.1.4 Binding Affinity Analysis Using Biacore  
It would also be of interest to analyse the binding affinity and kinetics of the selected 
clones using Biacore technology, which is able to provide a range of information regarding 
the binding interaction of the antibody fragments to the target antigen in real time. 
 
Biacore is a surface plasmon resonance (SPR)-based system for analysing biospecific 
interactions viz. specificity, affinity and kinetics.  The protocol requires one interacting 
molecule to be immobilised to a sensor chip and its counterpart is injected into a 
continuous buffer flow.  The interaction is monitored in real time, thereby offering the 
possibility of calculating the kinetic rate constant for the interactions [218].   
 
It is possible to use biacore in the selection process of scFv in phage display, allowing for a 
much quicker high throughput protein interaction analysis, by obtaining high quality 
kinetic data without the need of antibody purification, facilitating the screening of 
potential scFv leads.[218, 219]. 
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6.1.5 Repeat Screening  
In the event that the above analysis failed to yield any conclusive answers, it may be 
advantageous to screen the library again, this time alternating between a PSMA 
transfected cell line and the recombinant PSMA protein to see whether higher affinity 
scFv would be identified.  Perhaps selecting an alternative library could also yield higher 
affinity scFv, (such as a peptide library). 
 
 
6.2 BOMBESIN PROJECT 
 
6.2.1 In Vivo - Imaging  
A critical evaluation of the in vivo data obtained raised concerns about its reproducibility 
and the value of the initial findings, causing difficulties with interpretation.  It is therefore 
crucial to address these shortcomings. 
  
6.2.2 Standardisation of Imaging Studies 
Standardisation of the procedure is of upmost importance to reduce as much variation as 
possible.  A study of the effects of Matrigel on [99mTc]-DB 4 uptake would be beneficial, 
covering a range of GRP-R-positive cell lines, as well as negative controls.  Although 
Matrigel is commonly used in tumour formation, the uptake observed by Matrigel-assisted  
tumours was less than those produced without it.  It would be important to determine 
whether this was indeed due to the Matrigel composition, or to over-growth of the 
tumour, resulting in cell death or senescence.  
 
The pharmacokinetics of radiopharmaceutical uptake by tumours is particularly 
dependent on vascularity and tumour size.  Experience within our laboratories has found 
that smaller tumours show proportionately greater uptake of radiolabelled peptides than 
larger ones, possibly due to their greater proportion of proliferating cells and better 
vascularisation.  With increase in tumour size, regions of necrosis become common, and 
poor vascularisation has been seen within them [220].  An investigation to determine the 
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tumour size at which necrosis begins and vascularity deteriorates would be advantageous.  
Angiogenesis is a critical step in tumourigenesis which is necessary to supply the tissue 
with oxygen, nutrients and growth factors, as well as the delivery of the imaging 
radiopharmaceuticals used to diagnose such tumours.    With this in mind, it would be 
advantageous to see whether any differences could be observed in the different stages of 
tumour growth. 
 
A number of techniques can be utilised to measure vascularity, notably histology, Micro 
CT and ultrasound.  Histological measurements of angiogenesis is a possible procedure to 
measure vascularity using microvessel density (MVD), a widely-employed measure of 
angiogenesis in pathological specimens and tumour models.  Immunohistochemical 
procedures are used to stain for microvessels, and two methods to count the vessels are 
currently available; one which counts areas of high vascularity at low magnification, the  
‘hotspot’ method, and another which involves counting randomly selected areas such as 
tumour edges [221].  
 
Micro CT can visualise the detailed three-dimensional structure of the vascular system in 
any desired tissue.  Although this technique is limited to vessels larger than 10 µm in 
diameter [222], it could provide a means of measuring vascularity in tumours, and even 
enable a comparison between Matrigel and non-Matrigel tumours.  The contrasting agent 
Microfil® (Flowtech Inc, Carver, Massachusetts), a CT-dense casting medium which fills 
and opacifies blood vessels can be injected into perfused animals, which are then scanned 
for visualisation [223].     
 
A third option would be to look at vascularisation using contrast-enhanced ultrasound 
(CEUS), which utilises microbubbles, a gas-filled contrast agent administered into the 
circulation.  The high degree of echogenicity (reflection of ultrasound waves) of 
microbubbles into the surrounding soft tissue enhances the reflection of ultrasound 
waves, producing a sonogram.  CEUS can therefore be used to image blood perfusion in 
organs, and even to measure blood flow rate [224]. 
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6.2.3 Androgens and GRP-R expression 
The preliminary results obtained from RT-PCR have opened up an area of investigation 
which would be interesting to pursue.  Since the vast majority of patients receive 
hormonal therapy during the course of treatment for prostate cancer, it would be 
interesting to study the impact of hormonal ablation treatment on GRP-R expression, 
partly to extend our understanding of the disease, but mainly to reveal whether such 
patients would still be eligible for GRP-R-targeted imaging modalities.  Therefore further 
investigation into the level of GRP-R expression, both in vitro and in vivo, after androgen 
manipulation would be of interest. 
 
6.2.4 Phase I Clinical Trial 
[99mTc]-DB 4 has entered a phase I clinical trial at St. Bartholomew’s Hospital this year 
(2010), and the first PC patient assessment is imminent.  The trial is to study the potential 
side-effects of [99mTc]-DB 4 and to assess its efficacy at imaging PC patients.  The primary 
objectives are three-fold: 
1. To assess the safety of [99mTc]-DB 4 in patients with PC 
2. To assess the biodistribution of [99mTc]-DB 4 in these patients 
3. To assess the pharmacokinetics of [99mTc]-DB 4 in these patients  
As well as these objectives, the ability of [99mTc]-DB 4 to detect metastatic spread, and a 
comparison of the binding levels of [99mTc]-DB 4 with the levels of expression in GRP-R in 
prostate tumour samples and lymph node specimens will be undertaken. 
Trial participants will receive a single injection of [99mTc]-DB 4 over 1 minute and will 
undergo imaging by SPECT, CT scan and/or MRI for up to 3 hours after infusion.  Urine and 
blood samples will also be collected to determine how the radiopharmaceutical is 
processed within the body, and any tissue biopsy will be sent for immunohistochemistry.   
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8 APPENDICIES 
 
VECTOR MAP AND SEQUENCE OF pIT2 VECTOR 
 
 
 
 
 
 
Phagemid vector – pIT2 constructed by Dr. I. M. Tomlinson, Laboratory of Molecular Biology, MRC, Cambridge [90, 94] 
CAGGAAACAGCTATGACCATGATTACGCCAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATA  ATG  AAA  TAC  CTA  
 M      K        Y       L 
LMB3 
RBS 
TTG  CCT  ACG  GCA  GCC  GCT  GGA  TTG  TTA  TTA  CTC  GCG   GCC  CAG  CCG  GCC   ATG  GCC  GAG  GTG  TTT  
SfiI      NcoI_     
 L       P       T        A       A       A       G       L        L       L        L      A        A        Q       P       A       M      A       E        V       F 
GAC  TAC  TGG  GGC  CAG  GGA  ACC  CTG  GTC  ACC  GTC  TCG  AGC  GGT  GGA  GGC  GGT  TCA  GGC  GGA  GGT  
  D       Y      W      G       Q        G       T       L       V        T       V       S       S        G        G       G       G      S       G       G      G 
XhoI  Linker 
GGC  AGC  GGC  GGT  GGC  GGG  TCG  ACG  GAC  ATC  CAG  ATG  ACC  CAG  GCG  GCC  GCA  CAT  CAT  CAT  CAC   
  G        S      G        G       G        G        S       T        D        I       Q       M       T       Q       A       A       A      H      H       H    H 
SalI  NotI  His-tag 
CAT  CAC  GGG  GCC  GCA  GAA  CAA  AAA  CTC  ATC  TCA  GAA  GAG  GAT  CTG  AAT  GGG  GCC  GCA  TAG  ACT 
   H       H      G        A       A        E        Q      K        L       I       S       E        E        D       L       N        G      A        A        *      T 
myc-tag 
pHEN seq 
  
 VH  VL  Gene III Lac promoter 
E. coli ori  M13 
Ori 
AMP 
Sfil/Ncol 
XhoI 
SalI 
Not
I 
pIT2 
 Linker 
H M 
 
 
Amber Codon 
RBS 
His & Myc Tags 
pelB Leader 
VH 
Linker 
VL 
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The pIT2 vector contains a lac promoter and a pelB leader sequence (an amino-acid 
sequence that directs the protein to the cytoplasmic membrane of E. coli, where the 
sequence is removed by pelB peptidase) up-stream of the scFv insert, followed by His and 
Myc tags, an amber stop codon, and the gene encoding the pIII phage coat protein.  After 
infection with helper phage M13K07, scFv up-stream of the amber stop codon is displayed 
on the phage particle by use of a suppressor strain such as TG1.  Alternatively, scFv with 
both His and Myc tags are secreted into the supernatant using a non-suppressor strain 
such as HB2151. 
 
Amber Stop Codon 
 
The amber stop codon, UAG, stops protein synthesis and is positioned between antibody 
gene and phage gene III.  In some bacterial suppressor strains (SupE), such as TG1, there is 
a mutation in the aminoacyl-tRNA of this codon, which prevents it from being read as a 
stop, and consequently the antibody fragment is produced as a fusion protein together 
with coat protein pIII of the phage.  In non-suppressor strains, this codon is read as a stop, 
and the antibody fragment is secreted into the periplasm. 
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SCREENING LOWER-AFFINITY BINDERS FROM ELISA 
 
The initial selection of scFv identified the highest-binding antibody fragments from ELISA 
results; however, lower-affinity binders were not discarded as these may later have been 
shown to have improved affinity but lower secretion levels.  For that reason, further 
screening of these lower binders was also performed.  To facilitate rapid screening 
selected antibodies were not purified but instead the periplasmic fractions of the purified 
clones were evaluated.  FACS analysis of these lower binders shows that they were able to 
differentiate between the two cell lines, but showed decreased levels of affinity to the 
LNCaP C81 than other previously-screened clones. 
 
 
FACS analysis of other lower-affinity binders selected by phage display.  Non-purified periplasmic fractions 
were used on both LNCaP C81 and DU145.  Solid grey: DU145 with D2B anti-PSMA antibody; Solid black: 
LNCaP C81 with D2B anti-PSMA antibody; Red line: DU145 with tested clone; Blue line: LNCaP C81 with 
tested clone.  
 
R2A2 R2H1 
R3H2 R3E3 
R3E10 
R3G9 
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Marginally improved binding to the positive cell line LNCaP C81 with the clones tested was 
observed compared with the PSMA-negative cells, DU145.  It was concluded that high 
affinity antibodies had not been missed in the screening process. 
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pIT2 PHAGEMID VECTOR 
 
 
Digestion of the plasmid during the formation of diabody 
 
 
 
 
 
 
 
 
B 
 
                                                
 
 
(A) Schematic diagram illustrating the action of the restriction enzymes to linearise the plasmid and remove 
the glycine-serine linker.  (B) Agarose gel revealing one band representing the linearised plasmid from the 
four selected clones.  The linker was too small to be visualised. 
 
 
 
 
 VH       VL 
+ 
         VL 
 XhoI  SalI 
 VH 
Linker 
pIT2 
Linker too small 
to be visualised 
on agarose gel 
Linearised 
plasmid 
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HPLC Analysis of scFv and Diabodies  
 
HPLC analysis of the remaining monomeric and dimeric scFv clones, R2F3, R2H2 and R3F5, 
performed twice, with and without internal standard. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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C 
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HPLC chromatograms of monomeric and dimeric antibody fragments. A, C & E - Respectively R2F3, R2H2 & 
R3F5 scFv with and without internal standard.  B, D & F - Respectively R2F3, R2H2 & R3F5 diabody with and 
without internal standard. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E 
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RADIOLIGAND BINDING ASSAY 
 
Assays for Specific Binding Performed on All Prostate Cell Lines 
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Assays for specific binding performed on all PC cell lines, using radioligand binding assay.  Specific binding 
was not observed with either LNCaP C81 or LNCaP C81 (androgen-deprived).  
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PCR – Validation Experiment 
 
A validation experiment was performed on two randomly-selected cell lines, LNCaP 
(androgen-dependent) and LNCaP C42B, to verify that the efficiencies of the target (GRP-
R) and the reference (endogenous control) were approximately equal. 
 
A serial dilution series of cDNAs for both the target and endogenous control was 
performed and Ct values were obtained, from which delta Ct values were calculated.  Log 
input amount was plotted against ΔCt. 
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Relative efficiency plot of Log input amount of GRP-R vs. weight of β-actin RNA for (A) LNCaP C42B and (B) 
LNCaP (androgen-dependent)  
 
 
The absolute value from the slopes should be <0.1, which represents a low degree of 
experimental variation.  This validates the use of ΔΔCt
79 calculation for the relative 
quantification of the target, without the need to perform a standard curve on the same 
reaction plate.  Both graphs revealed values <0.1. 
                                                 
79
   ΔCt  Target - ΔCt Calibrator = 
ΔΔ
Ct  
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BIODISTRIBUTION AND IMAGING STUDIES 
 
Neuroendocrine AR42J Rat Pancreatic Cell Line 
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(A)  Biodistribution in mice (n= 3) per time group.  (B) Coronal pictures of an AR42J tumour-bearing mouse 
scanned after 1 and 4 h post injection with [
99m
Tc]-DB 4.  Arrows indicate the AR42J tumours on both left 
and right flanks.  Images were scaled to be the same size to enable direct comparison.   
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LNCaP C81 (androgen-independent) Prostate Cancer Cell Line 
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(A) Biodistribution in mice (n = 3) per time group.  (B) Coronal pictures of an imaged LNCaP C81 tumour-
bearing mouse scanned after 1, 2.5 and 4 h post injection with [
99m
Tc]-DB 4.  Arrows indicate the left 
tumours.  Images were scaled to be the same size to enable direct comparison.   
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LNCaP Androgen-Dependent Prostate Cancer Cell Line 
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(A) Biodistribution in mice (n = 3) per time group.  (B) Coronal pictures of an imaged LNCaP androgen-
independent (<15 passage number) tumour-bearing mouse scanned after 1, 2.5 and 4 h post injection with 
[
99m
Tc]-DB 4.  Arrows indicate tumour growth. Images were scaled to be the same size to enable direct 
comparison.   
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LNCaP C42B (Androgen Independent) Prostate Cancer Cell Line 
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(A) Biodistribution analysis on mice (n=3) per time point.  (B) Coronal pictures of an imaged LNCaP C42B 
tumour-bearing mouse scanned after 1, 2.5 and 4 h post injection with [
99m
Tc]-DB 4.  Arrows indicate 
tumour growth. Images were scaled to be the same size to enable direct comparison.   
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LNCaP C81 (Androgen-Deprived) Prostate Cancer Cell Line 
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(A) Biodistribution analysis on mice (n=3) per time point. (B) Coronal pictures of an imaged LNCaP C81 
androgen-deprived tumour bearing mouse scanned after 1, 2.5 and 4 h post injection with [
99m
Tc]-DB 4.  
Arrows indicate tumour growth. Images were scaled to be the same size to enable direct comparison.   
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LNCaP C42B (Androgen-Deprived) Prostate Cancer Cell Line 
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(A) Biodistribution analysis on mice (n=3) per time point.  (B) Coronal pictures of an imaged LNCaP C42B 
androgen-deprived tumour bearing mouse scanned after 1, 2.5 and 4 h post injection with [
99m
Tc]-DB 4.  
Arrows indicate tumour growth. Images were scaled to be the same size to enable direct comparison.   
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